




Exploring molecular patterns and determinants of 
melanoma cell susceptibility to  




for the award of the degree 
 “Doctor rerum naturalium” 
of the Georg-August-Universität Göttingen 
 
within the doctoral program Molecular Medicine 
















Prof. Dr. Ivan Bogeski 
Institute of Cardiovascular Physiology 
University Medical Centre, Georg-August University Göttingen 
 
Prof. Dr. Alexander Flügel 
Institute for Neuroimmunology and Multiple Sclerosis Research 
University Medical Centre, Georg-August University Göttingen 
 
Prof. Dr. Michael P. Schön 
Department of Dermatology, Venereology and Allergology 
University Medical Center Göttingen 
 
Further members of the Examination Board 
 
Prof. Dr. Ralf Dressel 
Department of Cellular and Molecular Immunology 
University Medical Centre, Georg-August University Göttingen 
 
Prof. Dr. Lutz Walter 
Department of Primate Genetics 
German Primate Center, Göttingen 
 
Prof. Dr. Thomas Meyer 
Department of Psychosomatic Medicine and Psychotherapy 




Date of oral examination: 16th June 2020 
 




I hereby declare that my doctoral thesis entitled 
“Exploring molecular patterns and determinants of melanoma cell susceptibility to natural killer 
cell cytotoxicity” has been written independently with no other sources and aids than quoted. 
 
 
Göttingen, April 2020    __________________________________ 




  List of publications 
IV 
List of publications 
Zhang, X., Gibhardt, C.S., Will, T., Stanisz, H., Korbel, C., Mitkovski, M., Stejerean, I., Cappello, 
S., Pacheu-Grau, D., Dudek, J., et al. (2019). Redox signals at the ER-mitochondria interface 
control melanoma progression. EMBO J 38, e100871 
Zhou, X., Friedmann, K.S., Lyrmann, H., Zhou, Y., Schoppmeyer, R., Knorck, A., Mang, S., 
Hoxha, C., Angenendt, A., Backes, Cappello, S., et al. (2018). A calcium optimum for cytotoxic T 
lymphocyte and natural killer cell cytotoxicity. J Physiol 596, 2681-2698 
Frischauf, I., Litvinukova, M., Schober, R., Zayats, V., Svobodova, B., Bonhenry, D., Lunz, V., 
Cappello, S., Tociu, L., Reha, D., et al. (2017). Transmembrane helix connectivity in Orai1 








  List of content 
V 
List of content 
Affidavit ...................................................................................................................................................... III 
List of publications .................................................................................................................................... IV 
List of content .............................................................................................................................................. V 
List of abbreviations ................................................................................................................................. IX 
List of figures .........................................................................................................................................XVII 
List of tables ............................................................................................................................................ XIX 
List of supplemental tables ................................................................................................................... XIX 
Abstract ...................................................................................................................................................... XX 
1 Introduction .......................................................................................................................................... 1 
1.1 Malignant melanoma: definition, origin, risk factors .............................................................. 1 
1.2 Melanoma progression: Important signalling pathways ......................................................... 1 
1.2.1 The RAS-RAF signalling pathway .................................................................................... 2 
1.2.2 The PI3K/AKT/mTOR pathway .................................................................................... 3 
1.2.3 Epithelial-to-mesenchymal transition (EMT)-like phenotype switching .................... 5 
1.3 Anti-melanoma therapies ............................................................................................................ 6 
1.4 Natural killer cells ........................................................................................................................ 8 
1.4.1 NK cell receptors ................................................................................................................ 9 
1.4.2 NK cell recognition of tumour cells ............................................................................... 11 
1.5 The cytotoxic effector mechanism .......................................................................................... 12 
1.6 NK cells in cancer immunotherapy ........................................................................................ 15 
1.7 Immunoediting of melanoma by NK cells ............................................................................ 18 
1.8 Aims ............................................................................................................................................. 20 
2 Material ................................................................................................................................................ 21 
2.1 Antibodies ................................................................................................................................... 21 
2.1.1 Primary antibodies ............................................................................................................. 21 
2.1.2 Secondary antibodies ........................................................................................................ 21 
2.1.3 Fluorochrome labelled antibodies ................................................................................... 21 
2.2 Buffer solutions and other reagents ........................................................................................ 22 
2.2.1 Purchased buffer solutions .............................................................................................. 22 
2.2.2 Prepared buffer solutions and other reagents ............................................................... 23 
2.3 Chemicals .................................................................................................................................... 24 
2.4 Inhibitors ..................................................................................................................................... 26 
2.5 Kits ............................................................................................................................................... 26 
  List of content 
VI 
2.6 Laboratory consumables ........................................................................................................... 26 
2.7 Laboratory devices ..................................................................................................................... 27 
2.8 Media ........................................................................................................................................... 28 
2.8.1 Purchased media ................................................................................................................ 28 
2.8.2 Prepared media .................................................................................................................. 29 
2.9 Oligonucleotides ........................................................................................................................ 29 
2.9.1 qRT-PCR Primer ............................................................................................................... 29 
2.9.2 Silencing RNA (siRNA).................................................................................................... 30 
2.9.3 Other mono-/oligonucleotides ....................................................................................... 30 
2.10 Cell lines ...................................................................................................................................... 30 
2.11 Plasmids....................................................................................................................................... 32 
3 Methods ............................................................................................................................................... 33 
3.1 Subculturing of cell lines ........................................................................................................... 33 
3.2 Determination of cell number ................................................................................................. 34 
3.3 Plasmid preparation ................................................................................................................... 34 
3.4 Transient transfection ............................................................................................................... 35 
3.4.1 Plasmid DNA transfection............................................................................................... 35 
3.4.2 siRNA transfection............................................................................................................ 36 
3.5 Cell proliferation and viability assay ........................................................................................ 36 
3.6 Isolation of peripheral blood mononuclear cells .................................................................. 37 
3.7 Isolation of natural killer cells .................................................................................................. 38 
3.8 Modulation of NK cell activity ................................................................................................ 39 
3.8.1 Stimulation with Interleukin-2 ......................................................................................... 39 
3.8.2 Irradiation ........................................................................................................................... 39 
3.9 Real-time Killing Assay ............................................................................................................. 39 
3.10 Determination of mRNA expression ..................................................................................... 42 
3.10.1 RNA isolation .................................................................................................................... 42 
3.10.2 Reverse transcription for cDNA synthesis .................................................................... 43 
3.10.3 Quantitative real-time polymerase chain reaction (qRT-PCR) ................................... 43 
3.11 Melanoma-NK cell-co-culture ................................................................................................. 45 
3.12 mRNA sequencing of melanoma-NK cell-co-culture .......................................................... 45 
3.12.1 Sample preparation............................................................................................................ 45 
3.12.2 mRNA-Seq library preparation ....................................................................................... 46 
3.12.3 mRNA data analysis .......................................................................................................... 47 
3.13 Flow cytometry .......................................................................................................................... 47 
  List of content 
VII 
3.14 Determination of protein expression level ............................................................................ 48 
3.14.1 Protein extraction .............................................................................................................. 48 
3.14.2 Bradford Assay .................................................................................................................. 49 
3.14.3 SDS-PAGE ........................................................................................................................ 49 
3.14.4 Immunoblot (Western Blot) ............................................................................................ 50 
3.15 Reverse Phase Protein Array (RPPA) ..................................................................................... 50 
3.16 Inhibitor treatment of melanoma cells ................................................................................... 52 
3.17 Statistics ....................................................................................................................................... 52 
4 Results .................................................................................................................................................. 53 
4.1 Effector-to-Target ratio determines effect size of NK cell killing ..................................... 53 
4.2 Interleukin-2 stimulation increases NK cell cytotoxicity ..................................................... 54 
4.3 Heterogeneous susceptibility of melanoma cells to primary NK cells .............................. 59 
4.4 Reverse phase protein array reveals proteins correlating with susceptibility to NK cells ... 
  ...................................................................................................................................................... 63 
4.5 Melanoma killing signature allows the prediction of susceptibility to NK cells ............... 65 
4.6 Single regulators of the melanoma cell susceptibility to NK cell killing ............................ 68 
4.6.1 DIABLO is a potential negative regulator of NK cell-mediated killing.................... 69 
4.6.2 SNAI1 is a positive regulator of NK cell-mediated killing of melanoma ................. 72 
4.7 Susceptibility of melanoma cells towards NK-92 killing shows heterogeneity similar to 
primary NK cells ........................................................................................................................ 74 
4.8 Inhibition of the PI3K-AKT-mTOR signalling pathway decreases melanoma 
susceptibility to NK cells........................................................................................................... 78 
4.9 Other parameters influencing the NK cell-mediated killing of melanoma ....................... 90 
4.10 Melanoma-NK cell-co-culture ................................................................................................. 91 
4.10.1 Co-culture with primary NK cells ................................................................................... 92 
4.10.2 Co-culture with NK-92 .................................................................................................... 94 
4.10.3 RNA sequencing reveals proteins involved in NK cell-mediated immune escape.. 97 
5 Discussion ......................................................................................................................................... 101 
5.1 Effector-to-Target ratio determines effect size of NK cell killing ................................... 101 
5.2 Interleukin-2 stimulation increases NK cell cytotoxicity ................................................... 102 
5.3 Heterogeneous susceptibility of melanoma cells to primary NK cells ............................ 103 
5.4 Reverse phase protein array reveals proteins correlating with susceptibility to NK cells ... 
  .................................................................................................................................................... 105 
5.5 Melanoma protein signature allows the prediction of susceptibility to NK cells ........... 111 
5.6 Single regulators of the melanoma cell susceptibility to NK cell killing .......................... 112 
5.6.1 DIABLO is a potential negative regulator of NK cell-mediated killing.................. 112 
  List of content 
VIII 
5.6.2 SNAI1- a positive regulator ........................................................................................... 113 
5.7 Susceptibility of melanoma cells towards NK-92 killing shows heterogeneity similar to 
primary NK cell killing ............................................................................................................ 114 
5.8 Inhibition of the PI3K-AKT-mTOR signalling pathway decreases melanoma 
susceptibility to NK cells ........................................................................................................ 118 
5.9 Melanoma-NK cell-co-cultures ............................................................................................. 121 
5.9.1 NK cell susceptibility of melanoma cells after co-culturing with NK cells ............ 121 
5.9.2 RNA sequencing .............................................................................................................. 123 
5.10 Concluding remarks................................................................................................................. 125 
Appendix ................................................................................................................................................... 126 
Bibliography .............................................................................................................................................. 134 
Acknowledgements .................................................................................................................................. 159 
  List of abbreviations 
IX 
List of abbreviations 
4E-BP1 Eukaryotic translation initiation factor 4E binding protein 1 
7-AAD 7-Aminoactinomycin D 
A 
ACT Adoptive cell transfer 
ADCC Antibody dependent cellular cytotoxicity  
AIM2 Absent in melanoma 2 
AM Acetoxymethyl ester 
AML Acute myeloid leukemia 
ANXA7 Annexin A7 
APC Antigen presenting cell 
APS Ammonium persulfate 
APAF-1 Apoptotic protease activating factor 1 
ATP  Adenosine triphosphate  
B 
B2M  Beta-2-microglobulin 
BAG-6  Bcl-2-associated athanogene 6 
BAD  Bcl-2-associated agonist of cell death 
BAK  Bcl-2 homologous antagonist killer 
BAX  Bcl-2-associated X protein 
BCL-2  B-cell lymphoma 2 
BID  BH3-interacting domain death agonist 
BiKEs  Bi-specific killer engagers 
BRAF  V-raf murine sarcoma viral oncogene homolog B 
BSA   Bovine Serum Albumin 
C 
C1S  Complement Component 1, Subcomponent 
CaCl2  Calcium chloride 
  List of abbreviations 
X 
CARs  Engineered chimeric antigen receptors 
CASP3  Caspase 3 
CD  Cluster of Differentiation 
CDKN1B Cyclin-dependent kinase inhibitor 1B 
CFP  Complement factor P 
COPS5 COP9 Signalosome Subunit 5 
CTL  Cytotoxic T cell 
CTLA-4 Cytotoxic T-lymphocyte–associated antigen 4 
D 
DAP10 DNAX-activation protein 10 
DAP12 DNAX-activation protein 12 
DEPC  Diethyl pyrocarbonate 
DEPTOR DEP domain-containing mTOR interacting protein 
DGE  Differential gene expression 
DIABLO Direct IAP-binding protein with low PI 
DISC  Death inducing signalling complex 
DMSO Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid  
DNAM-1 DNAX Accessory Molecule-1 
DPBS  Dulbecco's Phosphate-Buffered Saline 
dsRNA double stranded RNA molecule 
DVL3  Dishevelled segment polarity protein 3 
E 
E. coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid  
EGTA  Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
EGFR  Epidermal growth factor receptor 
EMT  Epithelial-to-mesenchymal transition 
  List of abbreviations 
XI 
ERK  Extracellular signal-regulated kinase 
E:T  Effector-to-target 
F 
FACS   Fluorescence activated cell sorting 
FADD  Fas associated death domain protein 
FCS  Fetal calf serum  
FDA  Food and Drug Administration 
FDR  False discovery rate 
G 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP  Green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GRB2  Growth factor receptor-bound protein 2 
H 
HCP5  HLA complex 5 
HER2  Human epidermal growth factor receptor 2 
HGF  Hepatocyte growth factor 
HK2  Hexokinase 2 
HLA  Human Leukocyte Antigen  
hPSCs  Human pluripotent stem cells 
HS  Heparan sulphate 
HSBP1 Heat Shock Factor Binding Protein 1 
I 
IDO  Indoleamine 2,3 dioxygenase 
IgG  Immunoglobulin G 
IL-2  Interleukin 2 
IFN-γ  Interferon gamma 
iPSCs  Induced pluripotent stem cells 
  List of abbreviations 
XII 
ITAM  Immunoreceptor tyrosine-based activation motif 
ITIM  Immunoreceptor tyrosine-based inhibition motif 
ITSM  Immunoreceptor tyrosine-based switch motifs 
K 
KHCO3 Potassium bicarbonate   
KIR   Killer cell immunoglobulin-like recepotors 
KLR  Killer cell lectin-like receptors 
KLRG1 Killer cell lectin-like receptor subfamily G member 1 
L 
L1AM  L1 cell adhesion molecule 
LB  Lysogeny broth 
LCK  Lymphocyte cell-specific protein-tyrosine kinase 
LIR  Killer lectin-like receptors 
M 
MEK  Mitogen-activated protein kinase 
MFI  Median fluorescence intensity 
MHC  Major histocompatibility complex  
MICA/B MHC class I chain-related genes A/ B 
MLST8 Mammalian lethal with SEC13 protein 8 
MLL5  Mixed lineage leukemia-5 
MOMP Mitochondrial outer membrane permeabilisation 
mSIN1  Target of rapamycin complex 2 subunit MAPKAP1 
mTOR  Mammalian target of rapamycin 
N 
NaCl  Sodium chloride 
NaF  Sodium fluoride 
NaN3  Sodium azide 
NAPSA Napsin A aspartic peptidase 
  List of abbreviations 
XIII 
NCR   Natural cytotoxicity receptors  
NH4Cl  Ammoniumchlorid 
NK cells Natural killer cells 
NKiToxMel NK cell-induced cytotoxicity against melanoma cells 
NRAS  Neuroblastoma RAS viral oncogene homolog 
O 
OXPHOS Oxidative phosphorylation 
P 
PBLs  Peripheral blood lymphocytes 
PBMCS Peripheral blood mononuclear cells 
PCA  Principal component analysis 
PDGFRB Platelet derived growth factor receptor beta 
PEA15  Proliferation and apoptosis adaptor protein 15 
PEG2  Prostaglandin E2 
PD-1  Programmed death 1 
PDGF  Platelet-derived growth factor 
PDK1  Pyruvate dehydrogenase kinase 1 
PFA  Paraformaldehyde 
PGR  Progesterone receptor 
PI3K  Phosphatidylinositol-3-kinase 
PI-3,4,5-P3 Phosphatidylinositol-3,4,5-triphosphate  
PI-4,5-P2 Phosphatidylinositol-4,4-bisphosphate 
PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha 
PKC  Protein kinase C 
PMSF  Phenylmethanesulfonyl fluoride 
PRAS40 Proline-rich Akt substrate of 40 kDa 
Protor 1 / 2 Protein observed with Rictor-1/-2 
PTEN  Phosphatase and tensin homolog deleted on chromosome 10 
  List of abbreviations 
XIV 
PTK2  Protein Tyrosine Kinase 2 
Q 
qPCR  Quantitative polymerase chain reaction 
R 
RAS  Rat sarcoma 
RAF  Rapidly accelerated fibrosarcoma 
RAPTOR Regulatory-associated protein of TOR 1 
RICTOR Rapamycin-independent companion of mTOR complex 2 
RNA  Ribonucleic acid 
RPPA  Reverse phase protein array 
RPS6  Ribosomal protein S6 
RPS6K Ribosomal protein S6 kinase 
RPS6KB1 Ribosomal protein S6 kinase B1 
RT  Room temperature 
S 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Standard error of the mean  
SGK1  Serum/glucocorticoid regulated kinase 1 
siRNA  small interfering RNA 
SMAC  Second mitochondria-derived activator of caspase 
SNPs  Single nucleotide polymorphisms 
T 
TCR  T cell receptor 
TEL2  Tel-related Ets factor 
TEMED Tetramethylethylenediamine 
TFs  Transcription factors 
TFRC  Transferrin receptor 
  List of abbreviations 
XV 
TGF-β  Transforming growth factor β 
TGM2  Transglutaminase-2 
TIGIT  T-cell immunoreceptor with Ig and ITIM domains 
TMEM158 Transmembrane protein 158 
TNF-β  Tumour necrosis factor beta 
TRAIL  TNF-related apoptosis inducing ligand 
Tregs  regulatory T cells 
TriKEs Tri-specific killer engagers 
TTI1  TELO2-interacting protein 1 homolog 
TWIST1 Twist-related protein 1 
U 
ULBPs  UL16-binding proteins 
UV  Ultraviolet  
V 
VDAC  Voltage-dependent anion channel 
VGP  Vertical growth phase 
W 
WT  Wild type 
WWTR1 WW Domain Containing Transcription Regulator 1 
X 
XIAP  X chromosome-linked inhibitor of apoptosis 
XBP1  X-Box binding protein 1 
XRCC1 X-Ray Repair Cross Complementing 1 
Y 
YBX1  Y-box-binding protein 1 
Z 
ZEB1  Zinc finger E-box-binding homeobox 1 
 
  List of abbreviations 
XVI 
Units 
°C  Centigrade 
Rpm   Rounds per minute 
g  Gram 
h   Hour 
l   Litre 
m  Meter 
mg  Milligram 
min   Minute 
U  Units 
V   Volt 
Prefix 
c   Centi (10-2) 
k   Kilo (103) 
µ  Micro (10-6) 
m   Milli (10-3) 
n  Nano (10-9) 
p   Pico (10-12) 
 
  List of figures 
XVII 
List of figures 
Figure 1. The RAS-RAF signalling pathway ............................................................................................. 3 
Figure 2. The PI3K/AKT/mTOR pathway ............................................................................................ 5 
Figure 3. Inhibitory NK cell receptors and their corresponding tumour ligands ............................... 9 
Figure 4. Activating NK cell receptors and their corresponding tumour ligands............................. 11 
Figure 5. Principles of NK cell-mediated tumour recognition ............................................................ 12 
Figure 6. The cytotoxic signalling cascade .............................................................................................. 14 
Figure 7. The immunoediting process ..................................................................................................... 19 
Figure 8. Real-time killing assay ............................................................................................................... 40 
Figure 9. Principle of the Reverse Phase Protein Array (RPPA)......................................................... 51 
Figure 10. Effector-to-target ratio determines effect size of NK cell killing..................................... 53 
Figure 11. Interleukin-2 stimulation increases cytotoxicity against cancer cells ................................ 55 
Figure 12. Interleukin-2 stimulation alters expression profile of NK cells ........................................ 57 
Figure 13. NK cell cytotoxicity stays nearly unchanged in the course of Interleukin-2 
stimulation ................................................................................................................................ 58 
Figure 14. NK cell-mediated killing of melanoma cell lines is heterogeneous .................................. 60 
Figure 15. MHC class I expression does not explain the susceptibility of melanoma cells 
towards NK cell killing ........................................................................................................... 61 
Figure 16. Activating ligands partially explain the susceptibility of melanoma cells towards NK 
cells ............................................................................................................................................ 62 
Figure 17. Melanoma protein signature determines susceptibility to primary NK cells .................. 64 
Figure 18. Linear regression analysis of the melanoma killing signature is used to establish a 
killing prediction model ......................................................................................................... 66 
Figure 19. Validation of the prediction model ....................................................................................... 68 
Figure 20. DIABLO abundance in melanoma correlates with their susceptibility to NK cells ..... 69 
Figure 21. GFP signal does not interfere with calcein-AM detection ................................................ 70 
Figure 22. Overexpression of DIABLO does not change susceptibility of melanoma towards 
NK cells .................................................................................................................................... 71 
Figure 23. DIABLO knockdown slightly increases susceptibility of melanoma towards NK 
cells ............................................................................................................................................ 72 
Figure 24. The expression of SNAI1 in melanoma cells is associated with their susceptibility 
to NK cells ............................................................................................................................... 73 
Figure 25. Overexpression of SNAI1 increases the susceptibility of melanoma cells towards 
NK cells .................................................................................................................................... 74 
Figure 26. Susceptibility of melanoma cell lines to NK-92 is heterogeneous ................................... 75 
Figure 27. Melanoma NK-92 killing signature determines susceptibility to NK-92 cells................ 77 
Figure 28. Effect size of the individual proteins from the melanoma killing signature might 
limit success of manipulating single hits .............................................................................. 80 
Figure 29. The effect of drugs targeting the PI3K-AKT-mTOR pathway on melanoma cell 
viability ...................................................................................................................................... 82 
Figure 30. Rapamycin decreased the susceptibility of melanoma cells to primary NK cells .......... 84 
Figure 31. MK2206 and BKM120 partially decreased melanoma cell susceptibility to NK cells .. 86 
Figure 32. Rapamycin treatment does not affect susceptibility of K562 to NK cells ...................... 87 
  List of figures 
XVIII 
Figure 33. Control experiments support altered melanoma cell susceptibility to NK cells after 
inhibitor treatments ................................................................................................................ 89 
Figure 34. Melanoma cell proliferation correlates with NK cell susceptibility. ................................. 90 
Figure 35. Melanoma staging is associated with increasing susceptibility of melanoma cells to 
NK cells. ................................................................................................................................... 91 
Figure 36. Development of NK cell resistance during melanoma-NK cell-co-cultures .................. 93 
Figure 37. Irradiated NK cells showed reduced but sufficient cytotoxicity against cancer cells .... 94 
Figure 38. WM3734-NK-92-co-cultures have reduced susceptibility to NK-92 cells ..................... 95 
Figure 39. Short-term (24 h) co-cultures with NK-92 reduces the susceptibility of melanoma 
cells to NK-92 and induce cross-resistance to primary NK cells .................................... 96 
Figure 40. 1205Lu-NK-92-co-cultures and cross-resistance to primary NK cells ........................... 97 
Figure 41. Principal component analysis (PCA) of WM3734-NK cell-co-cultures .......................... 98 
Figure 42. Pooling of samples for RNA sequencing analysis .............................................................. 98 
Figure 43. Melanoma cell phenotype determines susceptibility to NK cell killing. ........................ 110 
  List of tables 
XIX 
List of tables 
Table 1. Primary antibodies ...................................................................................................................... 21 
Table 2. Secondary antibodies .................................................................................................................. 21 
Table 3. Fluorochrome labelled antibodies ............................................................................................ 21 
Table 4. Purchased buffers........................................................................................................................ 22 
Table 5. Prepared buffer solutions........................................................................................................... 23 
Table 6. Chemicals ..................................................................................................................................... 24 
Table 7. Inhibitors ...................................................................................................................................... 26 
Table 8. Kits ................................................................................................................................................ 26 
Table 9. Laboratory devices ...................................................................................................................... 27 
Table 10. Purchased media ....................................................................................................................... 28 
Table 11. qRT Primer ................................................................................................................................ 29 
Table 12. Silencing RNA ........................................................................................................................... 30 
Table 13. Nucleotides ................................................................................................................................ 30 
Table 14. Cell lines ..................................................................................................................................... 31 
Table 15. Mammalian expression plasmids ............................................................................................ 32 
Table 16. Splitting ratio of cells ................................................................................................................ 33 
Table 17. qRT- PCR reaction mix............................................................................................................ 44 
Table 18. qPCR Cycling Program ............................................................................................................ 44 
Table 19. mRNA sequencing melanoma samples ................................................................................. 46 
Table 20. SDS matrix ................................................................................................................................. 49 
Table 21. Correlation of melanoma protein expression with NK cell susceptibility ........................ 65 
Table 22. Correlation of melanoma protein expression with NK-92 cell susceptibility .................. 76 
Table 23. Common differentially expressed genes ................................................................................ 99 
 
List of supplemental tables 
Supplemental table 1. DGE analysis of WM3734 after co-culturing with primary NK cells ....... 126 
Supplemental table 2. DGE analysis of WM3734 after co-culturing with NK-92 cells ................ 128 
Supplemental table 3. DGE analysis of WM3734 after recovering of NK-92-co-culturing ......... 131 
Supplemental table 4. DGE analysis of co-culture-recovered WM3734 compared to CTRL ...... 133 
 
  
  Abstract 
XX 
Abstract 
Malignant melanoma is the deadliest form of skin cancer. Due to its genetic heterogeneity and 
high potential to metastasize, the treatment of melanoma is challenging. Despite the promising 
result of T-cell based therapeutic strategies in combination with targeted therapies, therapeutic 
resistance or relapse occur. Hence, the advancement and improvement of melanoma 
immunotherapies need to be considered.  
Natural killer (NK) cells, which show an innate ability to recognize and kill cancer cells without 
prior sensitization, could be a useful additional therapeutic tool in melanoma immunotherapy. To 
investigate the therapeutic potential of NK cells, we assessed the cytotoxicity of primary NK cells 
as well as the NK-92 cell line to genetically diverse human melanoma cell lines. A broad range of 
susceptibility of different melanomas to activated NK cells was observed. Proteome analyses 
(RPPA) of melanoma cells indicated a correlation between melanoma protein expression and 
susceptibility to NK cells and allowed the establishment of a ‘melanoma killing signature’. Using 
this novel tool the NK cell-mediated killing of additional and untested melanoma cell lines was 
successfully predicted. Furthermore, manipulation of single identified proteins such as SNAI1 
and signalling pathways such as the PI3K-AKT-mTOR pathway affected the NK cell-mediated 
killing of melanoma cells.  
The success of immune therapy is not only dependent on the initial positive treatment effect but 
also the prevention of therapy resistance. Therefore, melanoma-NK cell co-cultures in order to 
identify new molecular targets, which might control NK cell escape mechanisms in melanoma, 
were established. NK cell resistance in melanoma cells seems to be strongly associated with the 
downregulation of MHC class I but also MHC class II molecules.  
In summary, this study identifies novel prognostic immunotherapy-response biomarkers and 
possible resistance mechanism and thus reveals new insights into the potential use of NK cells in 





  Introduction 
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1 Introduction 
1.1 Malignant melanoma: definition, origin, risk factors 
Skin cancers are the most common type of cancer (American cancer society, 2019). There are two 
major types of skin cancer: non-melanoma skin cancers, including basal-cell skin cancer (BCC) 
and squamous-cell skin cancer (SCC), and melanoma. Melanoma arises from genetically altered 
melanocytes, which in normal tissue are known to produce the pigment melanin (Shain and 
Bastian, 2016). Though malignant melanoma is less frequent than the other skin cancers, it is 
much more aggressive and lethal than other skin cancers (Siegel et al., 2019). Globally, 132.000 
new melanoma skin cancers are diagnosed every year (World Health organization, 2020). Of 
those, around 20.000 new cases alone are reported for Germany (Robert-Koch-Institut and e.V., 
2017). The incidence of melanoma has been increasing worldwide over the last two decades, 
especially in Australia, North America and Europe (American cancer society, 2019; Robert-Koch-
Institut and e.V., 2017; World Health organization, 2020). The risk factors of this disease are 
diverse as the development of melanoma is a complex multifactorial process. One of the major 
environmental risk factors is the exposure to UV radiation (Gandini et al., 2005b; Kulichova et 
al., 2014) and a history of sunburns (Whiteman et al., 2001). Especially the exposure to UVB can 
cause genetic damage and can initiate the malignant transformation of melanocytes (Jhappan et 
al., 2003). In the course of a lifetime, UV induced DNA damage accumulates and thereby also the 
risk to develop a malignant melanoma (Siegel et al., 2019). In addition to the UV irradiation, 
other endogenous factors also contribute to the melanoma risk. Fair skin (Howlader et al., 2018; 
Scherer and Kumar, 2010), the number (Bauer and Garbe, 2003; Holly et al., 1987) and type of 
melanocytic nevi (moles) (Gandini et al., 2005a; Grob and Bonerandi, 1998), as well as a family 
history (Debniak, 2004) which can be often associated with a certain genetic predisposition 
(Potrony et al., 2015), correlate with melanoma incidence.  
1.2 Melanoma progression: Important signalling pathways  
The survival rate associated with malignant melanoma strongly depends on disease stage and the 
mutation status of the patient’s tumour. After the development of distant metastasis, the survival 
rate decreases to 6-9 months (Balch et al., 2009). Therefore, not only an early disease diagnosis 
but also the administration of an effective patient personalized treatment to prevent disease 
progression is required. During melanoma development and progression, different signalling 
pathways contribute to cell proliferation and survival. These include:  
  Introduction 
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1.2.1 The RAS-RAF signalling pathway 
One of the most frequently mutated pathways in melanoma is the RAS-RAF signalling cascade 
(Davies et al., 2002). The starting point of this signalling pathway is the binding of an external 
ligand such as growth factors or cytokines to the extracellular side of a receptor tyrosine kinase. A 
subsequent phosphorylation cascade, involving rat sarcoma (RAS), rapidly accelerated 
fibrosarcoma (RAF), mitogen-activated protein kinase (MAP2K or MEK) transfer the signal via 
extracellular signal-regulated kinase (ERK) to the cell nucleus. The translocated ERK can activate 
several transcription factors and influence the expression of genes controlling cell growth and cell 
death (see Figure 1). Hence, mutations in these kinases often cause a constantly activated 
signalling pathway that contributes to dysregulated proliferation (Lopez-Bergami et al., 2008). 
Mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B), mostly V600E 
substitutions, are found in 35 %–50 % of melanoma whereas neuroblastoma RAS viral oncogene 
homolog (NRAS) is mutated in 10-25 % of melanoma lesions (Cancer Genome Atlas, 2015; 
Davies et al., 2002). The RAF-MEK-ERK pathway is upregulated in most melanocytic lesions, 
although additional genetic alterations, through mutations or other factors is not sufficient for the 
initiation of melanoma (Poynter et al., 2006). Nevertheless, mutations in BRAF and NRAS are 
associated with a poor prognosis and favour tumour progression (Houben et al., 2004; Kumar et 
al., 2003). Therefore, inhibitors targeting mutated BRAF or MEK are one of the frontline 
treatment strategies to halt or slow disease progression (Deutsche Krebsgesellschaft et al., 2019).  
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Figure 1. The RAS-RAF signalling pathway. Binding of growth factors to the extracellular side of a 
receptor tyrosine kinase triggers an intracellular phosphorylation cascade through RAS, BRAF and MEK 
that in turn activates ERK. This final kinase is translocated to the nucleus where it activates several 
transcription factors that mediate expression of genes promoting cell proliferation and survival. As a result 
of mutations in BRAF (e.g. BRAF V600E) or other downstream kinases, this signalling pathway cascade is 
often constitutively active in melanoma. Figure was adopted from (Cappello, 2015). 
1.2.2 The PI3K/AKT/mTOR pathway  
Another key player in multiple malignant processes is the pI3K/AKT/mTOR network shown in 
Figure 2 (Chalhoub and Baker, 2009; Saxton and Sabatini, 2017). Activation of receptor tyrosine 
kinase receptors or G protein‑coupled receptors recruits phosphatidylinositol-3-kinase (PI3K) to 
the membrane. There, PI3K phosphorylates phosphatidylinositol-4,4-bisphosphate (PI-4,5-P2) to 
phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3), which recruits protein kinase B, also called 
AKT to the plasma membrane (Porta et al., 2014). The phosphorylation of AKT by pyruvate 
dehydrogenase kinase 1 (PDK1) (at threonine 308) and mammalian target of rapamycin complex 
2 (at serine 473) modulates AKT activity (Sarbassov et al., 2005).  
In melanoma, the AKT activation (phosphorylated AKT) is strongly increased and correlates 
with disease progression (Dai et al., 2005). A common reason for the AKT activation in 
melanoma is the reduction of PTEN (phosphatase and tensin homolog deleted on chromosome 
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dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-
bisphosphate (Simpson and Parsons, 2001). Thereby the activation of AKT is promoted and cell 
survival is supported (Miller and Mihm, 2006). The gene PTEN is mutated in 30-50 % of 
melanoma cell lines and in ~ 10 % of primary melanomas (Guldberg et al., 1997; Wu et al., 2003) 
but also alterations at the protein level can occur without any gene mutation (Zhou et al., 2000). 
Also mutations in AKT itself have been found and show increased phosphorylated AKT levels in 
melanoma as well as other cancers (Davies et al., 2008). AKT has many different downstream 
targets, which regulate cell metabolism. One of them is the mammalian target of rapamycin 
(mTOR) complex 1, referred to as mTORC1. This complex consists of mTOR and six other 
proteins (see Figure 2) that regulate the functionality of the whole complex (assembly, substrate 
specificity as well as the stability) (Laplante and Sabatini, 2012). The central part of this complex 
is the catalytic serine/threonine kinase mTOR that has substrates involved in various cellular 
processes. Best characterised is the involvement of the mTOR pathway in regulating protein 
synthesis by the activation of p70S6 kinase as well as the phosphorylation of eukaryotic 
translation initiation factor 4E binding protein 1 (4E-BP1) (Ma and Blenis, 2009). Besides 
mTORC1, a second mTOR-containing complex exists. The mTORC2 consist of seven proteins 
that show overlap with mTORC1 (Figure 2). Upon mTORC1 stimulation, mTOR activates 
p70S6 kinase and inactivates 4E-BP1 to promote cell proliferation and survival (Proud, 2011). 
Beside the AKT activation, the mTOR complex 2 regulates cytoskeletal organisation and cell 
survival. In contrast to mTORC1, mTORC2 shows low sensitivity to rapamycin, a potent mTOR 
inhibitor (Saxton and Sabatini, 2017). 




Figure 2. The PI3K/AKT/mTOR pathway. The activation of a receptor tyrosine kinase by a growth 
factor leads to the phosphorylation of the intracellular tyrosine residues. This recruits PI3K to the 
membrane where it phosphorylates PIP2 to PIP3. This process can be reversed by PTEN. PIP3 recruits 
AKT that is phosphorylated at S473 by the mTORC2, and at T308 by PDK1. Activated AKT leads to the 
indirect activation of the mTORC1 by repressing the tuberous sclerosis proteins 1 and 2 (TSC1/2) 
complex. The mTORC1 stimulates protein synthesis and proliferation via the activation of p70S6 kinase 
and inhibition of the 4E-BP1. Beside the indirect activation of mTORC1, also the mTORC2 can stimulate 
cell survival via serum and glucocorticoid-regulated kinase 1 (SGK1). Furthermore, it regulates the 
cytoskeleton organisation by phosphorylation of protein kinase C (PKC). Figure was adopted from (Yu 
and Cui, 2016). 
1.2.3 Epithelial-to-mesenchymal transition (EMT)-like phenotype switching  
During malignant transformation and the metastatic process, melanocytes as well as melanoma 
cells experience an epithelial-to-mesenchymal transition (EMT)-like phenotype switch (Li et al., 
2015a). Although melanocytes originate from the neural crest and are not of epithelial lineage, 
they also undergo a phenotype switch with similar characteristics as EMT. In the course of this 
phenotype switch, melanoma cells undergo morphological as well as functional changes by losing 
epithelial characteristics such as cell polarity and cell-cell adhesion. At the same time they gain 
mesenchymal properties including high potential for migration and invasion (Derynck and 
Weinberg, 2019). These properties are caused among others by the loss of E-cadherin and an 
increase in N-cadherin expression (Kuphal and Bosserhoff, 2006; Yan et al., 2016). This switch of 
cadherin class is regulated by different transcription factors (TFs) such as Zinc finger E-box-
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regulating EMT is the zinc finger protein snail family transcriptional repressor 1 (SNAI1) which 
represses E-cadherin expression (Kaufhold and Bonavida, 2014; Poser et al., 2001). It has been 
shown that the aberrant expression of EMT transcription factors and the corresponding 
alteration of cadherin class expression correlate with melanoma metastasis and poor prognosis 
(Caramel et al., 2013; Yan et al., 2016).  
1.3 Anti-melanoma therapies 
The treatment of melanoma is strongly dependent on cancer stage and genetics i.e. the mutational 
profile of the disease (Deutsche Krebsgesellschaft et al., 2019). At early stages, when melanoma 
cells are still non-invasive (Stage 0, melanoma in-situ) or only invaded in the upper parts of the 
dermis (Stage I, Breslow depth < 1mm), the affected section of the skin can be removed by 
excisional surgery. After melanoma cells have reached deeper regions of the dermis (Stage II, 
Breslow depth > 1mm) not only the primary tumour has to be removed, but also the spreading 
of melanoma cells to lymph nodes (Stage III) has to be excluded by sentinel lymph node biopsy. 
Adjuvant radiotherapy can reduce the risk of melanoma recurrence (Strojan, 2010). The last stage 
(IV) of melanoma is characterised by distant metastasis. With melanoma progression (Stage II-
Stage IV) the administration of additional drugs or immune-treatments to dampen tumour 
growth and prevent metastasis are recommended (American cancer society, 2020; The Skin 
Cancer Foundation, 2020). Conventional chemotherapy with, for example dacarbazine or 
cisplatin, is no longer used as a frontline therapy since other treatment strategies have shown 
better clinical results and less side effects (Wilson and Schuchter, 2016). A common therapeutic 
approach involves the use of targeted therapies that interfere with tumour cell proliferation as 
well as survival. The RAS-RAF signalling pathway (see chapter 1.2.1) plays an important role in 
tumour proliferation and patient survival and it is a frequent therapeutic target (Houben et al., 
2004; Kumar et al., 2003). Selective drugs such as vemurafenib, dabrafenib and encorafenib 
supress the activity of RAF and prevent the initiation of the signalling cascade (Chapman et al., 
2011; Koelblinger et al., 2018; Menzies and Long, 2014). Unfortunately, these drugs are only 
effective in melanoma patients with mutated constitutively active BRAF (most commonly 
V600E). When used in BRAF wildtype patients, adverse effects can be detected since these drugs 
can cause higher RAF signalling by inducing dimerization, membrane localization and interaction 
with RAS-GTP (Hatzivassiliou et al., 2010). Beside the suppression of BRAF, targeting its 
signalling downstream partner MEK has also been effective in the clinics with drugs such as 
trametinib, cobimetinib and binimetinib (Menzies and Long, 2014; Samatar and Poulikakos, 
2014). Another target for the inhibition of melanoma proliferation is the PI3K/AKT/mTOR 
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pathway (see chapter 1.2.2), that can be blocked with multiple drugs at different levels of the 
signalling chain. BKM-120 (Buparlisib) and other PI3K inhibitors are currently being tested in 
several clinical trials (Yang et al., 2019). In addition, the mTOR inhibitor rapamycin 
(Sirolimus/Everolimus) and the AKT inhibitor MK2206 (Dronca et al., 2014) in combination 
with other drugs showed promising clinical activity (Domingues et al., 2018). However, these are 
not considered as frontline therapeutic options yet (Deutsche Krebsgesellschaft et al., 2019). 
In the recent years, especially immune checkpoint blockade therapies have been successful in 
melanoma treatment (Seidel et al., 2018). These therapies are based on the decreased activation 
threshold of cytotoxic T-cells (CTLs). CTLs are part of the adaptive immune system and detect 
specific antigens in association with MHC class I molecules by the T-cell receptor (TCR) (Smith-
Garvin et al., 2009). However, this signal alone is not sufficient to activate CTLs. The additional 
engagement of B7-molecules with CD28, which is expressed on CTLs, allows positive co-
stimulation and activation (Smith-Garvin et al., 2009). To prevent autoimmunity, this process is 
regulated by cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4). CTLA-4 competes with 
CD28 for binding to B7 molecules and extenuate the CTL response (Rowshanravan et al., 2018). 
Currently, these processes can be regulated by immunotherapies, for example, the anti-CTLA-4 
antibodies ipilimumab and tremelimumab inhibit the interaction of CTLA-4 with B7 molecule 
expressing antigen presenting cells (APC) thus enhancing T-cell activation (Domingues et al., 
2018; Seliger et al., 2013). Beside CTLA-4, another target for immunotherapy is the inhibitory 
receptor PD-1 (programmed death 1); PD-1 dampens T-cell function by binding to its ligands 
PD-L1 and PD-L2. In melanoma, the ligands for PD-1 are also commonly expressed (Kitano et 
al., 2018). Antibodies targeting the PD-1/PD-L1 axis such as nivolumab and pembrolizumab 
(anti-PD-1) (Postow et al., 2015; Wei et al., 2018) are in the clinical use. Both antibodies, alone 
and combined, show encouraging effects in melanoma treatment (Larkin et al., 2015). In addition, 
PD-L1 antibodies such as atezolozumab and avelumab entered first clinical trials (Keilholz et al., 
2019; Sullivan et al., 2019).  
Former immunotherapeutic approaches include the use of immune-stimulating interleukin-2      
(IL-2) that was abandoned despite initial promising results due to the toxic side-effects in higher 
dosages (Hoffman et al., 1989; Rosenberg et al., 1985). In addition, the administration of INF-γ 
was shown to stimulate immune response and decrease tumour growth by promoting tumour cell 
apoptosis and inhibiting of tumour proliferation (Castro et al., 2018; Ni and Lu, 2018). However, 
clinical success of INF-γ treatment in melanoma as well as other cancers was limited due to its 
role in immune evasion and an observed INF-γ insensitivity in melanoma patients (Alavi et al., 
2018; Castro et al., 2018). 
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Current subject of clinical trials is the adoptive cell transfer (ACT) of autologous tumour-
infiltrating lymphocytes to attack melanoma cells. The ex vivo expansion and transfer of 
autologous, activated tumour-specific lymphocytes to melanoma patients showed promising 
clinical results (Mehta et al., 2018; Phan and Rosenberg, 2013; Rohaan et al., 2018; Saint-Jean et 
al., 2018). 
Nevertheless, the clinical response to targeted therapies as well as immune checkpoint blockade is 
limited as not all patients respond or can relapse (Almeida et al., 2019; Petrova et al., 2020; Seidel 
et al., 2018). Hence, the development of alternative therapeutic strategies that complement or 
improve current therapies is highly needed.  
1.4 Natural killer cells 
The success of current immunotherapies is usually attributed to the improvement of T-cell 
cytotoxicity against cancer cells. However, natural killer cells (NK cells) are also able to detect 
and eliminate tumour cells. Natural killer cells develop in the bone marrow and represent up to 
15 % of all lymphocytes (Abel et al., 2018). They are characterised as CD3 negative and CD56 
positive cells and can be divided into two major NK cell subsets differing in their CD16 and 
CD56 expression as well as their resting immunological potential (Freud et al., 2017). For 
example, CD16++ CD56dim NK cells show increased cytotoxicity in comparison to CD16± 
CD56bright NK cells (Arnon et al., 2006). However, these CD56bright NK cells have important 
immune regulatory functions by increased cytokine production of e.g. Interferon gamma (IFN-γ), 
tumour necrosis factor beta (TNF-β) as well as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), among others (Cooper et al., 2001). After stimulation with interleukin (IL)-2, 
both NK cell subsets increase their cytotoxic potential dramatically (Poli et al., 2009). In contrast 
to CTLs, NK cells are part of the innate immune system and are cytotoxic without previous 
antigen-specific stimulation (Farag and Caligiuri, 2006). Furthermore, NK cells complement the 
immunosurveillance of T-cells, which are dependent on the engagement of TCR and MHC-I 
antigens (Freud et al., 2017). MHC-I molecules are often downregulated in tumour cells, so these 
cells can evade T-cell recognition. However, tumour cells with particularly low MHC-I expression 
can be detected and eliminated by NK cells (Karre, 2002).  
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1.4.1 NK cell receptors 
NK cells recognise tumour cells by their large repertoire of germ-line encoded receptors, which 
have different structural and functional properties. Therefore, NK cell receptors can be divided 
into killer cell immunoglobulin-like receptors (KIR) and killer cell lectin-like receptors (KLR) 
(Murphy, 2012). Besides their structural properties, they can be further classified into activating 




Inhibitory receptors have an immunoreceptor tyrosine-based inhibition motif (ITIM), a long 
cytoplasmic domain with a conserved terminal amino acid sequence (V/I/LxYxxL/V). This 
ITIM contains tyrosine residues that can be phosphorylated by proto-oncogene tyrosine-protein 
kinase Src thus initiating a signalling cascade. After receptor-ligand engagement, the signal 
transduction results in the inhibition of NK cell activity, thereby preventing the elimination of the 
target cell (Cerwenka and Lanier, 2001; Farag and Caligiuri, 2006; Yokoyama, 2005). One of the 
best investigated inhibitory ligands are the major histocompatibility complex class I (MHC class 
I) molecules. As depicted in Figure 3, classical MHC-I molecules (HLA-A, B, C) are detected by 
KIR2DL (recognizes HLA-C alleles) and KIR3DL (recognizes HLA A, B alleles). Beside these 
KIR receptors, the lectin like NKG2A/CD94 heterodimer recognises HLA-E, a non-classical 
MHC-I molecule (Sivori et al., 2019). Although MHC-I molecules are the strongest inhibitory 
ligands, there are reports that stimulation of non-MHC-I dependent receptor can also dampen 
NK cell activation (Li et al., 2009; McNerney et al., 2005) 
 
Figure 3. Inhibitory NK cell receptors and their corresponding tumour ligands. 2DL/3DL indicate 
the number and type of immunoglobulin domains and, L= long cytoplasmic domain; NKG2A, B, are 













In contrast to the inhibitory receptors, activating receptors need an adapter molecule that carries 
the conserved terminal sequence YXX[L/I]6-9YXX[L/I]. This sequence is named 
immunoreceptor tyrosine-based activating motif (ITAM) and it initiates a phosphorylation 
cascade resulting in the activation of NK cells (Murphy, 2012). With the help of the adapter 
molecule DAP12, the KIR receptors KIR2DS and KIR3DS recognize HLA-C and other 
unknown ligands (Cerwenka and Lanier, 2001). The same adapter molecule DAP12 is used by the 
heterodimer CD94/NKG2C,E that detects HLA-E. These activating receptors compete with 
their inhibitory counterparts, but with a lower ligand affinity (Bryceson et al., 2006).  
The most important example of the activating KLR receptor is NKG2D. This receptor, unlike 
the other lectin like receptors, is a homodimer that is associated with the adaptor molecule DAP 
10. This adaptor molecule carries a phosphatidylinositol-3 kinase (PI3K) binding motif YxxM 
instead of an ITAM (Bryceson et al., 2006; Kumar, 2018). MIC (MHC class I chain-related genes) 
A and B as well as UL16-binding proteins 1-6 (ULBPs) are ligands for NKG2D (Casado et al., 
2009; Vivier et al., 2012). Essential members of the activating KIR receptors are the three natural 
cytotoxicity receptors (NCRs): NKp46, NKp30 and NKp44. The latter is de novo expressed after 
IL-2 stimulation, whereas NKp46 and NKp30 are constitutively expressed on NK cells (Arnon et 
al., 2006). NCRs also require an adapter molecule for signal transduction. In contrast to NKp44, 
which associates with the adaptor molecule DAP12, NKp46 and NKp44 use homodimers of 
CD3 ζ or heterodimers of CD3 ζ -FcεRγ heterodimers to initiate the phosphorylation cascade 
(Arnon et al., 2006). Although the ligands for NCRs are still not fully understood, the identified 
ligands are often only expressed on tumour cells or virus-infected cells. All natural cytotoxicity 
receptors recognize different viral proteins; e.g. hemagglutinins or hemagglutinin neuraminidases 
(Kruse et al., 2014) as well as heparan sulphate (HS) sequences, which are also shown to be 
upregulated on tumour cells (Barrow et al., 2019).  
Beside heparan sulphates (HS), the complement factor P (CFP) is a known ligand for the NCR 
NKp46 (Narni-Mancinelli et al., 2017). NKp30a, b is known to bind BCL2-associated 
athanogene 6 (BAG-6) (Binici et al., 2013) as well as B7-H6, which is only expressed on tumour 
cells (Bjornsen et al., 2019). Identified activating ligands for NKp44 (NKp44L) are an unusual 
isoform of MLL5 (mixed lineage leukemia-5), often referred as NKp44L (Rajagopalan and Long, 
2013) and PDGF-DD, one of the four polypeptides of the platelet-derived growth factor 
(PDGF) (Barrow et al., 2018). 
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Figure 4. Activating NK cell receptors and their corresponding tumour ligands. 2DS/3DS indicate 
the number and type of immunoglobulin domain; S= short cytoplasmic domain. Adaptor proteins and 
binding motifs are also shown in colour. Figure was adopted from (Cappello, 2015). 
Several other activating receptors were also shown to play an important role in tumour 
recognition. The DNAX Accessory Molecule-1 (DNAM-1), recognizes poliovirus receptor 
(CD155) and nectin adhesion molecule (CD112) (Chester et al., 2015; Long et al., 2013). The 
DNAM-1-mediated signalling cascade requires the phosphorylation of conserved tyrosine as well 
as asparagine residues (Kumar, 2018). The receptor CD244, also known as 2B4, leads to NK cell 
activation by the engagement to CD48 and the subsequent phosphorylation of Tyr-based motif 
S/TxYXXL/I, referred to as immunoreceptor Tyr-based switch motifs (ITSM), in their cytosolic 
tails (Chester et al., 2015; Kumar, 2018). 
In addition, CD16 plays a special role among the activating receptors, as it can to induce 
antibody-dependent cellular cytotoxicity (ADCC). CD16 is an Fεcγ receptor, which can bind 
antibodies, such as IgG. Therefore, NK cells are able to recognize antibody-coated target cells 
and act as mediators between innate and adaptive immunity. 
1.4.2 NK cell recognition of tumour cells 
The ‘missing self’ hypothesis of Klas Kärre was the first attempt to describe the recognition of 
tumour cells by NK cells. This hypothesis is based on the observation that tumour cells 
expressing low or no MHC class I molecules are more susceptible to NK cells than healthy 
(MHC-I positive) cells (Kärre, 1985). Nevertheless, the lack of inhibitory signals alone was shown 
to be insufficient to trigger NK cell activation and initiate tumour cell lysis (Arnon et al., 2006; 
Lanier, 2005). In fact, the balance of signals derived from all activating and inhibitory receptors 
determines the final NK cell activation status (summarised in Figure 5) (Dustin and Long, 2010). 
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inhibitor receptors tend to be stronger and overrule the signals from the activating receptors 
(Long et al., 2013). However, the integration of several activating stimuli can overcome the 
inhibitory signals, thus allowing the initiation of a cytotoxic signal cascade in the target cell 
(Cerwenka and Lanier, 2001). 
 
 
Figure 5. Principles of NK cell-mediated tumour recognition. NK cells have a large repertoire of 
activating and inhibitory receptors, which allow the recognition of tumour cells. The integration of all 
arriving stimuli determine the activation status of the NK cell. The engagement of many inhibitory ligands 
prevents an activation, whereas increasing activating stimuli can overcome NK cell inhibition, leading to 
the elimination of the target cell. Figure was adopted from (Cappello, 2015). 
1.5 The cytotoxic effector mechanism 
After the formation of an immunological synapse, NK cells are able to initiate a cytotoxic 
signalling cascade in target cells (summarised in Figure 6). The initiation point of this cascade has 
either an extrinsic or an intrinsic origin. Extrinsically, NK cells express ligands such as FasL or 
TRAIL (TNF-related apoptosis inducing ligand) that bind to death receptors such as Fas or 
TRAIL-R1/2 expressed on the target cell. This external receptor-ligand binding recruits FADD 
(Fas-Associated protein with Death Domain) that binds procaspase-8 and forms the death 
inducing signalling complex (DISC). Subsequent activation of caspase-8 initiates the caspase 
cascade (Russell and Ley, 2002). Although NK cells express death receptors, the intrinsic 
















  Introduction 
13 
During the granule exocytosis pathway, granules containing perforin and granzymes, are secreted 
in the immunological synapse (Cullen and Martin, 2008). The calcium-dependent polymerisation 
of perforin monomers allows the formation of pores in the target cell membrane and endosomes 
uptaken by the target cell. These pores allow either the direct lysis of the target cell or the entry of 
granzymes into the target cell cytosol. Granzymes are serine proteases, which trigger the caspase 
cascade either through BH3-interacting domain death agonist (BID)-dependent mitochondrial 
permeabilisation or through a direct activation of caspase-3 (CASP3) (Cullen and Martin, 2008; 
Russell and Ley, 2002). Granzyme B mediates the partial proteolysis of the BH3-only protein 
BID, so that the truncated BID (tBID) can be targeted to the mitochondria. There, it initiates the 
oligomerisation of BAK (Bcl-2 homologous antagonist killer) and/or BAX (Bcl-2-associated X 
protein) in the outer mitochondrial membrane; thereby promoting cytochrome c release. 
Together with the apoptotic protease activating factor 1 (APAF-1) and procaspase-9, cytochrome 
c allows the assembly of a large complex. This so-called apoptosome leads to caspase-9 activation 
and the initiation of the caspase cascade. Extrinsic and intrinsic initiation of the cytotoxic effector 
mechanism lead to the activation of a final caspase (CASP3) that cause apoptosis (Cullen and 
Martin, 2008). 
Furthermore, the activation of this cascade is supported by the parallel mitochondrial release of 
DIABLO (Direct IAP-binding protein with low PI). This second mitochondria-derived activator 
of caspases (Smac) inhibits the X chromosome-linked inhibitor of apoptosis (XIAP), thereby 
allowing the initiation of apoptosis (Martinez-Lostao et al., 2015). The mitochondrial outer 
membrane permeabilisation (MOMP) is further controlled by the anti-apoptotic Bcl-2 family, e.g. 
B-cell lymphoma 2 (BCL-2) that antagonizes the apoptosis mediators Bcl-2 homologous 
antagonist/killer (BAK) and Bcl-2-associated X protein (BAX). The members of the Bcl-2 family 
will be negatively regulated by BH3-only proteins such as Bcl2-associated agonist of cell death 
(BAD) (Martinez-Lostao et al., 2015).  




Figure 6. The cytotoxic signalling cascade. The cytotoxic signal cascade can be activated by the 
binding of the death receptor Fas to its ligand FasL (left). After the recruitment of FADD, that activates 
caspase-8, the final caspase-3 is activated and leads to the initiation of apoptosis. The release of lytic 
granules, containing granzymes and perforin represents the second mechanism starting the cytotoxic 
signal cascade (right). Calcium- dependent polymerisation of perforin forms pores in the target cell or 
endosomes so that the granzymes can enter the cell. Especially granzyme B leads to the release of 
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1.6 NK cells in cancer immunotherapy 
 
NK cells play a crucial role in immune surveillance as their cytotoxic activity was shown to 
correlate with a generally lower cancer risk (Imai et al., 2000). Moreover, the number or type of 
tumour-infiltrating NK cells have been shown benefits in therapy response and overall patient 
survival in cutaneous melanoma (Cursons et al., 2019; Ladanyi, 2015) as well as in other cancers 
(Barry et al., 2018; Chiossone et al., 2018; Cursons et al., 2019). Nevertheless, the success of NK 
cells as a tool for immunotherapy against solid tumours belies expectations. One of the possible 
reasons for the past failure of these therapies may lie in the tumour microenvironment that could 
dampen NK cell activity (Paul et al., 2016; Terren et al., 2019). Accordingly, to maintain or even 
boost the NK cell activity in cancer patients, different therapeutic strategies have been developed.  
Cytokine-based therapies have been used to increase NK cell cytotoxicity. To this end, IL-2 was 
the first cytokine with the desired properties that showed initial promising results in cellulo and in 
animal-model based studies (Grimm et al., 1982; Hoffman et al., 1989; Miller and Lanier, 2019; 
Rosenberg et al., 1985). However, the systemic administration of IL-2 alone achieved only limited 
clinical response and had even toxic and life-threatening effects when applied at higher doses 
(Hoffman et al., 1989; Miller and Lanier, 2019). These unsatisfactory results by IL-2 
supplementation can be, at least partially, explained by the unintended expansion and activation 
of immunosuppressive regulatory T cells (Tregs) (Miller and Lanier, 2019). Furthermore, the long-
lasting administration of IL-2 induces the downregulation of the NK cell IL-2 receptors (Pillet et 
al., 2011). These difficulties can be circumvented by ex vivo activation as well as the use of other 
interleukins such as IL-15, IL-12, IL-18 or IL-21 (Nayyar et al., 2019; Zhang et al., 2020). IL-15 
was shown to be the most promising therapeutic cytokine. IL-15 not only increased NK cell 
cytotoxicity more specifically (no cross activation of Tregs) but also enhanced NK cell expansion 
(Miller and Lanier, 2019). The administration of IL-15 achieved clinical success in haematopoietic 
cancers (Cooley et al., 2012; Nayyar et al., 2019) and showed also promising results in solid 
tumours including metastatic melanoma (Conlon et al., 2015). However, the short half-life of IL-
15 and the observed toxicities at higher dosages are still limiting the clinical usage (Robinson and 
Schluns, 2017). The development of super-agonist complexes such as ALT-803 (IL-15N72D/IL-
15Rα-FC) further improved the in vivo half-life time and the clinical efficacy (Felices et al., 2017).   
Another approach to enhance NK cell cytotoxicity is to reduce the threshold of NK cell 
activation by lowering inhibitory stimulation. This can be achieved by blocking the engagement 
of KIR receptors with MHC class I molecules on the target cells. The use of allogeneic NK cells 
prevents the inhibition by self-MHC molecules and facilitates NK cell activation (Souza-Fonseca-
Guimaraes et al., 2019). Unfortunately, this can also induce graft-versus-host effects, so that NK 
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cell donors with haploidentical HLA phenotypes are preferably used in adoptive cell transfer 
(ACT) (Souza-Fonseca-Guimaraes et al., 2019). Although, ACT has been successful in the 
treatment of haemopoietic cancers such as acute myeloid leukemia (AML) (Tanaka and Miller, 
2020), so far it fails in the treatment of solid tumours (Paul and Lal, 2017). Also, the direct 
inhibition of KIR receptors with antibodies such as lirilumab was only effective in 
haematopoietic malignancies (Konjević et al., 2017; Miller and Lanier, 2019). Another important 
inhibitory NK cell receptor is CD94-NKG2A, that recognizes HLA-E, and can be blocked by 
the antibody monalizumab (Li and Sun, 2018). The administration of checkpoint inhibitors has 
been successful for T-cell activation. Moreover, tumour-infiltrating NK cells were also shown to 
express PD-1 (Liu et al., 2017b) and can thus benefit from checkpoint inhibitors (Sanseviero et 
al., 2019). Accordingly, the clinical successes of anti-PD-1 therapy might also be contributed by 
increased anti-tumour NK cell activity (Hsu et al., 2018; Pesce et al., 2019). Additional checkpoint 
inhibitors targeting different inhibitory NK cell receptors (TIGIT, IL1R8) require further 
investigation (Khan et al., 2020; Nayyar et al., 2019).  
Another approach to boost anti-tumour NK cell activity is to strengthen the activating stimuli in 
order to overcome the inhibitory signals. Bi-specific antibodies, known as bi- specific killer 
engagers (BiKEs) promote the formation of an antigen-specific immunological synapse between 
NK cells and tumour cells and thereby enhance the NK cell-mediated killing of the antigen 
expressing target cell (Miller and Lanier, 2019; Shimasaki et al., 2020). One fragment of the BiKE 
binds to an activating NK cell receptor such as the CD16 receptor that induces ADCC (Felices et 
al., 2016). The part of the killer engager is directed against tumour associated antigens such as 
CD30 in Hodgkin lymphoma, CD33 in myelodysplastic syndromes, CD133 in colorectal cancer 
or human epidermal growth factor receptor 2 (HER2) in breast cancer (Li and Sun, 2018). To 
increase the NK cell cytotoxicity, tri-specific killer engagers (TriKEs) with additional linkage to 
IL-15 such as GTB-2550 (anti-CD16 x IL-15 x anti-CD33 TriKE) have recently entered their 
first clinical trials in haematopoietic malignancies (Miller and Lanier, 2019).   
The use of NK cell lines (NKL, NK-92, KYHG-1, YT and NKG) derived from malignant NK 
cell leukemia or lymphoma has several advantages and opens new possibilities to modify effector 
cell cytotoxicity (Miller and Lanier, 2019). The most promising NK cell line for clinical 
application is NK-92. The IL-2 dependent NK-92 cell line is known to express several activating 
surface proteins and receptors such as CD56, NKG2D, NKp30 and NKp46 (Klingemann et al., 
2016). Furthermore, it lacks most KIR receptors (with the exception of KIR2DL4) (Suck et al., 
2016). However, the activating receptors NKp44 and CD16 are absent and other inhibitory 
receptors such as CD94/NKG2A and LIR-1 are expressed, hence lowering its cytotoxic potential 
(Suck et al., 2016). Nevertheless, NK-92 was approved by the U.S. Food and Drug 
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Administration (FDA) and was already applied in clinical trials including patients with renal 
carcinoma and malignant melanoma with modest success but good tolerance (Arai et al., 2008).  
NK cell lines can be genetically modified to display different receptor profiles. For example, 
parental NK-92 cells lack CD16 expression and are therefore not able to mediate ADCC. The 
artificial expression of high-affinity CD16 (haNK) increases their cytotoxicity (Klingemann et al., 
2016), a modification that was shown to be very effective in combination with tumour epitope 
specific monoclonal antibodies in preclinical studies (Williams et al., 2018). Even more advanced 
are NK cell lines, which have been armed with engineered chimeric antigen receptors (CARs). 
CARs targeted to specific tumour epitopes such as CD19, CD7 and CD33 in leukemia and 
lymphoma have successfully entered their first clinical trials (Kloess et al., 2019; Liu et al., 2020). 
Also preclinical studies in solid tumours directed against HER2 or epidermal growth factor 
receptor (EGFR) showed promising results (Paul and Lal, 2017).  
In addition to NK cell lines, NK cells differentiated from human pluripotent stem cells (hPSCs) 
could be used as ‘off-the-shelf’ immunotherapy (Wang et al., 2019). HPSCs include human 
embryonic stem cells, hematopoietic stem/progenitor cells from umbilical cord blood and 
induced pluripotent stem cells (iPSCs) (Hu et al., 2019). These stem cell derived NK cells can be 
produced on a large scale and genetically modified (Nianias and Themeli, 2019; Shimasaki et al., 
2020; Zhu et al., 2018). 
One important aspect that might explain the modest clinical success of NK cell therapy in solid 
tumours so far, in comparison to hematopoietic malignancies are the immunosuppressive effects 
of the tumour microenvironment (see following chapter). Therefore, increasing number of 
clinical investigations try to improve the conditions for effector cells in the tumour. For example, 
several drugs can prevent the shedding of MICA/MICB and promote NK cell cytotoxicity 
against tumours (Ferrari de Andrade et al., 2018). Alternatively, soluble MICA/MICB can be 
neutralized by antibodies such as IPH4301 (Li and Sun, 2018; Nayyar et al., 2019). Also the 
secretion of other soluble factors such as transforming growth factor β (TGF-β) or adenosine in 
the tumour microenvironment was shown to suppress NK cell proliferation and function (Leone 
and Emens, 2018; Viel et al., 2016). The TGF-β neutralizing antibody Fresolimumab (GC1008) 
has been used in a Phase I study for the treatment of advanced malignant melanoma and renal 
cell carcinoma (Morris et al., 2014). Furthermore, Galunisertib (LY2157299 monohydrate), an 
inhibitor of TGF-β receptor 1 (TGFbR1) has also been evaluated in clinical trials in solid 
tumours (Fujiwara et al., 2015; Yingling et al., 2018).  
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1.7 Immunoediting of melanoma by NK cells 
Immunosurveillance describes the process by which immune cells detect and kill tumour cells 
due to their tumour ligand profile. (Schreiber et al., 2011). Malignant melanoma cells are 
immunogenic as they express ligands on their cell surface that can be recognized by NK cells and 
other immune cells (Kleffel et al., 2015; Morgado et al., 2011; O'Donnell et al., 2019). Most 
melanoma cell lines (85 %) express at least one NKGD receptor ligand that is also present on all 
cytotoxic immune cells including NK cells and CTLs. The most frequently expressed ligands are 
MICA/MICB (80 %), whereas ULBPs (ULBP1, 15 %; ULBP2, 25 %; ULBP3, 20 %) are less 
common (Casado et al., 2009). Besides NKG2D, also natural cytotoxicity receptors, especially 
NKp30, and DNAM-1, are crucial for melanoma detection by NK cells (Besser et al., 2013; 
Carrega et al., 2009; Chan et al., 2010; Morgado et al., 2011). However, it is well known that 
cancer cells are very adaptable and can evade immune surveillance (Chouaib et al., 2014). This 
dynamic process of tumour cells altered immunogenicity during cancer progression is known as 
cancer immunoediting (see Figure 7). After an initial elimination phase, some tumour cells with 
lower susceptibility to immune cells arise. During an equilibrium phase, the tumour mass under 
permanent immune-selection pressure begins to show increasingly higher numbers of poorly 
immunogenic tumour cell subpopulations. When these variant immune-edited cells are allowed to 
proliferate unrestrained and they become the dominant tumour cell population, the tumour 
becomes largely resistant to immune detection and is no longer restrained, i.e. tumour cells 
proliferate and survive without elimination (Dunn et al., 2004; Zitvogel et al., 2006). 
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Figure 7. The immunoediting process. During the elimination phase, immune cells, here reflected by 
NK and T-cells, are able to kill most transformed cells. In the following equilibrium phase, immune cells 
can still control tumour growth, but tumour cells with lower immunogenicity arise and proliferate. With a 
continuing selection process, the immunogenicity of the tumour cells decreases and more cells elude 
immune cell recognition.  These variant cells escape immune surveillance, proliferate and form a tumour. 
Figure was adopted from (Cappello, 2015). 
In addition, melanoma cells transform their ligand profile to diminish their immunogenicity 
(Balsamo et al., 2012; Carretero et al., 2008). An often-observed mechanism of immune escape in 
tumours including melanoma is the shedding of the NKG2D ligands such as MICA/MICB and 
ULBP-2 (Paschen et al., 2009; Salih et al., 2002). This will not only occupy the NKG2D receptor, 
but also contribute to its downregulation (Konjevic et al., 2007). An enhancing factor in this 
process is TGF-β that lowers the expression of NKG2D and in addition decreases MICA, 
ULBP2 and ULBP4 expression on the melanoma surface (Casado et al., 2009; Morgado et al., 
2011). In addition, the increase of MHC class I molecules on melanoma cell surfaces induced by 
IFN-γ has been reported (Balsamo et al., 2012; Stojanovic et al., 2013). Moreover, the general 
decrease of NCR ligands during melanoma progression and metastasis support the theory of 
immunoediting in melanoma (Morgado et al., 2011). Also soluble factors such as IDO 
(indoleamine 2,3 dioxygenase) and PEG2 (prostaglandin E2), released by the tumour cells, inhibit 
the expression of activating NK cell receptors and hence NK cell cytotoxicity (Pietra et al., 
2012b).  
Taken together, NK cells are a very promising tool for cancer immunotherapy. However, their 
full potential is currently not being exploited in the clinical practice. The reasons are multiple and 



















Melanoma is the deadliest form of skin cancer with increasing incidence. It is characterised by a 
high metastatic potential and the development of resistance to currently available therapies. 
Although targeted therapies and immune checkpoint therapies have shown clinical success, the 
treatment response is variable and many patients still relapse after an initial effective treatment. 
Therefore, advancement and improvement of melanoma immunotherapies are of major interest 
and necessity. Natural killer cells are a promising tool for immune therapy, as they possess an 
innate cytotoxicity against tumour cells without prior sensitization. 
In this doctoral thesis, I aimed to investigate the therapeutic potential of human natural killer 
(NK) cells against melanoma and to reveal new biomarkers that might predict which patients 
could best benefit from NK cell-based melanoma therapy. I addressed this purpose through the 
following aims:  
1.) Determination of NK cell susceptibility of heterogeneous melanoma cell lines reflecting 
different disease stages and mutation status  
2.) Identification and validation of melanoma biomarkers, which are related to the NK cell-
mediated killing 
3.) Unravelling of a protein signature, which helps to predict the susceptibility of unknown 
melanoma cell lines to NK cells  
4.) Regulation of NK cell killing potential by manipulating killing related proteins  
5.) Establishment and further characterisation of (long term) melanoma-NK cell-co-culture 
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2 Material  
2.1 Antibodies 
2.1.1 Primary antibodies 
Table 1. Primary antibodies used, under specification of host organism, dilution, supplier and catalogue 
number 
Antibody Host organism Dilution Supplier Catalogue number 
Calnexin rabbit 1:1,000 ENZO ADI-SPA-860-F 
Snail (L70G2) mouse 1:500 CST 3895S 
Smac/Diablo  mouse 1:500 CST 2954S 
2.1.2 Secondary antibodies 
Table 2. Secondary antibodies used, under specification of host organism, dilution, supplier and 
catalogue number 
Antibody Host organism Dilution Supplier Catalogue number 
IRDye 680LT Donkey mouse 1:10,000 Licor 926-68022 
IRDye 800CW Donkey rabbit 1:10,000 Licor 926-32213 
2.1.3 Fluorochrome labelled antibodies 
Table 3. Fluorochrome labelled antibodies used, under specification of host organism, dilution, 
supplier and catalogue number 
Antibody Fluorochrome Isotype Supplier Catalogue number 
B7-H6 PE IgG1, κ R&D FAB7144P 
Mouse  IgG1, κ  
Isotype Control 
PE IgG1, κ R&D IC002P 
CD16 APC/Cy7 IgG1, κ BioLegend 302017 
Mouse  IgG1, κ   
Isotype Control 
APC7Cy7 IgG1, κ BioLegend 400127 
CD56 (NCAM) PE/Cy7 IgG1, κ BioLegend 318317 
Mouse  IgG1, κ 
Isotype Control 
PE/Cy7 IgG1, κ BioLegend 400125 
CD314 (NKG2D) PerCP/Cy5.5 IgG1, κ BioLegend 320817 
Mouse  IgG1, κ 
Isotype 
PerCP/Cy5.5 IgG1, κ BioLegend 400149 
CD337 (NKp30) PE IgG1, κ BioLegend 325207 
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Antibody Fluorochrome Isotype Supplier Catalogue number 
Mouse  IgG1, κ 
Isotype Control 
PE IgG1, κ BioLegend 400113 
Granzyme B  Alexa Fluor® 647 IgG1, κ BioLegend 515405 
Mouse  IgG1, κ   
Isotype Control 
(ICFC) 
Alexa Fluor® 647 IgG1, κ BioLegend 
400135 
 
HLA-A,B,C Alexa Fluor® 647 IgG1, κ BioLegend 311416 
Mouse  IgG1, κ  
Isotype Control 
Alexa Fluor® 647 IgG1, κ BioLegend 400234 
MICA/MICB Alexa Fluor® 488 IgG2a,κ BioLegend 320912 
Mouse  IgG2a,κ 
Isotype Control 
Alexa Fluor® 488 IgG2a,κ BioLegend 400233 
Perforin FITC IgG2b, κ BioLegend 308103 
Mouse  IgG2b, κ 
Isotype Control 
FITC IgG2b, κ BioLegend 400309 
ULBP-2/5/6 PerCP IgG2a R&D FAB1298C 
Mouse IgG2a 
Isotype Control 
PerCP IgG2a R&D IC003C 
2.2 Buffer solutions and other reagents 
2.2.1 Purchased buffer solutions 
Table 4. Purchased buffers used, under specification of supplier and catalogue number 
Buffer solution Supplier Catalogue number 
4x LaemmLi Sample buffer Bio-Rad 1610747 
Coulter Isoton ii Diluenz Beckmann coulter 8448011 
DPBS (1x) Dulbecco's Phosphate-Buffered 
Saline  
Life Technologies 14190-094 
Trans-Blot®TurboTM 5x Transfer buffer Bio-Rad 10026938 
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2.2.2 Prepared buffer solutions and other reagents 
Table 5. Prepared buffer solutions used, under specification of composition and purpose 




70mg Serva Blue G  
50mL 96 % Ethanol 
100mL of 85 % phosphoric acid 





Erythrocyte lysis buffer 
 
 
155 mM NH4Cl 
9,99 mM KHCO3 







5 % FCS 
0.5 % BSA 
0.07 % NaN3 
0.1 % Saponin 






TGH buffer stock solution 
 
 
1 % Triton X-100  
10 % glycerol  
50 mM NaCl  
50 mM HEPES  
 1 mM EGTA  
1 % sodium deoxycholate  




TGH lysis buffer  
always prepared fresh 
 
88 % TGH buffer 
 1 mM Na3VO4  
 1 mM PMSF  
1mM NaF 




1x Transfer buffer 
 
20 % 5x Transfer buffer 
20 % Ethanol 
60 % H2Odest. 
 
Western Blot 
Stacking gel buffer 
 
0.5 M Tris base  




Separation gel buffer 
 
1.5 M Tris base (Trizma)  




10x Running Buffer 
 
250 mM Tris base 
1.92 M glycine 
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Buffer solution Composition Purpose 
10x TBS: 1L 
 
500 mM Tris-base 






0.1 % Tween20 
10 % 10x TBS 




Table 6. Chemicals used, under specification of supplier and catalogue number 
Chemicals Supplier Catalogue number 
2-Mercaptoethanol AppliChem A1108 
2-Propanol Sigma 19516 
7-Aminoactinomycin (7-AAD) Sigma A9400-1MG 
Acrylamid Rotiphorese Gel 40 Roth A515.1 
Ammoniumchlorid (NH4Cl) Sigma-Aldrich A0171 
Accutase® solution Sigma Aldrich A6964 
Agar AppliChem A-3858 
Ammoniumpersulfat (APS) Sigma Aldrich A3678 
Bovine Serum Albumin (BSA)  Sigma-Aldrich A9418 
Bromophenol Blue Sigma-Aldrich B0126 
Calcium chloride (CaCl2) Sigma-Aldrich 21115 
Calcein- AM Life Technologies C1430 
Chloroform Fisher Scientific 15677730 
Complete (Proteinase Inhibitor) Roche 04 693 132 001 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418 
Diethylpyrocarbonat (DEPC) Sigma C5758 
EDTA Sigma-Aldrich ED2SS 
Ethanol ROTIPURAN® Roth 9065 
Ethylene glycol-bis (2-aminoethylether) 
-N,N,N′,N′-tetraacetic acid (EGTA) 
Sigma-Aldrich E3889 
Fetal calf serum (FCS) Sigma F7524 
Glycerol Sigma-Aldrich G2025 
Glycogen Fisher Scientific 10814010 
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Chemicals Supplier Catalogue number 
HEPES Sigma-Aldrich H-7523 
Horse serum Thermo fisher 16050122 
Interleukin 2, human (IL-2)  Life Technologies 15596-026 
Insulin, human Sigma-Aldrich I9278 
Isopropanol AppliChem A3928 
Kanamycine Sigma 60615 
L-Glutamine solution Life Technologies 67513 
Methanol Sigma-Aldrich 34860 
Paraformaldehyde (PFA) Polysciences Inc. 380 
Potassium bicarbonate (KHCO3) Aldrich 237205 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich P7626 
Phosphoric acid 85 % Roth 9079 
Saponin Sigma S7900 
Serva Blue G SERVA 35050 
Sodium azide (NaN3) Sigma-Aldrich S2002 
Sodium chloride (NaCl) Roth 9265.1 
Sodium fluoride (NaF) Sigma-Aldrich S7920 
Sodium deoxycholate (C24H40O4) Sigma-Aldrich 30970 
Sodium dodecyl sulfate (SDS) BioChemica A2572 
Sodium hydrogen carbonate (NaHCO3) MERK 6329 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich S6508 
Tetramethylethylenediamine (TEMED) Sigma T7024 
TRIS PUFFERAN® Roth 5429 
Triton X-100 Eurobio 18774 
Trizol Life Technologies 15596018 
Trypan Blue Stain (0.4 %) Life Technologies 15250-061 
Tryptone AppliChem A1553 
Tween 20 AppliChem A4974 
Yeast extract AppliChem A1552 
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2.4 Inhibitors 
Table 7. Inhibitors under specification of the targeted protein, supplier and catalogue number 
 
Inhibitor Target Supplier Catalogue number 
NVP-BKM120 PI3K Selleckchem S2247 
Rapamycin mTOR Selleckchem S1039 
RiboLock RNase A,B,C Life Technlogies E00382 
MK2206 2HCL AKT1/2 Selleckchem S1078 
 
2.5 Kits 
Table 8. Kits under specification of supplier and catalogue number 
Kit Supplier Catalogue number 
Cell Titer Blue Cell Viability Assay Promega G8081 




GoTaq®qPCR Master Mix Promega A6002 
HiSpeed Plasmid Maxi Kit Qiagen 12662 
INTERFERin® siRNA transfection reagent Polyplus 409-10 




Superscript®IV Reverse Transcriptase Kit Invitrogen 18090050 
Trans-Blot® Turbo™ RTA  
Mini Nitrocellulose Transfer Kit 
Bio-Rad 1704270 
2.6 Laboratory consumables  
All general laboratory consumables, e.g. pipettes, reaction tubes, cell culture flasks, were 
purchased through Sarstedt (Nürnbrecht, Germany) or VWR (Randor, Pennsylvania, USA). 
Other special consumables are referred to in the respective method section. 
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2.7 Laboratory devices 
Table 9. Laboratory devices under specification of manufacturers and purpose 
Device Designation Manufacturers Purpose 
 
96 well plate reader 
Infinite M200 Pro Tecan 
Real-time Killing 
Assay 
CLARIOStar® Bmglabtech Proliferation 







Z2 coulter particle 




of cell numbers 










Universal 30 F   Hettich 
 Universal 32 R   
Labofuge 400R 














Heating block ThermoMixer F2.0 eppendorf 
Protein/DNA 
denaturation 





Cell cultivation HERASAFE Heraeus 




Invitrogen NK cell isolation 
Mikroscope 
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Device Designation Manufacturers Purpose 
pH meter pH/Ion level 2 ionoLab 
Adjustment of 
pH 
Power supply PowerPacTM Basic Bio-Rad SDS PAGE 
Quantitative PCR 
instrument 




Solution mixing  
MS1 IKA Labortechnik 
Hula Mixer Invitrogen 





Thermal Cycler  C1000TM  Bio-Rad 
DNA 
amplification 
Transfer sytsem Trans-Blot®TurboTM Bio-Rad Western Blot 




2.8.1 Purchased media 
Table 10. Purchased media under specification of supplier and catalogue number 
Medium Supplier Catalogue number 
AIMV Life Technologies 12055-091 
HBSS - Hank's Balanced Salt Solution PAA H15-009 
Leibovitz’s L-15 Medium  Biochrom AG F1314 
Lymphocyte Separation Medium 1077 PromoCell C-44010 
M2 Melanocyte Medium PromoCell C-24300 
MCDB153- Basalmedium Biochrom AG F 8105 
MEM Alpha Medium Life Technologies 11900-016 
Opti-MEM® Thermo Fisher 31985088 
RPMI-1640 Life Technologies 21875-034 
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2.8.2 Prepared media 
TU-Medium, 2 % FCS (500 mL):  
400 mL MCDB153- Basalmedium  
100 mL Leibovitz’s L-15 Medium 
  10 mL FCS 
840 µL CaCl2 (stock solution: 1M)   
250 µL Insulin (stock solution: 10 µg/mL) 
Sterile filtrated 
 
NK-92 cell medium (MEMα*): 
MEM Alpha Medium powder was dissolved in 950 mL H2Odest. and 29.3 mL 7.5 % soln. 
NaHCO3. Afterwards, the pH was adjusted to 7.0-7.4 and the solution was filled up to 1000 mL. 
400 mL MEM Alpha medium was supplemented with: 
 12.5 % FCS  
 12.5 % Horse serum   
  2 mM L-Glutamine 
And always supplemented freshly with 10 ng/mL Interleukin-2 
 
Lysogeny broth (LB)-medium (1 l): 
10 g Tryptone 
10 g NaCl 
 5 g yeast extract 
2.9 Oligonucleotides 
2.9.1 qRT-PCR Primer  
Table 11. qRT Primer used, under specification of target mRNA, forward as well as reverse primer 
sequence 
Target mRNA Forward primer 5´-3´ Reverse primer 5´-3´ 
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2.9.2 Silencing RNA (siRNA) 
Table 12. Silencing RNA used, under specification of target gen and sequence, concentration as well as 
supplier 
Target mRNA Target gen Concentration Target sequence 5‘-3‘ Supplier 











40 µM unknown Microsnyth 
2.9.3 Other mono-/oligonucleotides  
Table 13. Nucleotides used, under specification of supplier and catalogue number 
Nucleotides Supplier Catalogue number 
Oligo(dT)12-18 Primer Invitrogen 18418012 
dNTP mix Invitrogen 18109017 
2.10 Cell lines 
Human melanoma cell lines were previously described (Garman et al., 2017; Satyamoorthy et al., 
2003) and were a gift from Meenhard Herlyn (The Wistar Institute, Philadelphia, USA). Human 
melanocytes were used for comparisons to the melanoma cells in RNA sequencing and were 
provided by Dr. Hedwig Stanisz-Bogeski (Dermatology, Universitätsmedizin Göttingen, 
Göttingen). The melanocytes were isolated from neonatal foreskins obtained after donor 
circumcision. The cell lines K562 and NK-92 were provided by ATCC and DSMZ, respectively.  
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Table 14. Cell lines used, under specification of disease and mutation status according to Rockland 
Immunochemicals, Inc.; web site, https://rockland-inc.com/melanoma-cell-lines.aspx. The mutation data 
of the cell line K562 was obtained from the Sanger Institute Catalogue of Somatic Mutations in cancer; 
web site, http://www.sanger.ac.uk/cosmic. ND= not detected; N/A = not available 
Melanoma cell line Disease Stage 
Mutation status of 








V600E WT WT 
WM1366 Primary (VGP) WT WT WT 
WM164 Metastasis V600E WT WT 
WM3268 Primary (VGP) WT ND Q61K 
WM3482 Metastasis V600E WT WT 
WM3682 Lymph node metastasis WT WT Q61L 
WM3734 Brain metastasis V600E ND  WT 
WM3918 Metastasis WT ND WT 
WM47 Metastasis V600E ND WT 
WM793 Primary (VGP) V600E Mu/Hem Del WT 
WM88 Lymph node metastasis V600E WT WT 
WM858 Lymph node metastasis V600E WT WT 
WM9 Lymph node metastasis V600E Hem Del WT 
WM902B Primary (VGP) V600E Hem Del WT 
WM983B Lymph node metastasis V600E WT WT 
Other cell lines Disease  
Mutation status of 








N/A N/A N/A 
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2.11 Plasmids 
Table 15. Mammalian expression plasmids used, under specification of backbone, supplier, catalogue 
number and publication 
Plasmid Backbone Supplier Catalogue number Publication 
pSMAC-GFP peGFP-N1 Addgene 40881  (Tait et al., 2010) 






pmaxGFPTM pmax LONZA V4XC-2032 
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3 Methods  
3.1 Subculturing of cell lines 
The suspension cell lines K562 and NK-92 were subcultured three times a week and incubated in 
hydrophobic cell culture flasks (83.3910.502, Sarstedt). Depending on the splitting ratio (1:10 
over the week and 1:12 over the weekend) a part of the K562 cell suspension was transferred to a 
cell culture flask with fresh RPMI, 10 % FCS.  
NK-92 cells are sensitive to density and were always adjusted to a cell number of 3 x 10 5/mL 
during the week and to 2 x 10 5/mL over weekends. The complete cell solution was transferred to 
a 50 mL tube and centrifuged (200 x g, 5 min) to remove dead cells and debris. The cell pellet 
was resuspended in 1 mL MEMα* and the cell number was determined. The required cell number 
was transferred to a new cell culture flask and filled up to 25 mL medium with 10 ng/mL IL-2. 
This cell line was cultured in standing cell culture flasks to reduce the attachment surface and 
optimise cell density.  
Melanoma cells are adherent and they were regularly subcultured twice a week. Used medium and 
debris were discarded by removing the used medium supernatant and washing the cells with 
1x DPBS. To detach the melanoma cells from the cell culture flask and loose cell-cell contacts, 
1 mL accutase® solution, an enzyme mixture, was added. After 3 min, the detached cells were 
resuspended in fresh cell culture medium and a part of this cell suspension was transferred to a 
new cell culture flask for adherent cells (83.3911.002, Sarstedt) and additional medium was added 
to a final volume of 12 mL. The usual splitting ratios and used cell culture media of each cell line 
is summarised in Table 16 . The cells were further cultured in humidified incubators at 37 °C and 
with a 5 % CO2 atmosphere. 
Table 16. Splitting ratio of cells under specification of culture properties, medium and splitting ratio 
Melanoma cell line Medium Splitting ratio 
1205Lu TU, 2 % FCS 1:5 
451Lu TU, 2 % FCS 1:3 
WM1366 TU, 2 % FCS 1:6 
WM164 TU, 2 % FCS 1:5 
WM3268 TU, 2 % FCS 1:3 
WM3482 TU, 2 % FCS 1:3 
WM3682 TU, 2 % FCS 1:4 
WM3734 TU, 2 % FCS 1:3 
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Melanoma cell line Medium Splitting ratio 
WM3918 TU, 2 % FCS 1:4 
WM47 TU, 2 % FCS 1:4 
WM793 TU, 2 % FCS 1:4 
WM88 TU, 2 % FCS 1:4 
WM858 TU, 2 % FCS 1:6 
WM9 TU, 2 % FCS 1:4 
WM902B TU, 2 % FCS 1:5 
WM983B TU, 2 % FCS 1:5 
Suspension cell line Medium Splitting ratio 
K562 RPMI, 10 % FCS 1:10 
NK-92 MEMα* 2-3 x 105 cells/mL 
 
3.2 Determination of cell number 
The determination of cell number is a crucial step in many experiments. Cells were either counted 
using the Z2 coulter particle and size analysis from Beckmann Coulter or by the Countess II FL 
Automated counter from Fisher Scientific. The first apparatus is a Coulter counter that counts 
and measures cell size in suspension by detecting the changes in electrical resistance of the liquid. 
The cell suspension was diluted with Coulter Isoton ii Diluenz (1:200). A volume of 500 µL from 
this prepared solution was drawn trough the micro channels and cells that have a defined size 
range were counted. The displayed cell number in 1 mL has to be multiplied by the dilution 
factor 200 to get the original cell density. The second cell counting method is based on using a 
haemocytometer. The cell suspension was diluted 1:1 with trypan blue that will stain only dead 
cells. Then, 10 µL of this solution was loaded to a reusable glass slide (cell lines) or disposable 
slides (blood samples). The instrument from Fisher Scientific automatically counts cells with set 
size, shape and brightness.  
3.3 Plasmid preparation 
1 µg/µL plasmid was added to chemical competent E.coli XL1 blue cells and incubated for 30 
min on ice. Subsequently, the cells were heated to 42 °C for 45 sec. After a second incubation of 
2 min on ice, the cells were added to 250 µL lysogeny broth (LB) medium and incubated for 1 h 
at 37 °C and 300 rpm. Then bacteria suspension was plated to agar plates with kanamycin for 
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bacterial selection. After over-night incubation, one bacteria clone was picked and added to 5 mL 
LB medium supplemented with kanamycin. After few hours of incubation at 37 °C and 300 rpm, 
1 mL of this pre bacteria culture solution was transferred into 150 mL kanamycin supplemented 
LB medium and was incubated for another night at 37 °C and 300 rpm. Subsequent plasmid 
purification was performed using HiSpeed Plasmid Maxi Kit of QIAGEN according to the 
manufacturer’s instructions.  
The LB culture was centrifuged at 2500 x g for 15 min at 4°C. The bacteria pellet was 
resuspended in 10 mL Buffer P1 (supplemented with RNAse and LyseBlue reagent). 
Subsequently, 10 mL Buffer P2 was added and the reaction tube was inverted 4–6 times until the 
solution was turned blue. After an incubation (5 min, RT), 10 mL prechilled buffer P3 was added 
and the solution was mixed by inverting until it was completely colorless. Then the lysate was 
poured into the barrel of the QIAfilter Cartridge and was incubated for 10 min at RT. In the 
meantime, the HiSpeed Tip was equilibrated with 10 mL Buffer QBT. Then the cell lysate was 
filtered into the equilibrated HiSpeed Tip by inserting the plunger into the QIAfilter Cartridge. 
Afterwards, the HiSpeed Tip was washed with 60 mL Buffer QC. The DNA was eluted with 
15 mL Buffer QF and was precipitated by adding 10.5 mL isopropanol. After a short mixing, the 
eluate–isopropanol mixture was incubated for 5 min. During this incubation, the QIAprecipitator 
was placed over a waste bottle. Afterwards, the mixture was transferred into the syringe and the 
plunger was inserted under constant pressure in order to filter the eluate–isopropanol mixture 
through the QIAprecipitator. To wash the DNA, this process was repeated with 2 mL 70 % 
ethanol. Then the membrane was dried by pressing air through the QIAprecipitator forcefully 
several times. Finally, the DNA was eluated into a collection tube by filtering 1 mL Buffer TE to 
a new 5 mL syringe This eluate was transferred to the 5 mL syringe and elute for a second time 
into the same 1.5 mL tube. 
3.4 Transient transfection  
Genes of interest can be overexpressed or downregulated by introducing artificial genetic material 
such as DNA or RNA into melanoma cells. 
3.4.1 Plasmid DNA transfection 
The FuGene® HD transfection reagent was used to add plasmids (circular DNA molecules) into 
melanoma cells. This transfection reagent belongs to the chemical non-liposomal transfection 
methods and is characterised by a high transfection efficiency and reduced toxicity to the cells. 
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Melanoma cells (7 x 105) were seeded into 60 mm cell culture dishes one day before transfection. 
Opti-MEM® and FuGene® reagent were pre-warmed to room temperature. After the 
equilibration, 2.3 µg of the plasmid was diluted in 230 µL Opti-MEM®. Then 9.2 µL of 
FuGene® transfection reagent was added and the components were mixed. During 15 min of 
incubation at RT, the FuGene® transfection reagent forms vesicles containing the construct. 
Afterwards 240 µL of the transfection mixture was added dropwise to the dish. The prepared 
dishes were further incubated at 37 °C and 5 % CO2. To remove the remaining transfection 
reagent, the medium was changed 6 h after transfection. The dishes were further cultivated in the 
incubator until used for experiments. 
3.4.2  siRNA transfection  
Genes were silenced by RNA interference (RNAi) using the transfection reagent 
INTERFERin®. The cells are transfected with siRNA that can bind to its target mRNA and 
form a double stranded RNA molecule (dsRNA). This dsRNA is cleaved with the help of the 
RNA-induced silencing complex (RISC) and thereby hinder the subsequent protein translation. 
Melanoma cells (7 x 105) were seeded into 60 mm dishes one day before transfection. Then, 1 nM 
siRNA was diluted in 100 µL Opti-MEM®, with mixing. After adding 2 µL INTERFERin® the 
solution was homogenized immediately. In the subsequent incubation of 20 min, the siRNA and 
INTERFERin® formed transfection complexes. In the meantime, half of the growth medium 
was replaced by fresh culture medium. After complex formation, 100 µL of the transfection 
mixture was added and homogenized by gently swirling the dish. For further cultivation, the 
dishes were incubated at 37 °C and in 5 % CO2. 
3.5 Cell proliferation and viability assay 
Important hallmarks of cancer development include uncontrolled proliferation and survival 
(Hanahan and Weinberg, 2011). The determination of cell proliferation/survival potential can 
give information about melanoma cells’ aggressive nature/status/phenotype/cell cycle. 
Furthermore, the efficacy of drugs can be estimated and the ideal drug concentration can be 
determined by monitoring tumour cell proliferation and viability. In this study, the CellTiter-
Blue® Cell Viability assay was used to monitor cell behavior. This assay is based on the indicator 
dye resazurin. Metabolites of viable cells reduce resazurin into resorufin that differs in its spectral 
properties (Ex: 579 nm, Em: 584 nm). This change in fluorescence can be detected and can be 
used to determine the number of viable cells. 
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If not stated differently, 50,000 melanoma cells were resuspended in 200 µL medium/well and 
were seeded to a black, clear bottom 96-well plate. When melanoma cells were treated with drugs, 
the cells were resuspended in 50 µL medium and seeded in the wells. Then, the remaining 50 µL 
medium containing different drug concentrations was added. Furthermore, additional medium 
controls were prepared to subtract background signal. The plates were incubated for 2 h, 24 h, 
48 h, 72 h at 37 °C and 5 % CO2. After the indicated time, 20 μL of CellTiter-Blue® reagent 
were added to each well and mixed. After 3 h, the fluorescence signal of resorufin was measured 
with the plate reader Mithras LB940 of Berthold Technologies. The absolute fluorescence signal 
was normalised to the starting (t = 2 h) values. 
Taken that cancer cells have often an uncontrolled cell cycle, the obtained fluorescence signal not 
necessarily correlate with cell number. The production of metabolites between different 
melanoma cell lines might differ a lot, so that the proliferation potential of different cell lines was 
determined by counting the melanoma cell numbers (see chapter 3.2.). 
3.6 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) are isolated from leucocyte reduction chambers 
(LRS chambers). These are a waste product from the thrombocyte donation of the local blood 
banks of the Institute of Transfusion Medicine at the UMG and the Institute of Clinical 
Hemostaseology and Transfusion Medicine at UKS. 
For the isolation, 17 mL of the lymphocyte separation medium 1077 was filled in a leucosep tube. 
During the following centrifugation (1000 x g, 30 s, RT), the medium was pressed through the 
filter to allow subsequent blood cell separation by a density gradient. The LRS chambers were 
adjusted above the leucosep tube so that after cutting, the lower and upper pipe of the LRS 
chamber allowed a steady blood flow (Knorck et al., 2018). After the separation medium was 
overlayed with blood, the LRS chamber was flushed with 20 mL HBSS to remove the remaining 
blood. Subsequently, the leucosep tubes were filled with HBSS to dilute the blood and facilitate 
the cell separation. In the next centrifugation (450 x g, acceleration: 1, deceleration: 0, 30 min, 
RT) the blood cells migrated depending on their density and formed different visible layers. The 
white leucocyte ring was localized between the yellow blood plasma and the transparent 
separation medium above the leucosep filter. This leucocyte ring was transferred to a fresh 50 mL 
tube, filled up with HBSS and centrifuged (250 x g, 15 min, RT). Remaining erythrocytes in the 
cell pellet were lysed by the use of erythrocyte lysis buffer (2-3 mL, 2 min). To stop the activity of 
this buffer, the 50 mL tube was filled up with HBSS and was centrifuged (200 x g, 10 min, RT). 
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After that, the cell pellet was resuspended in 20 mL cold isolation buffer (1x DPBS + 5 % FCS). 
The PBMCs were stored at 4 °C until further use. 
3.7 Isolation of natural killer cells  
Natural killer cells (NK cells) were isolated with the Dynabeads® Untouched™ Human NK cells 
Kit from Life Technologies. The following protocol is based on 100 x 106 PBMCs: 
The PBMC cell suspension was transferred to a 15 mL tube and centrifuged (220 x g, 8 min, 
4 °C). Thereafter, the cell pellet was resuspended in cold isolation buffer (1x DPBS + 5 % FCS) 
and 200 µL FCS as well as 200 µL antibody mix was added. This mix contains antibodies for 
CD3, CD14, CD36, CDw123, HLA class II DR/DP and CD235a (Glycophorin A) that target 
erythrocytes and all lymphocytes, excluding NK cells. Additional FCS reduced unspecific binding 
of the antibodies. During this incubation (20 min), 1 mL Dynabeads® solution was washed with 
equal volume of isolation buffer by using the Dyna-Mag 15 magnet and placed on ice until next 
use. After antibody incubation, 20 mL isolation buffer was added and gently mixed to remove 
unspecific-bound antibodies. Then the cell suspension was centrifuged (350 x g, 8 min, 4 °C) and 
the cell pellet was resuspended in 1 mL isolation buffer. The resuspended cells were added to the 
washed Dynabeads® that bind the antibodies, which cover the non-required PBMCs. A 
subsequent incubation of 15 min at RT was stopped by adding 10 mL cold isolation buffer. The 
tube containing the cell-Dynabeads® solution was placed in the Dyna-Mag 15 magnet for 
approx. 6 min. All lymphocytes that were loaded with Dynabeads® were pulled to the walls of 
the tube by magnetic attraction. The NK cells were found in the clear, magnet bead free, 
supernatant that was transferred to a new tube. The remaining Dynabeads® were resuspended 
with 10 mL isolation buffer and the magnet isolation process was repeated. In the last step, the 
magnet isolation procedure was repeated with the united supernatants to remove remaining 
Dynabeads® from the NK cell solution. Finally, the purified NK cell suspension was centrifuged 
(200 x g, 8 min, RT) and NK cells were resuspended in AIMV + 10 % FCS and seeded into 
24 well plate (2 x 106/ mL). 
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3.8 Modulation of NK cell activity 
3.8.1 Stimulation with Interleukin-2  
After isolation, NK cells were stimulated with 0.05 µg/mL IL-2. This procedure extends the 
cultivation period and augments NK cell cytotoxicity to tumour cells in general (Henney et al., 
1981), but also to melanoma cells by increasing the numbers of activating receptors on the NK 
cell surface (Morgado et al., 2011).  
3.8.2 Irradiation 
Unwanted proliferation of NK cells in the co-culture experiments was blocked by irradiation 
(30 Gy, Cs 137 γ-emitter) that will induce apoptosis after 6 hours in NK cells (Seki et al., 1994) 
and will limit their survival. 
3.9 Real-time Killing Assay 
The key experimental technique used in this study is the real-time killing assay, which was applied 
to evaluate the susceptibility of melanoma cells towards NK cells. In comparison to other 
established cytotoxicity assays, it allows a kinetic resolution of the killing process (Kummerow et 
al., 2014). The cytotoxic assay is based on the detection of calcein-AM labeled target cells that 
release the fluorescent dye during the killing process (Figure 8). Although NK cells preferentially 
lyse target cells, a part of the targets are also killed via apoptosis or even via a mixture of both 
killing types (Backes et al., 2018). The time course of NK cell-induced target cell apoptosis can 
vary but was shown to last around 38 min on average. In contrast, target cell lysis required only 
~7 min (Backes, 2016). Therefore, NK cell-mediated apoptosis might be not detected at the 
initial phase of the assay but in its further course. Nevertheless, the real-time killing assay is a 
suitable method to investigate the principles of the NK cell-induced cytotoxicity against 
melanoma cells (NKiToxMel).  
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Figure 8. Real-time killing assay. Target cells were loaded with 0.5 µM calcein-AM and seeded in a 96-
well plate (25,000 / well). After target cells were settled, NK cells (125,000 NK cells; E:T ratio of 5:1) 
were added to the destined wells. The NK cell-mediated killing of melanoma cells was detected and 
recorded by the decrease of fluorescence signal. Living target cells and Triton X-100 lysed cells were used 
as controls. 
The target cells were loaded with 0.5 μM calcein-AM for 15 min under continuous rotation and 
darkness. The acetoxymethyl ester (AM) group allows the passive diffusion of the dye into the 
cell. The cellular esterases cleave the AM group from the dye and prevent the leakage from the 
cell. To remove remaining fluorescence solution, the cells were washed with AIMV* (AIMV with 
10 mM HEPES). Then the cell number was determined and the target cells were seeded (25.000 
cells in 200 μL / well) into a black, clear bottom 96-well plate (BD, 353219). After at least 
20 minutes at room temperature, the target cells were settled and the effector cells (125,000 NK 
cells/ 50 μL) were slowly added to the destined wells. During NK cell-mediated lysis of the target 
cells, calcein-AM is released into the supernatant. The decrease of fluorescence signal can be 
detected by plate readers. Immediately after the effector cells were added, the fluorescence was 
measured. To determine the cytotoxicity, additional controls were needed. Target cells lysed by 
20 μL lysis buffer (AIMV*+10 % triton X) were used as a positive control (100 % killing), 
whereas non-treated living target cells were used as a negative killing control. Corresponding 
background controls used were 250 μL AIMV* medium and 250 μL AIMV* medium with 20 μL 
lysis buffer. The single conditions were pipetted in triplicates to minimize variance of 
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10 min) the plate readers infinite M200 Pro from Tecan (AG Hoth, Universität des Saarlandes) 
and the CLARIOSTAR® from BMG labtech were used.  
Reader conditions: 
M200 Pro:  
Kinetic measurement; Kinetic cycles: 25; Interval time: 10 min 
Mode: Fluorescence Bottom Reading 
Target Temperature: 37 °C; CO2 concentration: 5 % 
Excitation Wavelength: 485 nm 
Emission Wavelength: 535 nm 
Excitation Bandwidth: 9 nm; Emission Bandwidth: 20 nm 
Gain: Optimal Gain; Number of Flashes: 24 
Integration Time: 40 μs; Lag Time: 0 μs; Settle Time: 0 ms 
 
CLARIOSTAR® 
Measurement type: Fluorescence; Bottom optic used 
Target Temperature: 37 °C; CO2 concentration: 5 % 
Plate mode settings 
Number of cycles: 25; Cycle time: 600 s; Number of flashes per well: 8 
Scan mode: orbital averaging; Scan diameter: 3 mm 
Optic settings 
Excitation Wavelength: 483-14 nm 
Dichroic filter: auto 502.5  
Emission Wavelength: 530-30 nm  
Gain: adjusted from full plate; Focal height: 4.2 mm 
 
The means of the triplicates were determined for every measured point in time t. After 
subtraction from the averaged corresponding background control, the cytotoxicity (%) was 
quantified with the following equation: 
 




Y: Fluorescence of the sample (killing condition) at point in time t 
NC: Fluorescence of the negative control at the corresponding time t 
PC: Fluorescence of the positive control at the corresponding time t 
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Since the killing condition and the negative control do not inevitably have the same starting 
fluorescence, the difference was corrected using the following index (I): It= 0 = Yt=o/NKt=0)  
Experiments with index ≤ 0.95 were excluded.  
3.10 Determination of mRNA expression 
3.10.1 RNA isolation 
Total RNA from melanoma cells was isolated with TRIzol® reagent from Invitrogen. The main 
components of TRIzol™ Reagent are phenol and guanidine isothiocyanate. Guanidine 
isothiocyanate lyses the cells and prevents RNA degradation by inhibiting RNase activity. Fresh 
cell pellets were homogenised in 800 µL TRIzol® reagent and were stored at -80 °C until further 
use. Further RNA isolation was based on a phenol-chloroform extraction (Chomczynski and 
Sacchi, 1987). First, the samples were centrifuged (12,000 x g, 10 min, 4 °C) and the supernatant 
transferred to a fresh 1.5 mL reagent tube. After 5 min of incubation at room temperature 
200 µL chloroform was added and mixed by vigorous shaking of the tube. The second 
centrifugation step (12,000 x g, 15 min, 4 °C) rendered the phase separation visible. The lower 
red organic layer contains denatured proteins, whereas RNA is dissolved in the upper aqueous 
layer. DNA can be found in the interphase between the distinct two layers. The aqueous phase 
was transferred to a new 1.5 mL reagent tube. RNA was precipitated from the aqueous layer by 
adding 500 µL isopropanol and 1 µL glycogen (5 µg/µL). The 10 min incubation was stopped 
with another centrifugation step (12,000 x g, 10 min, 4 °C). Afterwards the RNA pellet was 
washed in 1 mL 75 % ethanol (7,500 x g, 10 min, 4 °C) and dried. The complete dry RNA pellet 
was dissolved in 10-20 µL DEPC treated water.  
An alternative to the TRIzol® based isolation of RNA is the NucleoSpin® RNA Plus kit from 
Macherey-Nagel. The cell pellet was resuspended and lysed in 350 µL LBP buffer. To remove the 
genomic DNA, the homogenized sample was transferred to a gDNA-removal column 
preassembled with a 2 mL collection tube. After centrifugation (11,000 x g, 30 s) the column was 
discarded. A volume of 100 µL binding solution was added to the flowthrough and mixed 
rigorously before transferring the whole lysate mix to a RNA binding column with collection 
tube. The flow-through was discarded following centrifugation (11,000 x g, 15 s). Then the 
column was washed once with 200 µL buffer WB1 (11,000 x g, 15 s) and a second time with 
600 µL buffer WB2 (11,000 x g, 15 s). To dry the column membrane completely, an additional 
250 µL WB2 was added and then centrifuged (11,000 x g, 2 min). Finally, the RNA was eluted by 
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adding 30 µL RNase-free water and centrifuging at 11,000 x g for 1 min. The RNA yield can be 
increased by repeating the elution step.  
The RNA concentration was determined with the help of a spectrophotometer (NanoDrop). 
Isolated RNA was either used directly for cDNA synthesis or was stored at -80 °C until further 
use.  
3.10.2 Reverse transcription for cDNA synthesis  
The isolated RNA was used as a template to synthesise DNA via reverse transcription. This 
process produces complementary DNA (cDNA), which can be used in later polymerase chain 
reactions (PCR) and also later help to quantify mRNA levels. The cDNA synthesis was 
performed by Andrea Paluschkiwitz. 
For this purpose, 800 ng RNA was mixed with 50 µM Oligo-(dT)20 primers as well as 10 mM 
dNTP-Mix in a final volume of 13 µL. This RNA-primer mixture was heated up to 65 °C for 
5 min and then incubated on ice for 1 min. Then the RT reaction mix was prepared. For one 
reaction 4 µL 5x SSIV Buffer, 1 µL 100 mM dithiothreitol (DTT), 1 µL ribonuclease inhibitor 
and 1 µL SuperScript™ IV Reverse Transcriptase (200 U/μL) was mixed. The prepared RT 
reaction mix was combined with the annealed RNA. For optimal reaction, the mixture was 
incubated at 50-55 °C for 10 min. Finally, the incubation at 80 °C for 10 min inactivated the 
reaction. The synthesized cDNA was either used immediately for PCR amplification or was 
stored at -20 °C until further use.  
3.10.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
To quantify and compare the gene expression of melanoma cells, quantitative real-time 
polymerase chain reaction (PCR) was used. The shown qRT-PCRs were performed by Andrea 
Paluschkiwitz. This method allows the detection as well as the quantification of the cDNA 
amplification with the aid of a fluorescence dye that reversibly intercalates with double-stranded 
DNA. With every PCR cycle, more dsDNA is synthesized and the fluorescence signal increases. 
For this purpose, we used the GoTaq®qPCR Master Mix of Promega that contains not only the 
BRYT Green® Dye (Ex: 493 nm; Em: 530 nm) but also all components for qPCR except cDNA, 
primers and water. The following qRT-PCR reaction mix (1 x) was used: 
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Table 17. qRT- PCR reaction mix 
Reagent Volume (µL) 
2x GoTaq qPCR Master Mix 25 
Primer forward 10 µM 1.5 
Primer reverse 10 µM 1.5 
H2Odest.  12 
1:10 cDNA (<500 ng) 10 
Total volume 50  
 
Mastermix (40 µL) was pipetted into each well of a 96 PCR-plate (Sarstedt 72.1978.202) and 
10 µL of the 1:10 prediluted cDNA (<500 ng). To avoid evaporation during the cycling heating, 
the plate was covered with an adhesive seal (4titude, 0560).  After spinning down, the plate was 
placed in an Agilent Mx3005P qPCR instrument using the following cycling program (Table 18).  
Table 18. qPCR Cycling Program  
Cycles Temperature (°C) Time (min) Stage 





95 00:15 Denaturation 











The further analysis of the gene expression levels was done with the MxPro software. The 
different melanoma cell lines were compared by analyzing the CT values that represent the PCR 
cycle after which the fluorescent signal reaches a fluorescent threshold (background). The target 
gene expression was normalised to the housekeeping gene TATA-binding protein (TBP). The 
ΔCT (CT gene of interest - CT housekeeping gene) was inserted in the formula 2-ΔCT to calculate 
the relative expression fold change and facilitates the comparative analysis. 
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3.11 Melanoma-NK cell-co-culture 
Initially, 2-5 x 105 melanoma cells were seeded in a 25 cm3 cell culture flask. After 4 h, melanoma 
cells settled down and were challenged with either IL-2 activated primary NK cells or the cell line 
NK-92. After 3-4 days, melanoma cells that survived NK cell killing were split and exposed to a 
new NK cell donor. Remaining NK cells from the previous co-culture were removed by two PBS 
washes. This co-culture cycle was repeated over several weeks. During these cycles, the effector-
target ratio was increased from 1:2 to 4:1 with primary NK cells and from 1:2 to 7:1 with NK-92. 
Untreated melanoma cells with the same culture and splitting conditions were used as a control. 
The melanoma cells of the co-cultures were further characterised using RNA sequencing. For 
that purpose, the isolated RNA requires high purity. To reduce the contamination with RNA of 
NK cells, irradiation (30 Gy) of NK cells right before co-culture experiments induces NK cell 
apoptosis after 6 hours (Seki et al., 1994) and hence limits their survival. Unfortunately, the 
radiation in this dosage has also shown to partially impair the cytotoxic potential of resting NK 
cells (Rana et al., 1990). However, IL-2 stimulated NK cells showed mainly to retain their ability 
to kill K562 and WM3734 (Figure 37). At regular intervals, the susceptibility of to the surviving 
melanoma cells to NK cells were determined.  
3.12 mRNA sequencing of melanoma-NK cell-co-culture 
3.12.1  Sample preparation 
The melanoma cell line WM3734 that have been co-cultured with primary NK cells/NK-92 was 
harvested and their RNA was isolated via phenol-chloroform extraction (see 3.10.1). Isolated 
RNA of two melanocyte cell lines Mel B and Mel W were used as healthy controls. The RNA of 
WM3734 co-cultured with primary NK cells were isolated by Gertrud Schwär. The following 
table shows the collected samples for the performed mRNA sequencing. 
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Table 19. mRNA sequencing melanoma samples under specification of co-culture (I -IV indicate 
different starting points of co-culture), E:T ratio and recovery time 
Sample Co-cultured with E:T Ratio Recovery time 
WM3734  
(I) 
Primary NK cells 2 :1 none 
/ Control / 
WM3734  
(II) 
Primary NK cells 4 : 1 none 
/ Control / 
WM3734  
(III) 
Primary NK cells 4 : 1 none 
Primary NK cells 5:1 none 
/ Control / 
WM3734 
 (IV) 
NK-92 1:7 none 
NK-92 1:7 3 days 
NK-92 1:3 none 
NK-92 1:3 3 days 
/ Control / 
Mel B / / / 
Mel W / / / 
 
3.12.2 mRNA-Seq library preparation  
Further sample preparation, data procession and analysis was done by the epigenetics group of 
Prof. Dr. Jörn Walter of Saarland University in Saarbrücken. mRNA- Seq library preparation and 
the subsequent sequencing was performed by Dr. Gilles Gasperoni as follows. To purify the 
isolated melanoma RNA, the samples were additionally treated with DNaseI to minimize DNA 
contamination. From ~ 200 ng total RNA, mRNA was captured by using streptavidin coated 
tubes (mRNA Capture Kit, Roche). Remaining DNA and ribosomal RNA was removed by 
washing the tubes three times. After that, the first-strand cDNA synthesis was performed by 
adding M-MLV Reverse Transcriptase (Promega) at 37 °C for 1.5 h. Subsequent degradation of 
the RNA template by 5 U RNase H allowed the generation of the double stranded cDNA. For 
this purpose, 10 U DNA Polymerase I (Thermo Fisher Scientific) and 200 U T4-Ligase (NEB) 
were added and incubated for 2.5 h at 16 °C. After another washing step, the cDNA was 
fragmented using the Tn5 transposase from the Nextera Library Preparation kit (Illumina) for 
5 min at 55 ° C. Before fragments were enriched by PCR amplification (9-12 cycles) with the 
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NEB Next PCR Master mix, the samples were purified using the MinElute PCR purification kit 
(Qiagen). The last step before sequencing is the final mRNA-Seq library purification with 0.8 x 
Agencourt AMPure XP beads (Beckman Coulter). Then the libraries were sequenced for 
100 basepairs using a V3 single read flow-cell on a HiSeq 2500 (Illumina).  
3.12.3 mRNA data analysis 
The mRNA sequencing data were further processed and analysed by Dr. Karl Nordström. Low 
quality sequence reads (Q<30) were excluded and adapter sequences were trimmed with 
TrimGalore! (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The remaining 
reads were then aligned to the hg19 reference genome using STAR aligner (Dobin et al., 2013). 
PCR duplicates were detected with the help of the MarkDuplicates function from Picard tools 
(http://broadinstitute.github.io/picard/). In a last step, the reads were summarised with 
featureCounts (Liao et al., 2014) and a differential analysis via edgeR was performed.  
3.13 Flow cytometry 
Flow cytometry allows the examination of different cell parameter such as size, granularity and 
surface as well as intracellular protein expression. In this study, the expression profile of ligands 
and receptors involved in the melanoma NK cell interaction were determined. All used 
fluorochrome conjugated antibodies are listed in Table 3.  
To stain the NK cell receptors and their ligands on the melanoma cell surface the following 
protocol was used. 1x 106 cells were washed (300 x g, 4 min, RT) and resuspended in 100 μl 
staining buffer (1x DPBS + 5 % FCS). NK cells express Fc gamma R III/II that could lead to 
non-specific antibody binding. Therefore, 5 μL of Human TruStain™ (BioLegend 422302), an Fc 
receptor blocking solution, was added to the NK cell suspensions and was incubated for 10 min 
on ice. Melanoma cells do not express this receptor and do not need this blocking. After an 
additional washing step, the staining of NK cells and melanoma cells followed the same protocol. 
5 µL of each antibody was added to 100 µL of the cell suspensions of each sample and was 
incubated at 4 °C, for 25 minutes in the dark. To reduce unspecific binding of the remaining 
antibody, the cells were washed with 1 mL staining buffer (300 x g, 4 min, RT). Afterwards, the 
cells were resuspended in 200-500 μL staining buffer and transferred to a 5 mL tube. For 
intracellular staining, the cells needed to be fixed and permeabilised after the first staining. 
Therefore, the cells were washed for a second time and resuspended in 100 µL staining buffer 
containing 4 % paraformaldehyde. After 20 minutes of incubation, the cells were washed twice 
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with staining buffer to remove the PFA. To permeabilise the cell membrane, the cell pellet was 
resuspended in 200 µL permeabilisation buffer solution, containing 0.1 % saponin. The following 
incubation of 10 min at 4 °C was stopped by another centrifugation (300 x g, 4 min, RT). To 
ensure the permeability of the cell membrane, the subsequent intracellular staining was 
performed in 100 µL permeabilsation buffer with 5 µL antibody. After 20 min at 4 °C, 500 μL 
permeabilisation buffer was added to remove unbound antibody. In a final step, cells were 
centrifuged (300 x g, 4 min, RT) and were resuspended in 200 μL staining buffer.  
For subsequent analysis unstained controls, corresponding isotype controls as well as 
fluorescence minus one (FMO) controls in case of multicolour staining were used. 
To ensure the fluorochrome stability, the tubes were stored in the dark at 4 °C. The fluorescence 
measurements were performed with the FACS Verse of BD (AG Prof. Markus Hoth, Saarland 
University) and FACS Canto II of BD (AG Prof. Schwappach, University Göttingen). 
Analysis: 
For analysis the softwares FlowJo Version 10 and FACS Diva were used.  
Cell debris was excluded by low forward scatter (FSC) and sideward scatter (SSC). The 
fluorescence signal of the remaining cells was detected and quantified. For the quantification and 
statistical analyses, the background fluorescence of the isotype controls were subtracted from the 
signal obtained by stained cells. 
3.14 Determination of protein expression level 
The mRNA levels do not always represent the actual intracellular protein level. Protein 
biosynthesis is a highly regulated process, which involves different control steps where the 
translation can be prematurely terminated. Additionally, the protein half-life can be influenced by 
degradation processes. Therefore, the expression of protein levels can give more information 
about the actual effect of the investigated protein.  
3.14.1 Protein extraction 
Melanoma cells were lysed with the freshly prepared TGH lysis buffer (see chapter 2.2.2). The 
cell lysates were prepared on ice to reduce protein degradation. Before lysis buffer was added the 
cell plates or flasks were rinsed twice with cold 1x DPBS to remove medium residues. Depending 
on plate size and cell confluence, a certain volume of TGH lysis buffer was added. Then the cells 
were scraped off the plates with the help of a rubber cell scraper. The cell solution was 
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resuspended and collected in a 1.5 mL tube. After 10 min of incubation on ice, the cell lysates 
were shortly resuspended again and incubated for another 10 min on ice. To remove cell 
fragments, the cell lysates were centrifuged (11,000 x g, 10 min, 4 °C) and only the clear 
supernatant containing the cell proteins was transferred to a new 1.5 mL tube. The protein 
samples were frozen at – 80 °C until further use.  
3.14.2 Bradford Assay 
To determine the protein concentration of melanoma cell lysates, the Bradford reagent was used.  
The basis of this reagent is Coomassie Brilliant Blue G-250 that shows an absorbance shift 
(465 nm to 595 nm) after binding to protein. A volume of 1 µL of protein lysate was mixed with 
200 µL Bradford reagent and 799 µL H2Odest.. Next, 200 µL of each sample were loaded on a 
96 well plate in triplicates. The absorbance at 595 nm was detected with the Mithras LB940 plate 
reader. The total protein concentration was calculated with the help of a BSA-based standard 
curve (0.5 -20 µg/mL).  
3.14.3 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
the proteins of the prepared lysates by their molecular weight. After applying a voltage, the 
proteins move through a discontinuous polyacrylamide matrix in the direction of the anode. The 
negative charged SDS functions as a surfactant and binds to the amino acids of the proteins. The 
size of the protein correlates with the SDS binding and the resulting negative charge. The matrix 
consists of a stacking gel (5 %) and a separation gel (10 %) as shown in Table 20.  
Table 20. SDS matrix. Composition of stacking and separation gel  
Component 5 % Stacking gel 10 % Separation gel 
H2Odest. 3.08 mL 4.91 mL 
4x TG-buffer 1.25 mL 2.5 mL 
40 % Acrylamide 0.63 mL 2.5 mL 
10 % APS 37.5 µL 75 µL 
TEMED 7.5 µL 15 µL 
The protein lysates were mixed with 4x LaemmLi Sample Buffer (with 355 mM beta-
mercaptoethanol) and denatured at 95 °C for 3 min. Then the samples were loaded into the 
cavities of the gels and a voltage of 80 V was applied. After entering the separation gel, the 
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voltage was increased to 100 V. To determine the protein size the Precision Plus Protein™ Dual 
Color Standard (Bio-Rad, 1610374) was used.  
3.14.4 Immunoblot (Western Blot) 
Following SDS-PAGE, the separated proteins were transferred onto a nitrocellulose membrane 
by using a semi-dry Trans-Blot® Turbo™ Transfer System from Bio-Rad. Before the transfer, 
the nitrocellulose membrane was equilibrated for 3 min in Turbo transfer buffer. At the same 
time, the paper stacks that were used as ion reservoirs were soaked with the same transfer buffer. 
Then the transfer pack was assembled in the following order: bottom ion reservoir stack, 
nitrocellulose membrane, gel and top ion reservoir stack. This transfer pack was placed on the 
bottom (+) cassette and closed with the top (-) cassette. After applying 2.5 A, up to 25 V for 
10 min, the negatively charged proteins were transferred to the nitrocellulose membrane. 
Following this, the membrane was blocked in 1 x TBS + 5 % BSA % at RT for 1 h to prevent 
unspecific antibody binding. Primary antibodies were diluted in 1 x TBS solution supplemented 
with 1 % BSA according to Table 1. After incubation overnight at 4 °C, the membrane was 
washed three times with 1x TBST for 5 min to remove remaining unbound primary antibody. In 
the next step, the IRDye® secondary antibodies were diluted 1:10,000 in 1 x TBST buffer and 
incubated for 1h at RT on a rocker. These secondary antibodies are labelled with a fluorescent 
dye that allows detection by a fluorescent imaging system. Subsequently, remaining secondary 
antibody was removed by washing three times with 1x TBST for 10 min. To visualise the protein 
bands, the membrane was scanned with the Odyssey® CLx Imager from Li-cor.  
3.15 Reverse Phase Protein Array (RPPA) 
The reverse phase protein array (RPPA) is a high throughput approach that allows the 
simultaneous detection and quantification of hundreds of proteins expressed in cells and tissues. 
(Tibes et al., 2006). Therefore, protein lysates were immobilised on nitrocellulose-coated slides 
and probed with primary antibodies. Subsequently, biotinylated secondary antibodies allow the 
detection and quantification of the protein expression (Figure 9). 
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Figure 9. Principle of the Reverse Phase Protein Array (RPPA). Serial diluted cell lysates were arrayed 
on nitrocellulose-coated slides. Specific primary antibody binds target proteins of the lysate spots followed 
by a secondary biotinylated antibody for detection and later visualisation of the protein expression. 
The lysates from different melanoma cell lines were prepared by The Wistar Institute 
(Philadelphia, USA). The RPPA and data processing were performed by the MD Anderson 
Center RPPA core facility (Houston, TX, USA). First, serial-diluted lysates (prepared by Tecan 
Robotic Liquid Handling System) of every melanoma cell line were printed on nitrocellulose-
coated slides using a 2470 Microarray printer of Aushon Biosystems. The small size of the lysate 
spots allows the printing of more than 5000 array spots per slide. To ensure the quality of the 
RPPA, control lysates were placed on each slide. The DAKO Universal Staining System probed 
each slide with a different validated primary antibody under appropriate conditions. Then the 
slides were probed with the corresponding biotin‐conjugated secondary antibody to allow the 
signal amplification by forming an avidin-biotin-complex using the Vectastain Elite ABC kit 
(Vector Lab). The visualisation of the signals were achieved by a secondary streptavidin-
conjugated HRP and following DAB colorimetric reaction. After scanning of the slides, the spot 
intensities were generated by further data analyses and quantification using Array-Pro Analyzer 
software (MediaCybernetics). The different signal intensities of the dilution series of every sample 
were used to create a supercurve fitting (Hu et al., 2007) and increase accuracy of the protein 
concentration determination (in log2 scale). In a last step, the data were normalised by using 
median-centering across antibodies (MD Anderson, 2019). 
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3.16 Inhibitor treatment of melanoma cells 
Melanoma cells (7 x 105) were seeded into 60 mm cell culture dishes 4 hours before inhibitor 
treatment. After the cells settled, the melanoma cells were treated with inhibitors targeting PI3K-
AKT-mTOR pathway (Table 7). Dimethyl sulfoxide (DMSO) was used as a control since all the 
inhibitors were dissolved in DMSO. During the treatment (24 h or 96 h), the cell culture dishes 
were incubated at 37 °C and in 5 % CO2 atmosphere. 
3.17 Statistics 
Data were analysed using Microsoft Excel 2016. Unless noted otherwise, experiments are shown 
as means ± SEM. Statistical significance was determined by two-tailed unpaired or paired 
Student's t-test as indicated. Significance is marked with * for p <0.05, ** for p <0.01 and *** for 
p <0.001. 
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4 Results 
4.1 Effector-to-Target ratio determines effect size of NK cell killing 
The number of tumour infiltrating lymphocytes were associated with enhanced patient survival 
(Cursons et al., 2019; Fortes et al., 2015; Thomas et al., 2013). In this regard, effector-to-target 
ratios (E:T ratios), which represent the NK cell tumour infiltration in a real setting are from 
major biological interest. In a study from 2012, Balsamo and colleagues investigated the NK cell 
infiltration of primary cutaneous melanoma and found that the E:T ratio ranged between 0.03:1 
and 0.5:1 (Balsamo et al., 2012). Based on this knowledge and the most frequently used E:T ratios 
in other studies that used in vitro cytotoxicity assays, four E:T ratios between 0.5 to 1 and 10 to 1 
were tested in two cancer cell lines, K562 and WM3734 (see Figure 10).  
 
Figure 10. Effector-to-target ratio determines effect size of NK cell killing. Calcein-AM (0.5 μM) 
loaded target cells were analysed in four 240 min cytotoxic assays (A and D) with the following E:T ratios: 
0.5:1, 1:1, 5:1 and 10:1. Effector cells were IL-2 stimulated NK cells. K562 (red) and WM3734 (green) 
were used as target cells. For further statistical analysis, the killing after 60 min (B and E) as well as the 
killing after 240 min (C and F) were used. Bars and graphs indicate means ± SEM. Statistical significance 
of paired, two-tailed Student's t‐test is indicated with * for p <0.05, ** for p <0.01 and *** for p <0.001. 
K562 cells were used as a positive control to evaluate the cytotoxicity of the used NK cell donors 
as they showed to be highly susceptible to NK cells due to their ligand profile (Tremblay-McLean 
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expected, and target cells were killed to 100 % after 80 min in E:T ratios higher than 5:1. During 
the initial killing phase, shown in Figure 10 B, the lower E:T ratios showed a much lower killing 
(±16 %) in comparison to the higher E:T ratios (5:1 or 10:1) (±30 %). After 240 min (see Figure 
10 C), the lower E:T ratios only reached a killing of ~39 % and ~69 % at the 0.5:1 and 1:1 ratio, 
respectively. The cytotoxic efficiency of the 5:1 and 10:1 ratios did not differ dramatically in 
K562. In contrast, the melanoma cell line WM3734 was less susceptible to NK cells (Figure 10 
D). Even the highest E:T ratio did not exceed a killing of ~31 % (Figure 10 E) after 1 h and 
~61 % after the 4 h measurement (Figure 10 F). Half the amount of NK cells (E:T ratio of 5:1) 
were still able to kill ±46 % of WM3734 after 240 min. The lowest E:T ratios showed similar flat 
killing curves with an initial killing of ~5 % that increased to ~10-15 % until the end of the 
experiment.  
The cytotoxicity assay requires an adequate dynamic range to detect both an increase as well as a 
decrease of the cancer cell susceptibility to NK cells after treatment with different pharmaceutical 
substances or genetic manipulation. Lower E:T ratios that represent the real intratumoral NK cell 
infiltration were not sufficient to detect smaller differences of melanoma killing in the used 
cytotoxicity assay. In an E:T ratio of 5:1, NK cells kill ~50 % of WM3734 cells and allow the 
adequate detection of an increase as well as a decrease of NK cell-induced cytotoxicity against 
melanoma cells (NKiToxMel). Furthermore, this ratio is sufficient to eliminate 100 % of K562 
cells that serve as a positive control for NK cell cytotoxicity. If not stated differently, an E:T ratio 
of 5:1 was used for subsequent experiments.  
4.2 Interleukin-2 stimulation increases NK cell cytotoxicity  
Interleukin-2 regulates NK cell activity and can increase their cytotoxicity (Henney et al., 1981; 
Lehmann et al., 2001). To investigate if and how IL-2 stimulation affects NKiToxMel, non-
stimulated and IL-2 stimulated (0.05 µg/mL) NK cells from the same donor were used in 
cytotoxic assays. In Figure 11, the results depicting NK cell cytotoxicity against three different 
melanoma cell lines, as well as the control K562, are summarised. In all cell lines, the non-
stimulated NK cells showed significantly lower cytotoxicity than the IL-2 stimulated NK cells 
(see Figure 11 A). This was not only visible at the initial phase of the experiment (Figure 11 B), 
but it also appears at the endpoint of the killing assay (Figure 11 C). Non-stimulated NK cells 
were still able to kill all K562 cells during the observation time of the cytotoxic assay, but they 
needed 2 hours longer than stimulated NK cells (~80 min). Among the investigated melanoma 
cell lines, 1205Lu cells showed the highest susceptibility towards IL-2 stimulated NK cells and 
had an almost identical time course compared with K562-killing by non-stimulated NK cells. In 
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the first hour (Figure 11 B) more than half (~56 %) of the 1205Lu were eliminated. At the end of 
the assay, all 1205Lu were killed by stimulated NK cells (see Figure 11 C). Non-stimulated NK 
cells only killed ~10 % after 60 min and reached a killing plateau of ~34 % after 220 min. 
WM3734 had an intermediate susceptibility to NK cells. Figure 11 C shows that IL-2 stimulated 
NK cells killed ~42 % of WM3734 cells, whereas their susceptibility to non-stimulated NK cells 
is reduced to ± 12 %. WM88 are the least susceptible melanoma cells among those that were 
tested, as non-stimulated NK cells were not able to kill WM88 to any detectable amount. Even 
after stimulation, NK cells only marginally killed this melanoma cell line (12 %).  
 
Figure 11. Interleukin-2 stimulation increases cytotoxicity against cancer cells. NK cell-mediated 
killing of the melanoma cell lines 1205Lu, WM3734 and WM88 as well as the control cell line K562 was 
determined in 4 h a cytotoxic assay (A). NK cells from four different donors either IL-2 stimulated (1-2 
days) or non-stimulated were used as effector cells. For further statistical analysis the killing after 60 min 
(B) as well as the killing after 240 min (C) were used. Bars and graphs indicate means ± SEM. Statistical 


















































































  Results 
56 
As previously shown (Cappello, 2015), the difference between non-stimulated and IL-2 
stimulated NK cells are due to alterations in the NK cell receptor profile and differences in the 
content of lytic granules before and after stimulation. The representative histograms (Figure 12 
A) depict altered expression levels of the NK cell receptors CD16, NKp30, NKG2D, the 
adhesion molecule CD56 as well as perforin and granzyme B. The median fluorescence intensity 
(MFI) was used to compare the expression profile of non-stimulated and IL-2 stimulated NK 
cells (see Figure 12 B). To exclude fluorescence signals, which were caused by non-specific 
antibody binding, the MFI of the corresponding isotype controls were subtracted. In comparison 
to the other analysed parameters, the median fluorescence intensities (MFIs) of the activating 
receptors NKp30 and NKG2D were low (Net MFI of 50 and 187, respectively) in non-
stimulated NK cells. After IL-2 stimulation, the MFI increased to 154 for NKp30 and 908 for 
NKG2D. The detected amount of CD56 expression on the NK cell surface increased almost 
fourfold (MFI of 882 to MFI of 3215) after stimulation. The CD16 surface expression showed 
only a small increase from MFI of 3600 to 4800 after IL-2 stimulation. In addition to the higher 
expression of activating NK cell receptors, the NK cells tended to have a higher content of 
intracellular granzyme B and perforin (from 2822 to 5642 and from 6264 to 9120, respectively). 
These findings are also in agreement with observations from other groups (Balsamo et al., 2013) 
and partially explain the lower cytotoxicity of non-stimulated NK cells to melanoma cells. 
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Figure 12. Interleukin-2 stimulation alters expression profile of NK cells. The expression levels of 
CD16, NKp30, NKG2D, CD56, perforin and granzyme B were analysed with flow cytometry. (A) 
Histograms show the cell distribution according to the emitted fluorescence of the indicated fluorochrome 
conjugated antibodies (see Table 3). The following colour code was used: light grey: non-stained samples; 
dark grey: corresponding isotype controls; blue: non-stimulated NK cell samples; red: IL-2 stimulated NK 
cells (B) The bar graphs show the net median fluorescence intensity (MFI) (minus MFI of corresponding 
isotype control). Bars indicate SEM of 3 NK cell donors. Data were analysed with Flow Jo software 
Version 10. Data were previously shown in (Cappello, 2015)  
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The NK cells were used on different days after IL-2 stimulation. Therefore, it was important to 
estimate the dependence of NK cell cytotoxicity towards melanoma in relation to the duration of 
IL-2 stimulation. As depicted in Figure 13 A, the duration of IL-2 stimulation influenced the NK 
cell cytotoxicity towards cancer cells only marginally. Figure 13 B shows that NK cells after 1-3 
days of IL-2 stimulation had significant higher cytotoxicity (~73 % and ~54 % after 60 min) 
towards the cell lines K562 and 1205Lu. WM3734 cells and WM88 cells were best eliminated by 
NK cells stimulated for 4-7 days with IL-2 (compare Figure 13 C). Nevertheless, these minor 
alterations in NK cell cytotoxicity in the course of IL-2 stimulation can be neglected as the 
general susceptibility of melanoma cells to NK cells is unchanged.  
 
Figure 13. NK cell cytotoxicity stays nearly unchanged in the course of Interleukin-2 stimulation. 
The susceptibility of the melanoma cell lines to NK cells that were stimulated with IL-2 over multiple 
days: K562 1-3 d (n=84), 4-7 d (n=39), 8-11 d (n=33); 1205Lu 1-3 d (n=15), 4-7 d (n=2), 8-11 d (n =5); 
WM3734 1-3 d (n=50), 4-7 d (n=21), 8-11 d (n=8); WM88 1-3 d (n=5), 4-7 d (n=8). (A) Kinetics of 4 h 
cytotoxic assay. For further statistical analysis the killing after 60 min (B) as well as the killing after 240 
min (C) were used. Bars and graphs indicate means ± SEM. Statistical significance of unpaired, two-tailed 
Student's t‐test is indicated with * for p<0.05. 
Altogether, the data presented here indicate that IL-2 stimulation increased the NK cell 
cytotoxicity against cancer cells. This increase could be partly explained by the IL-2 induced 
upregulation of activating NK cell receptors that were required for detection of tumour cells. 
Since the duration of the IL-2 stimulation marginally altered the general NK cell cytotoxicity 
against tumour cells; isolated NK cells were used for cytotoxicity assays between one and 11 days 
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4.3 Heterogeneous susceptibility of melanoma cells to primary NK cells  
To reveal the therapeutic potential of NK cells in melanoma treatment, we initially assessed the 
susceptibility of eight genetically diverse melanoma cell lines to primary NK cells (Figure 14). As 
seen in Figure 14 A, the performed cytotoxic assays revealed heterogeneous susceptibility of the 
different melanoma cell lines to primary NK cells. The most susceptible melanoma cell line was 
1205Lu that was killed to ~91 %, whereas WM88 was largely resistant (14 %) to the NK cell-
mediated killing (Figure 14 B). These differences were already visible after 60 min (Figure 14 C), 
where the cell lines 1205Lu and WM88 also showed the highest (52 %) and lowest (8 %) killing, 
respectively. The endpoint killing of the other investigated melanoma cell lines ranged from 31 % 
(WM1366) to 68 % (WM3918) although the killing after 60 min showed similar results (26 % and 
20 %, respectively). This can be partially explained by a different shape of the killing curves. As 
seen in Figure 14 A, the killing of WM1366 cells stagnated after 1 hour of the experiment while 
the killing of WM3918 cells showed a more linear progression. A similar pattern of linear 
progression was found in the cell lines WM9 and WM983B. Both cell lines were initially killed to 
less than 18 % and reached maximal killing values of 42 % and 46 % after 4 h. WM3734 cells 
showed an initial susceptibility to NK cells of 31 % and stagnated in the next two hours to about 
50 %. A slower stagnation of the killing was visible in the cell line 451Lu, which showed at the 
first half of the measurement a comparable killing curve to WM3734 with also 31 % killed after 
60 min but reached an endpoint killing of 62 %. The heterogeneity between the different cell 
lines after 60 min were much smaller and less statistically significant (Figure 14 D) compared to 
the killing results after 240 min (Figure 14 E). 
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Figure 14. NK cell-mediated killing of melanoma cell lines is heterogeneous. Melanoma cells are 
loaded with calcein-AM (0.5 μM) and exposed to NK cells (E:T ratio of 5:1) for 4 h. Melanoma cells in 
the cytotoxic assays are: n (1205Lu): 19; n (WM3918): 20; n (451Lu): 6; n (WM3734): 79; n (WM983B): 10; 
n (WM9): 11; n (WM1366): 7 and n (WM88): 20. (A) Killing kinetics of 4h cytotoxic assay. Quantification 
of killing efficiency after 60 min (B) and after 240 min (C) were used to perform Student's t‐tests (D+E). 
Bars and graphs indicate means ± SEM. Statistical significance of unpaired, two-tailed Student's t‐test is 
indicated with * for p<0.05, ** for p <0.01 and *** for p<0.001. Data was partially obtained from 
(Cappello, 2015). 
The NK cell cytotoxicity is determined in part by the engagement of NK cell receptor with their 
corresponding ligands (Long et al., 2013). One of the best investigated inhibitory ligands are 
MHC class I molecules (HLA-A,B,C) that protect target cells against NK cell killing (Karre, 
2002). To estimate if and how MHC class I surface expression affect the susceptibility of 
melanoma cells to NK cells, the expression of this inhibitory ligand in selected cancer cell lines 
was further analysed by flow cytometry. Figure 15 A shows that the expression of MHC class I 
molecules in melanoma cell lines (coloured histograms) was more dominant compared to the cell 
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antigens (Net MFI of ~300) on their cell membranes, whereas the melanoma cell lines expressed 
much higher levels of MHC class I (Net MFI < 10000) (see Figure 15 B). In comparison to 
WM88 and 1205Lu (both around ~ 18,000), the expression level of this inhibitory ligand in 
WM3734 cells (~ 38,000) was slightly increased. Hence, there was no linear correlation between 
NK cell susceptibility of melanoma cells and their levels of MHC class I expression.  
 
Figure 15. MHC class I expression does not explain the susceptibility of melanoma cells towards 
NK cell killing. The expression levels of MHC class I (HLA-A,B,C) in WM88 (orange, n=4), WM3734 
(green; n=3), 1205Lu (blue; n=4) as well as K562 (dark grey; n=4) were determined by flow cytometric 
analysis. (A) Representative histogram shows the cell counts according to the emitted fluorescence signal 
of the HLA-A,B,C Alexa 647 antibody coated target cells. Controls were unstained samples as well as 
isotype controls. (B) The bars show the net median fluorescence intensity (MFI) (minus MFI of 
corresponding isotype control) in correlation to the NK cell-mediated killing. Bars indicate means ± SEM. 
Data were analysed with Flow Jo software Version 10. 
However, the inhibitory ligands alone do not determine the NK cell activation (Karre, 2002). In 
addition, the stimuli received by activating NK cell receptors are needed for the initiation of NK 
cell killing. The ligands for the activating NKG2D receptor MICA/MICB (80 %) and ULBPs 
(15-25 %) are frequently expressed in melanoma (Casado et al., 2009). Furthermore, NCRs (in 
particular NKp30 that targets among others B7-H6 molecules) were shown to be important for 
the NK cell-induced toxicity against melanoma cells (NKiToxMel) (Morgado et al., 2011). To test 
if activating ligands on the melanoma surface affect the susceptibility to NK cells, the expression 
profile of MICA/MICB, ULBP-2/-5/-6 and B7-H6 in three melanoma cell lines were 
determined using multicolour staining. Figure 16 A shows that ULBPs and B7-H6 were only 
marginally expressed in the analysed melanoma cell lines. Only MICA/MICB expression were 
visibly heterogeneous in the distinct melanoma cell lines. However, additional flow cytometric 
analysis showed that the expression levels of all activating ligands increased with higher 
susceptibility of melanoma cells to NK cells (Figure 16 B). WM88 cells had the lowest expression 
of activating ligands (Net MFI <10), whereas the cell line WM3918 showed the highest levels of 
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had moderate MICA/MICB levels (net MFI of 60). ULBPs and B7-H6 were only marginally 
expressed (Net MFI <10). In conclusion, the expression profile of the activating ligand 
MICA/MICB were in line with the measured susceptibility of melanoma to NK cells. Since the 
other activating ligands were only marginally expressed, no further conclusions about their role in 
the NK cell-mediated killing could be drawn.   
 
Figure 16. Activating ligands partially explain the susceptibility of melanoma cells towards NK 
cells . Flow cytometric analysis of the expression levels of MICA/MICB, ULB-2/-5/-6 and B7-H6 in 
WM88 (orange, n=3), WM3734 (green; n=3), WM3918 (purple; n=3). (A) Representative histograms 
show the cell counts according to the emitted fluorescence signal of the indicated antibody coated target 
cells. Controls were unstained samples, isotype controls as well as FMO controls. (B) The bar graphs 
show the net median fluorescence intensity (MFI) (minus MFI of corresponding isotype control) in 
correlation to the NK cell-mediated killing. Bars indicate means ± SEM. Data were analysed with Flow Jo 
software Version 10. 
In conclusion, the obtained data shows that the susceptibility of melanoma cells to NK cells was 
highly heterogeneous. There were some indications that this heterogeneity was partially caused by 
a distinct activating ligand profile on the surface of melanoma cells. However, MHC class I 
molecules as an inhibitory NK cell ligand were not associated with the NKiToxMel. 
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4.4 Reverse phase protein array reveals proteins correlating with susceptibility to 
NK cells 
The investigated melanoma cell lines were derived from different disease stages and have 
different genetic backgrounds. Therefore, the factors determining the observed heterogeneity in 
susceptibility to NK are rather complex. As flow cytometry only allows the investigation of a 
limited number of proteins, we used reverse phase protein array (RPPA) (see page 50) to identify 
melanoma proteins correlating with the observed NK cell killing. This method allows the 
simultaneous detection and quantification of more than 300 cancer related proteins (Tibes et al., 
2006). The melanoma protein lysates were arrayed on slides and probed with primary antibodies 
that were detected with biotinylated, secondary antibodies (MD Anderson, 2019). After the 
quantification of the signal intensities, the protein expression data were normalised by using 
median-centering across antibodies. In Figure 17, all proteins that showed high Pearson 
correlation coefficient (>±0.7) between protein expression and NK cell-mediated killing were 
summarized in a heat map. For better visualisation of the heat map, the log2MedCen intensities 
values were transformed into the standard scores (z-score) scaled by individual gene (row). As 
seen in the heat map (Figure 17), melanoma cell lines that have a higher susceptibility to NK cells 
showed an opposed expression profile to the melanoma cells with higher NK cell resistance. 
Using this analysis, we identified a number of proteins that positively (yellow) or negatively 
(purple) correlate with the killing efficiency. Interestingly, SNAI1, a transcription factor that 
promotes EMT (Poser et al., 2001), showed a strong association with NK cell mediated killing of 
melanoma. Other EMT related proteins that were identified were TWIST2 (Kang and Massague, 
2004; Mao et al., 2012), protein tyrosine kinase 2 (PTK2) (Giehl and Menke, 2008) and Napsin A 
Aspartic Peptidase (NAPSA) (Zhou et al., 2018a). Surface receptors such as transferrin receptor 
(TFRC), platelet derived growth factor receptor beta (PDGFRB), progesterone receptor (PGR) 
were part of the heat map as well. In addition, several proteins involved in the regulation of 
general cell metabolic processes were identified as possible regulators of NKiToxMel. Among 
them, hexokinase (HK2) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are 
important glycolytic enzymes (Lunt and Vander Heiden, 2011), while RPTOR Independent 
Companion Of MTOR Complex 2 (RICTOR) and proline-rich Akt substrate of 40 kDa 
(PRAS40) (Saxton and Sabatini, 2017) are regulating components of the mTOR signalling axis. 
DIABLO, an mitochondrial protein that promotes the initiation of apoptosis (Du et al., 2000) 
was the top hit of the negative correlated proteins. Additional identified proteins involved in 
programmed cell death were BAD and CASP3 (Elmore, 2007). 
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Figure 17. Melanoma protein signature determines susceptibility to primary NK cells. Heat map of 
the protein expression profile of eight melanoma cell lines shown in Figure 14. Protein expression of the 
RPPA are given as median centered log2 intensities. The correlation between NK cell killing and protein 
expression was determined by the Pearson correlation coefficient. For better visualisation of the heat map 
the log2MedCen intensities values were transformed into the standard scores (z-score) scaled by individual 
gene (row). Proteins that correlated directly (yellow) with the killing efficiency were: SNAI1, COP9 
signalosome subunit 5 (COPS5), HK2, PRAS40, RICTOR, TFRC, PDGFRB, L1 Cell Adhesion Molecule 
(L1CAM), WW Domain Containing Transcription Regulator 1 (WWTR1), BAD (pS122), PTK2, Heat 
Shock Factor Binding Protein 1 (HSBP1), GAPDH and X-Ray Repair Cross Complementing 1 (XRCC1). 
A negative correlation was observed in the case of NRAS, MET, PDGFRB (pY716), PGR, Annexin A7 
(ANXA7), (TWIST2), NAPSA, CASP3, Lymphocyte Cell-Specific Protein-Tyrosine Kinase (LCK) and 
DIABLO. The heat map was generated by using the gplots package in R.  
As discussed above, melanoma proteins that highly correlated with NK cell killing are involved in 
several distinct cellular processes. The expression pattern of these identified molecular 
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determinants of melanoma susceptibility towards NK cell killing was named ‘melanoma killing 
signature’ and was applied to predict NK cell-induced cytotoxicity against different untested 
melanoma cell lines.  
4.5 Melanoma killing signature allows the prediction of susceptibility to NK cells  
The prediction of treatment success is a crucial part in developing a proper therapeutic strategy. 
Since in vitro studies could give indications about the success of treatment, the protein expression 
profile of the different melanoma cell lines was used to develop a simple prediction model. The 
original median centered log2 intensities (Log2MedCen) of all proteins that showed a higher 
Pearson correlation coefficient than ±0.7 are depicted in Table 21. The intensity values of 
negatively correlated proteins (highlighted in grey) were inverted and the average expression of 
the melanoma killing signature was determined for each melanoma cell line for later linear 
regression analysis.  
Table 21. Correlation of melanoma protein expression with NK cell susceptibility 
 Cell line WM88  WM1366  WM9  WM983B  WM3734  451Lu  WM3918  1205Lu  
Correlation 





















SNAI1 -0.07 -0.005 -0.035 0.119 0.129 0.064 0.255 0.328 0.906 
COPS5  -0.044 0.03 0.043 0.142 0.116 0.049 0.1 0.204 0.825 
HK2 -0.241 -0.101 0.144 0.042 0.146 0.244 0.102 0.212 0.825 
BAD (pS112) -0.352 -0.152 0.18 -0.015 -0.108 0.031 -0.132 0.334 0.73 
RICTOR 
(pT1135) 
-0.488 -0.138 0.266 0.371 -0.308 -0.041 0.304 0.65 0.75 
PRAS40 -0.395 0.161 -0.101 0.039 0.024 0.34 0.196 0.242 0.76 
GAPDH -0.859 0.369 -0.296 -0.176 0.231 0.453 0.299 0.411 0.717 
TFRC -0.584 -0.226 0.191 -0.034 0.084 0.802 0.491 0.246 0.746 
WWTR1 -0.052 0.03 0.166 0.605 0.462 1.238 0.062 1.386 0.731 
L1CAM -1.726 -0.365 -0.51 0 -0.715 0.535 1.701 0.252 0.739 
PDGFRB -0.173 0.371 -0.203 -0.029 -0.016 -0.2 2.081 2.223 0.745 
XRCC1 -0.296 -0.101 -0.45 0.069 -0.048 -0.064 -0.129 0.432 0.709 
HSBP1 (pS82) -0.359 -0.376 -0.234 -0.659 -0.22 -0.269 0.303 0.218 0.719 
PTK2 -0.086 -0.606 -0.201 -0.276 0.05 0.429 0.055 0.455 0.723 
NRAS -0.078 0.033 -0.025 0.079 -0.045 0.049 0.144 0.088 0.706 
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 Cell line WM88  WM1366  WM9  WM983B  WM3734  451Lu  WM3918  1205Lu  
Correlation 
Killing (%) 14.3 31.0 42.1 45.0 50.3 62.0 69.4 90.9 
PDGFRB 
(pY716) 
-0.079 0 -0.205 0.14 0.04 0.191 0.281 0.239 0.755 
MET -0.015 0.018 -0.064 -0.029 0.043 -0.051 0.065 0.317 0.707 
ANXA7 -0.166 -0.213 -0.165 -0.133 -0.088 -0.163 0.059 0.006 0.76 
PGR -0.104 0.054 -0.076 -0.093 0.028 0.081 0.013 0.178 0.757 
NAPSA -0.124 -0.077 0.006 0.223 0.122 0.099 0.104 0.243 0.805 
TWIST2 -0.128 0.019 0.018 -0.054 -0.059 0.055 -0.004 0.111 0.768 
CASP3 -0.057 -0.101 0.065 0.007 -0.001 0.065 0.019 0.153 0.828 
LCK -0.256 -0.323 -0.094 0.02 -0.137 0.194 0.127 0.225 0.885 
DIABLO (Smac) -0.129 -0.035 -0.056 0.082 0.187 0.468 0.266 0.47 0.9 
 Average  -0.286 -0.072 -0.068 0.018 -0.003 0.192 0.282 0.401 
  
Simple linear regression analysis showed a strong correlation (r > 0.96) between this average 
expression (log2MedCen) of the melanoma killing signature and the NK cell-mediated killing of 
the same melanoma cell lines (Figure 18).  
 
Figure 18. Linear regression analysis of the melanoma killing signature is used to establish a 
killing prediction model. The average expression of the melanoma killing signature (Table 21) correlates 
with NK cell-induced cytotoxicity against melanoma cells.  
Given the high correlation, we postulated that we could use the average expression of the 
melanoma killing signature to predict the NK cell-induced cytotoxicity against additional 
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melanoma cell lines. To validate this prediction model, we calculated the expected NK 
susceptibility of eight additional, previously untested melanoma cell lines with the help of the 
simple linear regression equation (Figure 19 A). Subsequently, the susceptibility of these eight 
melanoma cell lines was determined experimentally using the above-described killing assay 
(Figure 19 B). As expected, the new panel of melanoma cell lines were killed to varying amounts 
by primary NK cells. The most resistant melanoma cell line was WM3268 that was only killed 
about 23 % after 4 h, whereas WM3682 was highly susceptible (~81 %) to primary NK cells. In 
addition, the endpoint killing of WM858 cells (~71 %) was comparable to the susceptibility 
results of the cell line WM793 (~69 %), whereas WM858 cells were initially killed faster. In 
comparison to WM3482 cells that show a stagnant course of killing curve with a maximal killing 
of 33 %, the cell line WM902B has a linear course of killing that reached after 240 min almost 
47 %. Furthermore, WM164 cells and WM47 cells were eliminated to ~55 % and ~62 %, 
respectively. In Figure 19 C, the experimental data of the cytotoxic assays are compared to the 
melanoma susceptibility of the prediction model. Although, the NK cell-mediated killing of 
WM3682 and WM3268 was predicted to be similar (35 % and 39 %, respectively), only the low 
susceptibility of WM3268 (~23 %) to NK cells was experimentally validated. A better match was 
achieved with WM47 (~61 %) that was predicted to be eliminated about 53 % after 4 h. The 
experimental data of WM902B (~47 %) and WM164 (~55 %) were a slightly lower than the 
predicted killing (~62 %, ~69 %), but showed good correlation. The predicted susceptibility of 
WM858 (~70 %), WM793 (~64 %) and WM3482 (~33 %) almost matches the results of the 
killing assays (66 %, 65 %, 38 %). WM3682 was the only cell line that showed immense 
aberration between predicted and experimental killing. The susceptibility of WM3682 might have 
other genetically reasons and be dominated by distinct proteins than the majority of the 
investigated melanoma cell lines. Therefore, this cell was excluded from subsequent linear 
regression analysis. Although the prediction model sometimes over- or underestimated the 
experimental NK cell-mediated killing of the seven melanoma cell lines, Figure 19 D shows that 
the correlation of predicted and validated killing was relatively high (0.67).  
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Figure 19. Validation of the prediction model. (A) The susceptibility of eight additional melanoma cell 
lines was calculated with the help of their protein signature. (B) Subsequent cytotoxicity assays with the 
tested melanoma cell lines: n (WM3682): 10; n (WM858): 10; n (WM793): 7; n (WM47): 9; n (WM164): 3; 
n (WM902B): 3; n (WM3482): 8 and n (WM3268): 3. Effector cells were IL-2 activated primary NK cells. 
Graphs indicate means ± SEM (C) Predicted as well as validated killing after 240 min. Bars of the 
validation indicate means ± SEM. (D) Correlation of predicted and validated end killing (240 min) of all 
investigated cell lines with trend line and under specification of their correlation (with exclusion of 
WM3682).  
These data clearly indicated that this model can be used to predict the rough NK cell cytotoxicity 
against melanoma cells and might help in estimating if a patient would benefit from a NK cell-
based therapy.  
4.6 Single regulators of the melanoma cell susceptibility to NK cell killing 
The killing data of the additional validated melanoma cell lines was further used to identify the 
pivotal proteins involved in the susceptibility of melanoma to NK cell killing. Therefore, the 
additional seven melanoma cell lines were included in the previously described RPPA analysis 
(chapter 4.4). This additional analysis identified the proteins SNAI1 and DIABLO with Pearson 
correlation coefficients <±0.7 as the most important determinants of NKiToxMel. All other 
proteins of the melanoma killing signature showed lower correlation with NK cell killing.  
In order to validate SNAI1 and DIABLO as regulators of melanoma cell susceptibility to NK 
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4.6.1 DIABLO is a potential negative regulator of NK cell-mediated killing 
DIABLO is a mitochondrial protein that promotes apoptosis by binding inhibitors of apoptosis 
proteins (Verhagen et al., 2000). Taken that the expression levels of DIABLO showed highest 
inverse correlation with NKiToxMel (Table 21), the role of DIABLO in melanoma susceptibility 
to NK cell killing was investigated in more detail.  
To examine the expression of DIABLO in melanoma cell lines, the initial ‘prediction model cell 
panel’ melanoma cell panel was analysed using immunoblot analyses. In Figure 20, the protein 
abundance of DIABLO in 8 different melanoma cell lines (training panel) is shown. The 
expression was normalised to the reference protein calnexin. Similar to the RPPA data, the 
expression of DIABLO decreased with increasing susceptibility to NK cells. For example, WM88 
cells expressed double the amount of DIABLO (0.77) in comparison to 1205Lu (0.38).  
 
Figure 20. DIABLO abundance in melanoma correlates with their susceptibility to NK cells(A) 
Representative immunoblot. (B) Mean and SEM of five analysed immunoblots under specification of the 
protein expression normalised to the loading control Calnexin. The coloured dots correspond to each cell 
line presented in (A) in order of appearance from left to right. 
After validation of the endogenous protein abundance, the expression of DIABLO was 
genetically altered to examine if and how DIABLO abundance affects NKiToxMel. Transient 
overexpression of a gene of interest with a plasmid construct is an established approach to 
investigate a functional role of a given protein. The use of a GFP labelled plasmids allows an easy 
validation of transfection efficiency. Hence, melanoma cells were transfected with pmax GFP, a 
plasmid with high transfection efficiency and GFP signal intensity. After 24 h, the targets cells 
showed a strong GFP signal and were used in our future cytotoxic assays. Because it was possible 
that GFP may interfere with the fluorescence signals from calcein-AM also used in the cytotoxic 
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and non-transfected WM88 cells (A) and WM47 (B) show almost identical killing curves. 
Therefore, the interference of the much weaker GFP signals in the calcein-AM based cytotoxic 
assay could be excluded.  
 
Figure 21. GFP signal does not interfere with calcein-AM detection. WM88 (A) and WM47 (B) were 
transfected with pmax GFP. After 24 h transfected as well as melanoma cells were challenged with one 
primary NK cell donor (A) and NK-92 cell line (B) in a 4 h real-time killing assay. 
The 1205Lu line has one of the lowest DIABLO expression and was thus used to test if and how 
DIABLO-GFP overexpression affects NKiToxMel. The GFP construct allowed monitoring of 
the DIABLO expression and determination of the harvesting time after transfection. The 
overexpression of DIABLO after 24 h of the performed transfection showed an almost 30-fold 
increased expression of DIABLO-GFP (Figure 22 A-B). Notably, in the cells overexpressing 
DIABLO-GFP, the endogenous expression of DIABLO was reduced by about 20 %. However, 
despite the validated overexpression, the susceptibility of 1205Lu was not influenced by the 
higher protein abundance of DIABLO. As seen in Figure 22 C, the killing curve of DIABLO-
GFP transfected 1205Lu cells was almost congruent with the killing curve of the peGFPC1 
control. Both curves showed an initial killing of ~30 % (Figure 22 D) that increased to a value of 
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Figure 22. Overexpression of DIABLO does not change susceptibility of melanoma towards NK 
cells. 1205Lu cells were transfected with a DIABLO-GFP construct or with the control plasmid 
peGFPC1. After 24 h cells were harvested and the DIABLO expression was analysed. (A) Representative 
immunoblot (B) The band intensities of 3 immunoblots were quantified with Image StudioTM Lite 
Software. The band intensities of DIABLO (DIABLO-GFP; endogenous DIABLO) were normalised to 
the band intensities of the loading control Calnexin. (C-E) The susceptibility of DIABLO overexpressing 
1205Lu cells were determined in 4 h real-time killing assays. 1205Lu cells transfected with DIABLO-GFP 
or with the empty plasmid peGFPC1 were exposed to primary NK cells (n=6) in E:T ratio of 5:1. (C) 
Killing kinetics of 4 h cytotoxic assay. (D) Killing after 60 min and (E) killing after 240 min. All bars and 
graphs indicate means ± SEM. 
Given the fact that DIABLO interacts with other proteins such as XIAP, increasing levels of 
DIABLO alone, without changing expression levels of its interaction partners might not affect 
the NKiToxMel. That is why the downregulation of DIABLO was tested next. For this purpose, 
the WM3734 cells that showed higher expression of DIABLO were transfected with two 
different siRNAs (#1, #2). One day after the initial transfection, the transfection procedure was 
repeated. After additional 24 h, WM3734 cells were harvested and further analysed. As shown in 
Figure 23 A and B, the protein abundance of DIABLO after 24 h of double transfection was 
reduced by 22 % (#2) and 41 % (#1). The transfection with DIABLO #2 was not sufficient to 
alter the NKiToxMel whereas DIABLO #1 siRNA slightly increased the susceptibility of 
WM3734 to primary NK cells (Figure 23 C). The initial killing (Figure 23 D) could be 
significantly increased from 47 % to 53 % after DIABLO knockdown. This increased 
susceptibility to NK cells of about 6 % was also detectable 4 h after the NK cell treatment (68 % 
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Figure 23. DIABLO knockdown slightly increases susceptibility of melanoma towards NK cells. 
WM3734 cells were transfected with non-silencing RNA or with two different siRNA (#1 and #2) 
targeting DIABLO. The next day, the procedure was repeated and WM3734 cells were harvested and 
further analysed after additional 24 h. The DIABLO expression of WM3734 after DIABLO knockdown 
was analysed. (A) Representative immunoblot. (B) The band intensities of 4 immunoblots were quantified 
with Image StudioTM Lite Software. The band intensities of DIABLO were normalised to the band 
intensities of the loading control Calnexin. (C-E) The susceptibility of WM3734 after DIABLO 
knockdown was determined in 4 h real-time killing assays. Target cells were exposed to primary NK cells 
(n=4) in E:T ratio of 5:1. (C) Killing kinetics of 4 h cytotoxic assay. (D) Killing after 60 min and (E) killing 
after 240 min. All bars and graphs indicate means ± SEM. Statistical significance of unpaired (B) or paired 
(D), two-tailed Student's t‐test is indicated with * for p<0.05 and ** for p<0.01 
Although the abundance of DIABLO showed the expected heterogeneity in the melanoma cell 
lines and was even associated with their susceptibility to NK cells (Figure 20), short-term altered 
expression level of DIABLO did not resulted in dramatic changes in NKiToxMel. These data do 
not exclude the potential role of DIABLO in susceptibility of melanoma to NK cell killing. 
Longer overexpression times or the stable knockdown of DIABLO might be needed to alter 
NKiToxMel more efficiently. 
4.6.2 SNAI1 is a positive regulator of NK cell-mediated killing of melanoma 
Contrary to DIABLO, previous data (see above) indicated that the protein SNAI1, also known as 
Snail, positively influences the susceptibility of melanoma cells towards primary NK cells. SNAI1, 
a zinc finger protein, is a key regulator of EMT by repressing E-cadherin expression (Kaufhold 
and Bonavida, 2014; Wang et al., 2013). To test the expression of SNAI1 in the investigated 
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performed. Figure 24 shows that, the mRNA levels of SNAI1 in eight melanoma cell lines were 
associated with their susceptibility to primary NK cells. The 2-Δ Cq expression values were 
normalised to the housekeeping gene TBP. The melanoma cell lines WM88 and WM1366 with 
lowest susceptibility to NK cell killing did not express SNAI1. The majority of the other 
melanoma cell lines showed mRNA levels of SNAI1 higher than 0.8. Only WM3918 revealed 
low SNAI1 mRNA level (0.22) that mismatched with their high NK cell susceptibility. 
Nevertheless, increasing SNAI1 mRNA level was associated with higher NKiToxMel. 
 
Figure 24. The expression of SNAI1 in melanoma cells is associated with their susceptibility to 
NK cells.  The mRNA expression levels (2-Δ Cq) of 8 melanoma cell lines were normalised to the 
housekeeping gene TBP. The melanoma cell lines used were WM88 (orange, n=5), WM1366 (light blue, 
n=5), WM9 (red, n=5), WM983B (yellow, n=5), WM3734 (green, n=5), 451Lu (rosé, n=5), WM3918 
(purple, n=4) and 1205Lu (dark blue, n=5).  
As WM88 cells were shown to be SNAI1 negative, this cell line was used for further 
overexpression experiments. Hence, WM88 was transfected with a SNAI1-GFP construct or the 
corresponding empty plasmid peGFPC1. As seen in Figure 25 A, WM88 cells already showed a 
stable GFP signal after 24 h. Additionally, the overexpression was validated by immunoblot 
analysis (Figure 25 B). The SNAI1 expression in WM88 could be significantly increased more 
than 50 times (Figure 25 C). Subsequent real-time killing assays depicted in Figure 25 D showed 
that the SNAI1 overexpression led to a higher NKiToxMel. The initial killing (Figure 25 E) of 
SNAI1-GFP transfected WM88 was almost doubled in comparison to the control plasmid. This 
trend continued and strengthened during the whole course of the cytotoxic assay. After 240 min, 
the killing of WM88 was significantly increased from ~12 % (peGFPC1 plasmid) to 23 % (Figure 
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Figure 25. Overexpression of SNAI1 increases the susceptibility of melanoma cells towards NK 
cells. WM88 was transfected with a SNAI1-GFP construct or with the control plasmid peGFPC1. After 
24h cells were harvested and SNAI1 expression was analysed. (A) Representative immunoblot. (B) The 
band intensities (n=6) of immunoblots were quantified with Image StudioTM Lite Software. The band 
intensities of SNAI1 were normalised to the band intensities of the loading control Calnexin. (C-E) The 
susceptibility of SNAI1 overexpressing WM88 cells was determined in 4 h real-time killing assays. WM88 
cells transfected with SNAI1-GFP or peGFPC1 control plasmid were exposed to primary NK cells 
(n=10) in E:T ratio of 5:1. (C) Killing kinetics of 4 h cytotoxic assay. (D) Killing after 60 min and (E) 
killing after 240 min. All bars and graphs indicate means ± SEM. Statistical significance of paired (D+E) 
and unpaired (B), two-tailed Student's t‐test is indicated with ** for p<0.01. 
SNAI1 was validated as a positive regulator of the NK cell-mediated killing of melanoma cells 
since elevating SNAI1 expression was associated with higher susceptibility of melanoma cells to 
NK cell killing and the overexpression of SNAI1 increased NKiToxMel.  
4.7 Susceptibility of melanoma cells towards NK-92 killing shows heterogeneity 
similar to primary NK cells  
The use of primary NK cells in clinical applications can be challenging since NK cell proliferation 
and reliable NK cell cytotoxicity are limiting factors. Therefore, the use of NK cell lines or iPSC-
derived NK cells as an ‘off-the-shelf therapeutic’ with enhanced cytotoxicity by genetic 
modifications as well as increased expansion potential are attractive alternatives in adoptive cell 
transfer (Suck et al., 2016). For this reason, the cytotoxicity of the NK cell line NK-92 against 
nine different melanoma cell lines and the control cell line K562 was tested. Figure 26 A shows 
that also NK-92 induced heterogeneous melanoma killing, with a pattern similar to the one of the 
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26 B) is in average lower when compared to the primary NK cells. Even the positive control cell 
line K562 was only killed to 88 % after 240 h. Comparable to the primary NK cells, the 
melanoma cell line 1205Lu showed the highest (~64 %) susceptibility to NK-92, whereas WM88 
was resistant (1 %) against NK-92 killing. In addition, Figure 26 C shows that the initial NK-92 
killing of melanoma was lower on average than primary NK cell killing (7 %). The susceptibility 
of the other cell lines ranged between 11 % (WM3482) and 52 % (WM3682). WM983B and 
WM3734 were again in the middle range (29 % and 25 %, respectively) of the determined 
effector killing. One group of melanoma cells consisting of WM47, WM3918 and WM858 
showed much lower susceptibility (< 25 %) towards NK-92 than expected from the previous 
experiments with primary NK cells. Despite this discrepancy, the cytotoxicity of primary NK 
cells and NK-92 against melanoma cells showed a good correlation (Figure 26 D), although the 
cytotoxic potential of NK-92 against melanoma cells was lower. 
 
Figure 26. Susceptibility of melanoma cell lines to NK-92 is heterogeneous. The melanoma cell 
lines used in the 4h real-time killing assays were: 1205Lu (n=5), WM793 (n=3), WM983B (n=4), WM3734 
(n=16), WM858 (n=4), WM3918 (n=4); WM47 (n=5), WM3482 (n=3) and WM88 (n=11). As a positive 
killing control, K562 (n = 43) was used. (A) Killing kinetics of 4 h cytotoxic assay. (B) Killing after 60 min 
and (C) killing after 240 min. (D) Correlation of primary NK cell and NK-92 mediated end killing 
(240 min) of all investigated cell lines with trend line and under specification of their correlation. Bars and 
graphs indicate means ± SEM. 
Since the pattern of the NK-92 and primary NK cells showed similarities, the investigation of the 
proteins that are involved in the susceptibility of melanoma towards NK-92 could provide a 
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Accordingly, the RPPA data was correlated with the NK-92 killing results of the nine tested 
melanoma cell lines. The proteins with high Pearson correlation coefficients (> ± 0.7) were 
termed ‘melanoma-NK-92 killing signature’ and are summarised in Table 22.  
Table 22. Correlation of melanoma protein expression with NK-92 cell susceptibility  
 Cell line WM88  WM3482 WM47  WM3918  WM858  WM3734  WM983B WM793 1205Lu  
Correlation Killing 
(%) 























-0.03 -0.08 -0.03 -0.09 -0.03 0.02 0.01 0.19 0.23 0.85 
BAD 
(pS112) 
-0.35 -0.05 -0.03 -0.13 -0.26 -0.11 0.102 0.28 0.33 0.84 
XRCC1 -0.30 -0.01 -0.10 -0.13 -0.30 -0.05 0.07 0.44 0.43 0.82 
RPS6K 
(pT573) 
-0.51 -0.20 0.08 -0.44 0.00 0.29 -0.07 0.67 0.62 0.82 
TGM2 -0.08 -0.14 -0.05 0.07 0.45 0.31 0.08 0.30 0.55 0.81 
HK2 -0.24 -0.16 -0.23 0.10 -0.18 0.15 0.04 0.13 0.21 0.80 
SNAI1 -0.07 -0.07 0.08 0.26 0.32 0.13 0.12 0.33 0.33 0.79 
RPS6KB1 
(pT389) 
-0.49 0.30 -0.22 0.07 0.40 0.22 1.26 2.36 1.33 0.74 
MEK1 
(pS217) 
-0.15 -0.01 0.69 -0.48 0.12 0.07 0.20 0.68 0.59 0.73 
YBX1 -0.22 -0.07 -0.07 -0.10 0.15 0.39 -0.08 0.31 0.33 0.73 
CDKN1B -0.04 -0.05 0.00 0.03 0.03 -0.05 0.14 0.45 0.23 0.72 
XBP1 0.04 -0.18 0.12 -0.16 -0.06 0.58 1.47 2.59 1.57 0.72 
EGFR -0.16 -0.13 -0.08 0.49 1.54 0.43 2.12 3.34 1.88 0.71 
PGR 0.10 0.03 0.23 -0.01 0.05 -0.03 0.09 -0.26 -0.18 - 0.73 
PIK3R1 0.28 -0.11 0.27 0.05 -0.26 0.21 -0.45 -0.28 -0.56 - 0.73 
MET 0.02 -0.11 0.05 -0.06 0.02 -0.04 0.03 -0.25 -0.32 - 0.77 
BCL2 0.45 0.45 0.02 0.04 -0.27 -0.06 0.21 -0.03 -0.37 - 0.78 
HSP70 0.91 0.77 0.09 0.09 -0.11 0.06 0.07 -0.73 -0.29 - 0.79 
DVL3 0.38 0.42 0.01 -0.09 0.15 -0.02 -0.18 -0.25 -0.25 - 0.82 
DIABLO 0.13 -0.15 -0.09 -0.27 -0.07 -0.19 -0.08 -0.27 -0.47 - 0.87 
 
In addition, the results of this RPPA analysis were visualised in a heat map (Figure 27). The top 
positive regulator of NK-92 cytotoxicity against melanoma cells were phosphorylated (S116) 
proliferation and apoptosis adaptor protein 15 (PEA15), whereas DIABLO showed again the 
highest negative killing correlation. In addition, the identified proteins HK2, SNAI1, BAD 
(pS112), XCCR1, MET and PGR were also part of the previous presented melanoma killing 
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signature (Figure 17). Furthermore, ribosomal protein S6 kinase (RPS6K) (pT573), ribosomal 
protein S6 kinase B1 (RPS6KB1) (pT389) and phosphatidylinositol 3-kinase regulatory subunit 
alpha (PIK3R1) indicate the involvement of PI3K-AKT-mTOR signalling in melanoma 
susceptibility to NK-92 killing.  
 
Figure 27. Melanoma NK-92 killing signature determines susceptibility to NK-92 cells. Heat map 
of the protein expression profile of nine melanoma cell lines differing in their susceptibility to NK-92. 
Protein expression of the RPPA were median centered log2 intensities. The correlation between NK-92 
killing and protein expression was determined by the Pearson correlation coefficient. The increased 
expression of PEA15, BAD (pS112), XRCC1, RPS6K (pT573), Transglutaminase-2 (TGM2), HK2, 
SNAI1, RPS6KB1 (pT389), MEK1 (pS217), Y-box-binding protein 1 (YBX1), Cyclin-dependent kinase 
inhibitor 1B (CDKN1B), X-Box Binding Protein 1 (XBP1) and EGFR were associated with a higher 
susceptibility of melanoma towards NK-92. Inverse correlation (purple) of protein abundance and NK-92 
killing was found in PGR, phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1), MET, 
BCL2 apoptosis regulator (BCL-2), heat shock protein family A (HSP70), dishevelled segment polarity 
protein 3 (DVL3) and DIABLO. For better visualisation of the heat map the log2MedCen intensities 
values have been transformed by row (gene) using z-score. The heat map was generated by using the 
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The comparison of melanoma NK-92 killing signature (Figure 27) with the previous melanoma 
killing signature derived from primary NK cell killing (Figure 17) showed a protein overlap of 
35 %. The RPPA analysis of primary NK cell killing and NK-92 killing revealed only partial 
overlap of proteins involved in melanoma susceptibility to NK cell killing. Nevertheless, it 
identified that the same cell processes such as EMT and apoptosis as well as pathways such as 
PI3K-AKT-mTOR or RAS-RAF-MEK are involved in the melanoma killing by both NK cell 
types.  
4.8 Inhibition of the PI3K-AKT-mTOR signalling pathway decreases melanoma 
susceptibility to NK cells  
Although the molecular manipulation of the single top hits could alter the susceptibility of 
melanoma to NK cells, the effects were only partly significant. The reason might be that the 
effects on NK cell killing were dependent on the stability as well as the efficiency of the transient 
transfection. Furthermore, the previous RPPA analyses only takes into consideration the mere 
existence of a correlation between melanoma killing and protein expression into account. How 
strong the protein expression (fold-change) influenced the susceptibility of melanoma was 
however, not taken into consideration. Therefore, we reused the information from the RPPA to 
determine the magnitude of this influence. The correlation of the primary NK cell killing and the 
protein level (log2MedCen) allowed the creation of a linear trend graph with known intercept and 
slope for each protein in the RPPA panel. The graphs of the top hits DIABLO and SNAI1 are 
shown as examples in Figure 28 A+B. The slope of the graphs can be interpreted as the 
magnitude of change in NK cell-mediated killing as a function of the expression level of the 
protein of interest. The values of the slope together with the already determined Pearson 
correlation coefficients were further used to create a volcano plot (Figure 28 C) that visualised 
the statistical significance versus the effect size and allowed the identification of proteins with 
large fold-change and high statistical significance at the same time. The volcano plot shows that 
DIABLO and SNAI1 were the proteins with highest Pearson correlation coefficient but did not 
have the highest slope. In contrast, the protein abundance of CASP3 or COPS5 could alter the 
NK cell-mediated killing stronger, although their Pearson correlation coefficient is smaller. The 
lower effect size might partially explain the modest success in manipulating DIABLO, even 
though it was the top negative regulator of primary NK cell- and NK-92-mediated killing of 
melanoma cells. The manipulation of a single individual protein neglects the synergic effects of 
several proteins working together on the NKiToxMel. This protein interaction could enhance the 
actual effect on NK cell-mediated killing even if the expression level of the individual proteins 
involved are only slightly changed. Therefore, further investigations were focused on identifying 
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and manipulating signalling pathways i.e. functional characterisation rather than altering the 
expression levels of single proteins. In order to choose the most promising pathway, the RPPA 
analyses of primary NK cell killing and NK-92 killing were compared. In particular the melanoma 
NK-92 killing signature showed a clear indication of the involvement of the PI3K-AKT-mTor 
pathway in the NKiToxMel since RPS6K, RPS6KB1 and PIK3R1 were identified as hits (Figure 
27). Interestingly, RICTOR and PRAS40, other components of this pathway, were found to 
correlate with primary NK cell killing (Figure 17). In addition, several other PI3K-AKT-mTor 
connected proteins, such as RPS6K (pT573), RPS6KB1 (pT389) and phosphorylated 40S 
ribosomal protein S6 (RPS6) considerably correlated with the melanoma susceptibility to NK cell 




  Results 
80 
 
Figure 28. Effect size of the individual proteins from the melanoma killing signature might limit 
success of manipulating single hits . (A-B) Plot of NK cell-mediated killing versus the expression level 
(log2MedCen) of (A) DIABLO and (B) SNAI1 (C) Volcano plot visualises the p (-log10) value as 
measuring unit of statistical significance versus the fold-change. The effect size was determined by the 
slope of the linear trend graphs after plotting the NK cell killing versus the log2MedCen of the individual 
proteins. Left side (proteins marked in red) showed proteins that negatively influence NK cell killing, 
whereas proteins with direct correlation to NK cell killing were marked in green (right side). Proteins 
involved in PI3K-AKT-mTOR pathway are marked in blue. The dashed line shows the significance 
threshold of p = 0.05 with points above the line having p < 0.05 and points below the line having p > 
0.05. The volcano plot is generated by using IGOR Pro.  
 
Based on these findings, the role of the PI3K-AKT-mTor pathway on NK cell susceptibility of 
melanoma was examined in more detail. Given that the activation of this pathway is correlated 
with cell survival and proliferation (Saxton and Sabatini, 2017), there are already multiple drug 
inhibitors targeting various components.  
In Figure 29, the inhibitors used in the later experiments are presented together with their effects 
on the cell viability of WM3734 cells. BKM120 is a selective inhibitor of PI3K (Koul et al., 2012) 
A B
C
  Results 
81 
and showed a cytotoxic effect on WM3734 cells, especially at higher concentrations (>= 1 µM) 
and longer treatment periods (>48 h) (Figure 29 A). The cell viability decreased from 61 % to 
45 % after doubling the concentration (1 µM to 2 µM) after longer treatment. Short-term 
treatment only marginally reduced cell viability. After 24 h, 1 µM BKM120 seemed to increase 
cell viability while 2 µM BKM120 treatment caused a reduction of cell viability of about 20 %.  
A selective inhibitor for AKT is MK2206 (Nitulescu et al., 2016). As shown in Figure 29 B even 
after 72 h treatment with the highest concentration the viability of WM3734 was only marginally 
affected by this drug.  
Rapamycin is a potent inhibitor of the mTOR complex 1 (Saxton and Sabatini, 2017). However, 
only lower concentrations of rapamycin seemed to decrease the viability of WM3734 to 
maximum 77 % (2 µM, 24h), whereas cell viability was only marginally affected by higher 
concentrations (Figure 29 C). Although these inhibitors as single agents show only minor direct 
effects on cell viability according to the CellTiter-Blue® viability assay, the subsequently used 
concentrations of BKM120 (Niessner et al., 2016), MK2206 (Rebecca et al., 2014) and rapamycin 
(Molhoek et al., 2005; Rosenberg et al., 2015) were shown to affect melanoma cell proliferation 
and melanoma invasion or metastasis. Since the drugs were dissolved in DMSO, possible side 
effects of the solvent need to be considered and minimised. DMSO not only decreased 
melanoma cell proliferation and metabolic activity at high dosages (<1 %) (Ferk and Daris, 2018; 
Huberman et al., 1979) but also lower concentrations (>0.1 %) affected cytoskeleton organization 
and adhesion of mouse B16 melanoma cells (Lampugnani et al., 1987). In order to decrease 
undesirable effects, the drug concentrations were chosen in a way that DMSO effects are 
minimised but drug concentration is high enough to get a visible melanoma phenotype.  
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Figure 29. The effect of drugs targeting the PI3K-AKT-mTOR pathway on melanoma cell 
viability. WM3734 were treated with different concentrations of (A) BKM120 (n=4), a selective inhibitor 
of PI3K, (B) MK2206 (n=4), a selective inhibitor of AKT and (C) rapamycin (n=3), an inhibitor of 
mTOR over a period of 3 days. Melanoma cell viability was determined using the CellTiter-Blue® viability 
assay. 
To investigate if we could affect the NK cell-mediated killing of melanoma by manipulating the 
PI3K-AKT-mTOR pathway, melanoma cells were treated with different drug inhibitors (Figure 
29). WM3734 cells and 1205Lu cells have distinct NK cell susceptibility (50 % and 90 %, 
respectively) and should have a different PI3K-AKT-mTOR status according to the RPPA data. 
Besides short-term treatments with PI3K-AKT-mTOR inhibitors, additional investigations of 
longer treatment periods can give further information about the kinetics of drug action and could 
shed new light on the effects of these drugs on patient therapy. Figure 30 A shows that 24 h 
treatment of WM3734 cells with 2.5 nM rapamycin reduced the NK cell susceptibility 
significantly. The killing curves of rapamycin treated and DMSO treated cells started to separate 
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As seen in Figure 30 B, the rapamycin treatment decreased the susceptibility of WM3734 from 
31 % to 26 %, already after 1 h. During the course of the experiment, this trend continued and 
reached a significant maximal reduction in NKiToxMel of ~10 % (Figure 30 C). Longer 
treatment periods (96 h) resulted in similar killing curves of WM3734 cells (Figure 30 D) and 
decreased the susceptibility to NK cells after 1 h (Figure 30 E) as well as after 4 h of killing 
(Figure 30 F) about 10 %. 
As shown in Figure 30 G, the effect of short-term treatment with rapamycin were validated in 
1205Lu cells that also showed a reduced susceptibility to NK cells after drug treatment. In this 
cell line the killing mediated by primary NK cells was reduced in the initial phase of about 5 % 
(Figure 30 H) and in the end phase of about 10 % (Figure 30 I). The decreased NK cell 
susceptibility of 1205Lu cells was even more pronounced after 96 h drug treatment (Figure 30 J). 
The initial killing of pre-treated 1205Lu cells, as shown in Figure 30 K, was significantly reduced 
about 19 % in comparison to the DMSO control (33 %). During the course of the killing assay, 
this trend continued and reached a significant maximal reduction in NK cell-mediated killing of 
~28 % after 240 min (Figure 30 L).  
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Figure 30. Rapamycin decreased the susceptibility of melanoma cells to primary NK cells. 
WM3734 (green rectangle) and 1205Lu (blue rectangle) were pre-treated with 2.5 nM rapamycin or the 
corresponding DMSO control for 24 h (n (WM3724)=12; n (1205Lu)=6) and 96 h (n (WM3724)=6; n 
(1205Lu)=3). Afterwards cells were loaded with calcein-AM (0.5 μM) and were exposed to NK cells (E:T 
ratio of 5:1) for 4h. (A,D,G,J) Killing kinetics of 4h cytotoxic assay. For statistical analysis the killing after 
60 min (B,E,H,K) and after 240 min (C,F,I,L) were used. Bars and graphs indicate means ± SEM. 
Statistical significance of paired, two-tailed Student's t‐test is indicated with * for p<0.05, ** for p<0.01 
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Altogether, short-term as well as long-term treatment of rapamycin significantly decreased the 
susceptibility of melanoma cells. These findings further support the hypothesis that PI3K-AKT-
mTOR signalling in melanoma cells is a determining factor of NKiToxMel. 
The drug inhibitors BKM120 and MK2206 are known to target PI3K and AKT, respectively, 
more upstream in the PI3K-AKT-mTOR pathway than rapamycin (Niessner et al., 2016). As 
shown in Figure 31 A-C, the NK cell susceptibility of WM3734 cells was not affected by the 
short –term treatment (24 h) with 1 µM MK2206 nor 1 µM BKM120. However, 96 h BKM120 
treatment decreased the susceptibility of WM3734 cells to NK cells significantly (Figure 31 D). 
After 60 min of the assay (Figure 31 E), the killing was decreased about 16 % and about 9 % after 
240 min (Figure 31 F). On the other hand, long-term treatment with MK2206 did not affect the 
initial killing of WM3734 cells (Figure 31 E) and even increased the killing about 13 % at the end 
of the experiment (Figure 31 F). In the other melanoma cell line 1205Lu, 24 h treatments with 
both drugs reduced the susceptibility of this cell line to NK cells significantly (Figure 31 G). As 
shown in Figure 31 H, already after 60 min the pre-treatment of 1205Lu cells with either 
MK2206 or BKM120 significantly decreased their NK cell susceptibility by about 5 %. These 
effects were even more dominant during the following course of the cytotoxic assay. The killing 
of BKM120 pre-treated 1205Lu cells were reduced on average by about 10 %, whereby this 
reduction was not statistically significant for all time points. MK2206 treated 1205Lu cells 
showed a significantly reduced NK cell-mediated killing of 19 % after 240 min (Figure 31 I). 
Figure 31 J shows that 96 h pre-treatment of 1205Lu with BKM120 and MK2206 decreased the 
susceptibility of 1205Lu drastically. In comparison to the DMSO control (~74 %) primary NK 
cells killed the drug pre-treated melanoma cells only to ~58 % (MK2206) and to ~43 % 
(BKM120) after 4 h (Figure 31 L). This reduced susceptibility was already been observed after 
60 min (Figure 31 K) where the treatment with MK2206 and BKM120 reduced the killing of 
melanoma by 10 % and 22 %, respectively.  
In summary, it can be stated that 96 h treatment of melanoma cells with PI3K inhibitor BKM120 
decreased the NKiToxMel, whereas short-term treatment only affected the susceptibility of 
1205Lu cells to NK cell killing. Similar observations were made with the AKT inhibitor MK2206 
that reduced the NK cell meditated killing of 1205Lu cells. However, MK2206 treatment of 
WM3734 cell line increased its susceptibility to NK cell killing.  
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Figure 31. MK2206 and BKM120 partially decreased melanoma cell susceptibility to NK cells. 
WM3734 (green rectangle) and 1205Lu (blue rectangle) were pre-treated with 1 µM BKM120 (blue) or 
1 µM MK2206 (green) and the corresponding DMSO control for 24 h (n (WM3724)=3; n (1205Lu)=4) 
and 96 h (n (WM3724)=6; n (1205Lu)=3) . Then cells were loaded with calcein-AM (0.5 μM) and exposed 
to NK cells (E:T ratio of 5:1) for 4 h. (A,D,G,J) Killing kinetics of 4 h cytotoxic assay. For statistical 
analysis the killing after 60 min (B,E,H,K) and after 240 min (C,F,I,L) were used. Bars and graphs indicate 
means ± SEM. Statistical significance paired, two-tailed Student's t‐test is indicated with * for p<0.05, ** 
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A critical point of the performed experiments is that leftovers of the drug inhibitors might 
diminish NK cell cytotoxicity. In the course of the assay preparation, the target cells were 
carefully washed several times and resuspended in a fresh culture medium. This procedure 
removed residual drug so that the highest remaining drug concentration in the assay could not 
exceed pM range. Nevertheless, there is the possibility that melanoma cells internalise the drug 
and release it during the cytotoxic assay, hence affecting NK cell effector function. Active mTOR 
signalling is important for NK cell development (Marcais et al., 2017; Yang et al., 2018). 
Although longer rapamycin treatments (5 days) impaired NK cell cytotoxicity (Eissens et al., 
2010), short exposure (4 h) to even 100 nM rapamycin did not alter NK cell cytotoxicity to 
sensitive target cells (Yang et al., 2018). The other drug inhibitors MK2206 and BKM120 
decreased the cell proliferation of distinct immune cell populations (Abu-Eid et al., 2014; Ding et 
al., 2014) and impaired the cytotoxicity of NK-92 cells (Jiang et al., 2000; Yea et al., 2014). In 
order to test if these drugs could impair primary NK cell cytotoxicity against melanoma cells 
directly, several control experiments were performed.  
As depicted in Figure 32, the treatment of K562 cells with 2.5 nM rapamycin for 24 h did not 
impair the NK cell-mediated killing of K562. This observation thus indicated that it is unlikely 
that drug remaining in the medium or released from target cells after internalisation would inhibit 
the cytotoxicity of the NK cells.  
 
Figure 32. Rapamycin treatment does not affect susceptibility of K562 to NK cells. K562 cells were 
pre-treated with 2.5 nM rapamycin or the corresponding DMSO control for 24 h. Afterwards cells were 
loaded with calcein-AM (0.5 μM) and exposed to NK cells (E:T ratio of  5:1) for 4 h (n=5). (A) Killing 
kinetics of 4 h cytotoxic assay. For statistical analysis the killing after 60 min (B)) and after 240 min (C) 
were used. Bars and graphs indicate means ± SEM. Statistical significance of paired, two-tailed Student's t‐
test is indicated with * for p<0.05. 
In another experimental setting (Figure 33), the susceptibility of non-treated and drug pre-treated 
melanoma cells to NK cell killing was tested in the absence or presence of drug inhibitors or 
DMSO controls. Therefore, drug inhibitors and corresponding DMSO controls were added right 
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of WM3734 cells was not affected in the presence of rapamycin or the corresponding DMSO 
control independent of the pre-treatment of the melanoma cells. The presence of MK2206 
reduced the initial killing of non-pretreated WM3734 cells by ~ 8 % in comparison to the DMSO 
control (Figure 33 C). However, in the course of the assay the difference between MK2206 and 
the DMSO control was reduced by ~5 %. In addition, Figure 33 D shows that MK2206 pre-
treated WM3734 cells were not affected by additives during the killing assay. As seen in Figure 
33 E+F, the presence of BKM120 reduced the NK cell-mediated killing of non-pre-treated 
WM3734 cells by ~8 % and the killing of BKM120 by about 10 %. However, BKM120 pre-
treated WM3734 cells were less killed (~36 %) than non-treated melanoma cells (~46 %). 
Taken together, rapamycin did not show inhibitory effects on NK cell cytotoxicity in the used 
cytotoxicity assays, whereas the possible impairment of NK cells by the other drug inhibitors 
could not be completely excluded. However, the results indicate that MK2206 affects melanoma 
cells rather than NK cells since MK2206 treatment of WM3734 did not decrease NKiToxMel 
(Figure 31). Besides, MK2206 only reduced the NK cell-mediated killing of non-pre-treated 
WM3734 (Figure 33 C+D). Assuming that MK2206 impairs NK cell cytotoxicity, the killing of 
MK2206 pre-treated WM3734 cells should also be reduced in the presence of MK2206. Similar 
considerations lead to the assumption that 1 µM BKM120 during the assay impairs NK cell 
cytotoxicity. Nevertheless, the residual concentrations of BKM120 during the cytotoxicity assay 
should be considerably lower. Furthermore, it should be noted that the BKM120 pre-treatment 
of melanoma cells alone drastically decreased NKiToxMel.  
In sum, it can be concluded that the effects of the used drug inhibitors are mainly caused by 
altered susceptibility of melanoma cells to NK cells rather than the impairment of NK cell 
cytotoxicity.  
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Figure 33. Control experiments support altered melanoma cell susceptibility to NK cells after 
inhibitor treatments. WM3734 were pre-treated with three drug inhibitors or solvent control 24 h after 
treatment cytotoxicity assays were performed. In this killing assay either no additives, one of the used 
drugs or DMSO was added. Afterwards cells were loaded with calcein-AM (0.5 μM), washed and 
resuspended in the appropriate volume of AIMV medium. This medium contained either no additives, 
2.5 nM rapamycin (n=7); 1 µM MK2206 (n=4); 1 µM BKM120 (n=4) or the corresponding DMSO 
control. After seeding and settling of the melanoma cells, primary NK cells (E:T ratio of 5:1) were added 
and the cytotoxic assay was recorded for 4 h. (A) Killing kinetics of non-pre-treated WM3734 under the 
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4.9 Other parameters influencing the NK cell-mediated killing of melanoma 
Given that several proteins involved in cell survival and metabolism affected the NK cell 
susceptibility of melanoma, the proliferation status of seven melanoma cells was tested. 
Therefore, the same melanoma cell number was seeded and the percentage proliferation was 
determined after counting the total number of cells. Figure 34 A shows that the proliferation of 
seven melanoma cell lines is heterogeneous. WM88 cells were the least proliferative as this cell 
line only doubled their cell number after 72 h. The highest proliferation status was displayed by 
WM3918 cells that more than triplicated after 24 h and showed a mean cell proliferation of 
around 600 % after 72 h. The growth rate of WM983B and 1205Lu cell lines was slower as the 
cell number was not even doubled after 24 h. However, after 72 h the cell proliferation was more 
than 500 % in both cell lines. The other three cell lines 451Lu, WM1366 and WM3734 showed a 
median proliferation that was also characterised by a slow increase in cell number (<200 % 
proliferation) after 24 h but did not exceed 400 % after 72 h. As seen in Figure 34 B, the 
melanoma cell proliferation after 72 h correlates with the NK cell-mediated killing of melanoma.  
 
Figure 34. Melanoma cell proliferation correlates with NK cell susceptibility. (A) Same melanoma 
cell number of 1205Lu (n=4), WM3918 (n=4), WM983B (n=4), 451Lu (n=3), WM1366 (n=4), WM3734 
(n=3) and WM88 (n=3) was seeded and percentage proliferation was determined by counting the cells 
after 24 h, 48 h and 72 h. (B) Melanoma cell proliferation after 72 h was correlated with the susceptibility 
of these melanoma cells to NK cell killing.  
These findings support the hypothesis that the more proliferative melanoma cells present a better 
target for NK cell killing.  
Melanoma staging is not only associated with increasing mutation burden but it also influences 
therapeutic approaches. The mutation status of certain proteins such as BRAF, NRAS or PTEN 
did not indicate a link with the susceptibility of melanoma to NK cells. Nevertheless, the tested 
primary melanoma cell lines WM1366 and WM3268 with non-mutated BRAF were more 
resistant to NK cells than the other primary cell lines WM793 and WM902B. In order to see if 
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melanoma cells with a clear indication of isolation site were categorised in primary tumours 
(VGP), lymph node metastasis and distant metastasis (e.g. brain, lung etc.). As depicted in Figure 
35, increasing melanoma stage seems to be associated with higher melanoma susceptibility to NK 
cells. On average, primary melanoma cells were killed to ~43 % whereas melanoma cells of 
lymph node metastasis were more susceptible to primary NK cells (~60 %). Melanoma cells of 
distant metastasis were on average killed up to 68 % and showed the highest susceptibility to NK 
cells. Nevertheless, the variation of melanoma susceptibility within the stages was considerably 
high. In addition, the samples size might not be sufficient to represent the distinct melanoma 
stages and did not allow statistical analysis.  
 
Figure 35. Melanoma staging is associated with increasing susceptibility of melanoma cells to 
NK cells. NK cell-mediated killing of primary tumours/skin metastasis: WM3268 (green, n=3)WM1366 
(light blue, n=7); WM902B (blue, n=3) WM793 (red, n=7) lymph node metastasis: WM88 (orange, n=20), 
WM983B (red, n=10), WM9 (yellow, n=11), WM858 (brown, n=10), WM3682 (dark blue, n=10) and 
distant metastasis: 451Lu (light rose, n=6), WM3734 (green, n=79) and 1205Lu (blue, n=19) after 4 h real-
time killing assay are shown; E:T ratio of 5:1 are used.  
4.10 Melanoma-NK cell-co-culture 
The previous experiments showed that melanoma cells have an intrinsic susceptibility to NK cell 
killing. This susceptibility depends on the protein signature of the melanoma cells and can be 
pharmacologically as well as genetically manipulated. Given that melanoma phenotypes are often 
dynamic, the successes of immune-based therapies are not only dependent on the initial positive 
clinical effect but also on the prevention of therapy resistance. Therefore, melanoma-NK cell-co-
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4.10.1 Co-culture with primary NK cells 
For the establishment of NK-melanoma cell-co-culture, we used WM3734 cells that showed an 
average killing rate of around 50 % after 4 h. This was needed on the one hand to ensure survival 
during co-culture and on the other hand to allow possible shifts of NK cell susceptibility of 
melanoma in both positive and negative direction. Seeded melanoma cells were challenged with 
activated NK cells for 3-4 days. Surviving melanoma cells were subcultured and exposed to fresh 
NK cells again, a procedure that was repeated for 30 weeks. During this co-culture process, the 
effector-target ratio was constantly increased (Cappello, 2015). The susceptibility of the 
melanoma cells during the co-culture was monitored by real-time killing assays. The NK cell-
mediated killing of all WM3734-NK cell-co-cultures declined over time as initially susceptible 
melanoma cells acquired resistance. Figure 36 A shows an example of a long-term WM3734-NK 
cell-co-culture. With increasing E:T ratio and co-culture time, the susceptibility of WM3734 to 
NK cells decreased. The performed killing assays showed that the initial NK cell-mediated killing 
of 35 % in the second week was reduced to 20 % and 12 % in week 9 and 11, respectively. After 
29 weeks of co-culturing the WM3734 was resistant to NK cells (3 % killing). During the long 
culture period, also the non-treated control showed a decreased susceptibility to NK cells. 
Therefore, the ratio of reduction was calculated by the quotient of killing from co-culture and 
untreated control (Figure 36 B). In comparison to the non-treated control, the killing of co-
cultured WM3734 could be reduced from an initial 25 % to over 50-70 % between week 9 and 
11, to almost 85 % after 29 weeks of co-culture.  
The ratio of reduction is calculated by the following formula: 
𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 = 1 −
𝐾𝑖𝑙𝑙𝑖𝑛𝑔 𝑜𝑓 𝑐𝑜−𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (%) 
𝐾𝑖𝑙𝑙𝑖𝑛𝑔 𝑜𝑓 𝑛𝑜𝑛−𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (%)
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Figure 36. Development of NK cell resistance during melanoma-NK cell-co-cultures.(A) Endpoint 
killing of untreated WM3734 and a WM3734-NK cell-co-culture at indicated times during co-culture. In 
the real-time killing assay an E:T ratio of 5:1 was used. The displayed dashed line indicates the polynomial 
fit of susceptibility to NK cell during co-culture process with increasing E:T ratio.(B) Ratio of reduction 
(for calculation see equation above). Data were previously shown in (Cappello, 2015). 
After sufficient reduction of melanoma susceptibility to NK cell killing, subsequent RNA 
sequencing of the co-cultured melanoma cells revealed genes involved in the NK cell evasion 
process. RNA sequencing is a very sensitive method and requires a high purity of the RNA 
material of interest. As the melanoma cells are co-cultured with NK cells, the contamination with 
RNA of NK cells needed to be minimised. Therefore, before being added to the co-culture, NK 
cells were irradiated (30 Gy, Cs 137 γ-emitter) to induce delayed NK cell death and prevent NK 
cell proliferation. Furthermore, several washing steps before harvesting of melanoma cells 
ensured the purity of the melanoma co-culture.  
To estimate the effect of the irradiation on NK cell cytotoxicity, irradiated and non-irradiated 
NK cells of the same donor were used to kill the cell lines K562 and WM3734. As seen in Figure 
37, the irradiation seemed to reduce the cytotoxicity of the NK cells. The NK cell-mediated 
killing of K562 delayed elimination at the initial phase of the killing. Nevertheless, the irradiated 
NK cells were able to kill almost all K562 cells during the cytotoxic experiment. The killing of 
WM3734 cells seemed to be reduced during the whole course of the experiment. Even though 
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t‐test) in both cell lines. These impairments of the NK cell cytotoxicity were acceptable to 
guarantee RNA purity.  
 
Figure 37. Irradiated NK cells showed reduced but sufficient cytotoxicity against cancer cells. 
Primary IL-2 stimulated NK cells (n=5) were irradiated with 30 Gy and immediately added to calcein-AM-
loaded K562 or WM3734 (E:T ratio of 5:1). Non-irradiated NK cells were used as controls. The graphs of 
the 4 h real-time killing assay are shown as means ± SEM. Data were previously shown in (Cappello, 
2015). 
4.10.2  Co-culture with NK-92 
NK-92 is a NK cell line that is already used in several clinical trials (Arai et al., 2008; Klingemann 
et al., 2016) and is a promising tool for immunotherapies. Furthermore, NK-92 cell line shows 
more constant cytotoxicity than differing primary NK cells donors, so that the development of 
resistance is not subject to variation. This allowed comparable NK cell cytotoxicity over the 
duration of the co-culture experiment and higher E:T ratios.  
To compare the results of the co-culture experiments with primary NK cells, the same cell line 
WM3734 was used. The lower susceptibility of WM3734 to NK-92 (see chapter 4.5.) as well as 
the abundance of effector cells allowed the parallel establishment of WM3734-NK-92 co-cultures 
with different E:T ratios (1:1, 1:3, 1:7). Over a period of two weeks, the irradiated effector cells 
were freshly added two times a week. Before the last exposure to NK-92, the co-cultures were 
subcultured. One half was re-treated with NK-92, whereas the other half was not treated for 
3 days (recovery) before the cytotoxicity experiment. Figure 38 A depicts the NK-92-mediated 
killing of the three co-cultures as well as their corresponding recovery conditions in comparison 
to the untreated control. The susceptibility of WM3734 cells was reduced from ~22 % (untreated 
control) to less than 10 % after co-culture with NK-92 (Figure 38 B). With increasing E:T ratio in 
the co-culture, the susceptibility decreased from ~ 9 % (1:1) to over ~6 % (3:1) and ~3 % (7:1). 
Already after 3 days without NK-92 exposure the susceptibility (240 min) of the co-cultures 
increased by ~6 % in all E:T ratios.  
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Figure 38. WM3734-NK-92-co-cultures have reduced susceptibility to NK-92 cells. WM3734 cells 
were co-cultured with NK-92 cells at different E:T ratios (1:1, 3:1, 7:1) for 2 weeks. Two times per week 
NK-92 were replaced. After the last NK-92 exposure, only one half of the subcultured co-culture was re-
treated with NK-92. The other half was non-treated for three days (Recovery) before cytotoxicity 
experiment. Afterwards melanoma cells of the co-cultures as well as untreated control cells were used in 
real-time killing assays with NK-92 (E:T ratio of 5:1). (A) Killing kinetic of 4 h cytotoxic assay. (B) Killing 
after 240 min.  
To test how fast the resistance of melanoma to NK-92 cells developed, short-term co-cultures of 
24 h were analysed. After one day, the surviving melanoma cells were exposed to NK-92 but also 
to primary NK cells (E:T ratio of 5:1). Figure 39 A shows that WM3734 cells co-cultured with 
NK-92 for 24 h have reduced susceptibility to NK-92 (reduction of ~12 %) comparable to co-
culture results with primary NK cells. Given that WM3734 cells are less susceptible to NK-92 
compared to primary NK cells, no killing was detectable after 60 min (Figure 39 E) but showed a 
reduced NK-92 killing after co-culturing after 240 min (Figure 39 F). In addition, the NK-92 co-
cultured melanoma cells are also less susceptible to primary NK cells (Figure 39 A). Figure 39 C 
shows that this cross-resistance of 8 % was already significant at the initial phase of the cytotoxic 
assay. After 240 min, the susceptibility of WM3734 decreased significantly from 54 % (control) to 
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Figure 39. Short-term (24 h) co-cultures with NK-92 reduces the susceptibility of melanoma cells 
to NK-92 and induce cross-resistance to primary NK cells. WM3734 were co-cultured with NK-92 in 
an E:T ratio of 1:1 for 24 h. Then, melanoma cells of the co-cultures as well as corresponding controls 
were loaded with 0.5 µM calcein-AM and exposed to the effector cells NK-92 (right; n=3) or primary NK 
cells (left; n=5) (E:T ratio of 5:1). (A+B) Killing kinetic of 4 h cytotoxic assay. For statistical analysis, 
killing after 60 min (C+E) and after 240 min (D+F) were used. Bars and graphs indicate means ± SEM. 
Statistical significance of unpaired, two-tailed Student's t‐test is indicated with * for p<0.05 and ** for 
p<0.01. 
The observations made with WM3734-NK-92-co-cultures were also confirmed with 1205Lu-
NK-92-co-cultures. As seen in Figure 40 B, high E:T ratios of 3:1 or 7:1 during NK-92 co-culture 
induced resistance of 1205Lu cells to NK-92 (killing less than 6 %). After a short recovery time, 
the 3:1 NK-92-melanoma-co-culture reached the susceptibility of the non-treated 1205Lu control 
(~47 %). Additionally, the 7:1 NK-92-melanoma-cell co-cultures were killed to ~40 %. 
Furthermore, Figure 40 A shows that the susceptibility of 1205Lu towards primary NK cells was 
strongly reduced after co-culturing with NK-92. The control was killed to ~ 80 % whereas both 
co-cultures (3:1 and 7:1) were only killed to ~40 % by primary NK cells. This developed 
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Figure 40. 1205Lu-NK-92-co-cultures and cross-resistance to primary NK cells. 1205Lu were co-
cultured with NK-92 in E:T ratios of 3:1 and 7:1 for 2 weeks. Thereby, NK-92 were renewed two times a 
week. Before the last NK-92 exposure the co-cultures were subcultured. One half was re-treated with 
NK-92, whereas the other part was non-treated for three days (Recovery) before cytotoxic experiment. 
Then, melanoma cells of the co-cultures as well as corresponding control were loaded with 0.5 µM 
calcein-AM and exposed to primary NK cells (A) or NK-92 (B) (E:T ratio of 5:1). The 4 h killing kinetic 
of one performed real-time killing assay with NK-92 and one primary NK cell donor is shown.  
4.10.3 RNA sequencing reveals proteins involved in NK cell-mediated immune escape 
To investigate which genes are involved in the process of immune escape, total RNA of 
melanoma cells of different WM3734-NK cell-co-cultures and healthy melanocytes (Table 19) 
was sequenced using Illumina HiSeq 2500. The analysis showed that the samples clustered 
differently according to principal component analysis (PCA) (Lever et al., 2017). As shown in 
Figure 41 A, melanocytes were separated from the melanoma sample set. Within the melanoma 
samples, Figure 41 B showed that WM3734-NK cell-co-cultures and the corresponding controls 
clustered differently compared to WM3734-NK-92-co-cultures and their corresponding controls. 
A
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Figure 41. Principal component analysis (PCA) of WM3734-NK cell-co-cultures. Samples are 
grouped (A) by cell type (melanocytes vs. melanoma) and (B) by co-culture treatment. Non-treated 
WM3734 (control) are coloured pink; co-culture with primary NK cells are coloured orange, co-culture 
with NK-92 cell line are coloured green; black circled = Recovery.  
Due to the restricted sample number, different E:T ratios of the co-cultures and the respective 
controls were pooled (Figure 42) to allow differential gene expression (DGE) analysis. 
 
Figure 42. Pooling of samples for RNA sequencing analysis. WM3734 were co-cultured with primary 
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This analysis revealed that about 100 genes were differently expressed after the co-culturing 
process with primary NK cells (see table A1 in the appendix) and NK-92 cells (see table A2 in 
the appendix). To identify genes that play a central role in the susceptibility of melanoma cells to 
NK cells, only the overlap of differentially expressed genes in both data sets were further 
analysed. The comparison of both data sets identified 13 common differently expressed genes of 
WM3734 cells co-cultured with primary NK cells and NK-92 (see Table 23). Ten out of 13 genes 
were coding directly for MHC molecules or were associated with these molecules. MHC class I 
molecules were represented by HLA-B, beta-2-microglobulin (B2M) as well as HLA complex 5 
(HCP5). Most of the identified genes belong to the group of MHC class II molecules. Among 
them HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA. CD74 also 
known as HLA-DR antigens-associated invariant chain were coding for a polypeptide, which 
help to form and transport MHC class II molecules. The other genes: absent in melanoma 2 
(AIM2), complement component 1 subcomponent (C1S) and the transmembrane protein 158 
(TMEM158) were in the broadest sense associated with the proliferative/invasive status of the 
melanoma cells. Differently expressed genes of WM3734-NK-92 co-culture had approximately 3 
times higher fold change (logFC) and much higher false discovery rate (FDR) values compared to 
differently expressed genes of the primary NK cell co-culture.  
Table 23. Common differentially expressed genes of WM3734 co-cultured with primary NK cells and 
NK-92 under specification of logFC, FDR and association with cellular processes . For comparison 
analysis Notepad ++ was used. 
Gene logFC FDR Gene associated with 
 
NK-92 Primary NK-92 Primary 
  
AIM2 6.88 4.45 1.00E-06 7.27E-48 Phenotype switch 
B2M 2.74 0.65 0.006 0.003 MHC class I 
C1S 4.79 1.42 1.12E-05 0.001 Phenotype switch 
CD74 2.42 0.62 0.0002 0.0003 MHC class II 
HCP5 8.19 2.42 2.62E-08 0.006 MHC class I 
HLA-B 3.97 0.77 1.33E-08 1.49E-05 MHC class I 
HLA-DMB 2.47 1.11 0.0033776 7.93E-13 MHC class II 
HLA-DPA1 2.63 0.91 0.0011175 6.21E-11 MHC class II 
HLA-DPB1 2.48 0.88 0.0001648 1.03E-09 MHC class II 
HLA-DQA1 7.42 2.98 1.394E-15 2.69E-20 MHC class II 
HLA-DQB1 3.27 1.09 5.155E-07 1.14E-11 MHC class II 
HLA-DRA 2.49 0.9 0.0016177 6.21E-11 MHC class II 
TMEM158 2.74 2.02 0.0003767 2.69E-20 Ras activation 
 
In addition, the gene expression of the co-culture was compared with the expression profile of 
the co-culture after removal of the NK-92 for 3 days. This short recovery time changed the 
expression of 103 genes (see table A3 in appendix), where 59 of these genes were also 
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differentially expressed in the previous comparison. Hence, after NK-92 cells were removed, the 
expression profile of the recovered melanoma cells equalled the control again. This was further 
supported by the marginal DGE (see table A4 in the appendix) of these cells in comparison to 
the untreated WM3734 cells. 
Taken together, melanoma cells developed resistance to primary NK cells as well as NK-92 cells 
during long-term and short-term co-cultures. Subsequent RNA sequencing of melanoma co-
cultures revealed a limited number of common differentially expressed genes of WM3734 co-
cultured with primary NK cells and NK-92. These genes are mainly associated with MHC class I 
and II molecule expression and might explain the induced a cross-resistance of melanoma-co-
cultures with NK-92 cells to primary NK cells. In addition, the results of this study indicate that 
the resistance to NK cells is reversible and melanoma cells get susceptible again after short 
recovery time.  
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5 Discussion 
Melanoma is the most lethal form of skin cancer with increasing incidence worldwide (World 
Health organization, 2020). In addition to its high metastatic potential, the treatment of this 
cancer is challenged by its heterogeneity and adaptability to therapies. During the last years, 
targeted therapies in combination with immunotherapies showed most clinical success (Seidel et 
al., 2018). Nevertheless, the development and improvement of anti-melanoma therapies are 
required to prevent therapy resistance and relapses. In this study, the potential of NK cells to 
improve and complement current melanoma therapy was investigated.  
5.1 Effector-to-Target ratio determines effect size of NK cell killing 
Therapy success is not only dependent on persistent immunogenicity of melanoma cells but also 
on tumour infiltrating lymphocytes (Cursons et al., 2019; Fortes et al., 2015; Thomas et al., 2013). 
NK cell infiltration of primary melanoma tumours ranged between E:T ratios 0.03:1 and 0.5:1 
(Balsamo et al., 2012). In order to consider E:T ratios, which resemble intratumoural NK cell 
infiltration four different E:T ratios were tested. The lower E:T ratios 0:5:1 and 1:1 showed only 
marginal NK cell-mediated killing of the melanoma cell line WM3734 and revealed that even high 
NK cell infiltration might only induce small reduction of the tumour burden. Only significantly 
higher NK cell numbers (5:1 and 10:1) showed a potent cytotoxic effect (Figure 10). Although 
these ratios do not correspond to the NK cell infiltration into melanoma tumours, the 
cytotoxicity assay requires a dynamic range to investigate parameters influencing the NK cell-
induced cytotoxicity against melanoma cells. In contrast to WM3734 cells, the initial NK cell 
cytotoxicity to the leukemia cell line K562 was not only considerably higher but also increased 
almost proportional to the used NK cell number until reaching 100 % maximum. This is 
explainable by the low expression of the inhibitory MHC class I molecules with simultaneous 
presence of NK cell activating ligands (Tremblay-McLean et al., 2019). Moreover, it was shown 
that the NK cell detachment from a target was retarded or even inhibited after unsuccessful 
killing, hence reducing the serial killing of NK cells (Anft et al., 2020). This might contribute to 
the observed differences between the cell lines K562 and WM3734. Although the killing of 
melanoma was increased with higher E:T ratios, the killing was not much increased after 
doubling the NK cell numbers from E:T ratio 5:1 to 10:1. One possible explanation could be that 
a certain subpopulation of WM3734 cells is intrinsically less susceptible to NK cells and evade 
elimination. Besides that, also the challenging of melanoma cells with NK cells could induce 
rapid adaptions of the melanoma cell phenotype that might diminish the NK cell-mediated 
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killing. However, the questions if and how such adaptions affect melanoma susceptibility to NK 
cells in the relative short time of the experimental set up remain open.  
5.2 Interleukin-2 stimulation increases NK cell cytotoxicity 
Already in the early days of NK cell studies the stimulating character of certain cytokines on the 
cytotoxicity of NK cells was discovered and further used to increase the capability of the effector 
cells (Wu et al., 2017). Several studies showed that IL-2 stimulation increased NK cell cytotoxicity 
against cancer cells (Balsamo et al., 2013; Henney et al., 1981; Huenecke et al., 2010; Lehmann et 
al., 2001). Also in this study, it was shown that IL-2 stimulation is crucial to enhance NK cell 
cytotoxicity against melanoma cell lines and to a lower extend against K562 cells (Figure 12). The 
killing capability of NK cells is among others determined by the expression profile of activating 
and inhibitory receptors on the cell surface as well as the intracellular content of the lytic 
granules. Flow cytometric analysis of IL-2 stimulated NK cells showed an upregulation of the 
activating receptor NKp30 and NKG2D as well as higher levels of CD16. Furthermore, an 
increased intracellular content of perforin and granzyme B was observed (Figure 12). These 
alterations of the NK cell phenotype were also observed by other groups, which reported an 
upregulation of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46 as well as the 
de novo expression of NKp40 following IL-2 stimulation (de Rham et al., 2007; Pietra et al., 
2012a). Moreover, the density of NCRs on the effector surface has been shown to directly 
correlate with the NK cell-mediated killing of certain tumour cells (Pende et al., 2002). Similar 
observations have been made with the expression level of NKG2D and the NKG2D-mediated 
killing of melanoma (Morgado et al., 2011). Hence, a crucial role of these activating receptors in 
NK cell recognition of melanoma can be assumed. In addition, higher levels of perforin and 
granzyme B in NK cells subsequent to IL-2 stimulation were described by other scientific reports 
(DeBlaker-Hohe et al., 1995; Salcedo et al., 1993; Zhang et al., 2008). All of these alterations in 
the NK cell phenotype can at least partly explain the IL-2 induced increase in NK cell 
cytotoxicity. The different susceptibility of K562 cells and WM3734 cells could be explained by a 
distinct ligand profile. In comparison to melanoma cell lines, the cell line K562 lacks MHC class I 
molecules (Garson et al., 1985) and has thereby a lower activation threshold for NK cell 
cytotoxicity. Consequently, the NK cell-mediated killing of K562 cells should be less dependent 
on the expression of activating ligands, an aspect that might explain the lower effect of IL-2 
stimulation. Nevertheless, the correlation of MHC class I expression and NK cell susceptibility of 
K562 is controversial as several studies showed no direct connection of these parameters 
(Nishimura et al., 1994; Reiter et al., 1991). Due to the higher expression levels of activating 
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receptors, IL-2 stimulated NK cells could overcome inhibitory stimuli (e.g. HLA-A,B,C 
expression) and have a lowered activation threshold enhancing target cell elimination. Although 
other reports showed that longer stimulation periods slightly reduced activating receptors 
(Balsamo et al., 2013) or even led to NK cell exhaustion (Huenecke et al., 2010), the experimental 
data of this thesis did not support these findings. The duration of this stimulation only marginally 
affected the general NK cell cytotoxicity towards cancer cells independent of their NK cell 
susceptibility (Figure 13). Smaller observed differences in NK cell cytotoxicity can be explained 
by different temporal upregulation of individual NK cell receptors and their distinct involvement 
in the killing process of specific cancer cell lines. Nevertheless, IL-2 stimulation increases the NK 
cell cytotoxicity against melanoma cells by upregulation of activating receptors and reveals 
distinct susceptibility of melanoma towards NK cells.   
5.3 Heterogeneous susceptibility of melanoma cells to primary NK cells  
Melanoma is an immunogenic cancer as it was shown to express several ligands that bind 
activating immune receptors (Casado et al., 2009; Chan et al., 2010; O'Donnell et al., 2019). 
Within this thesis, the susceptibility of 20 melanoma cell lines with distinct genetic backgrounds 
and development stages to NK cells were analysed. The performed cytotoxic assays revealed a 
highly heterogeneous NK cell-mediated killing of melanoma cells (Figure 14). Distinct expression 
profiles that alter the number of activating and inhibitory ligands on the melanoma cell surface 
may be responsible for these results. One of the ligands are MHC class I molecules that are 
known to protect target cells against the NK cell-mediated killing according to the ‘missing self’ 
hypothesis of Kärre (Karre, 2002). However, the MHC class I molecules on the melanoma cell 
surface did not correlate with the measured susceptibility of distinct melanoma cell lines towards 
NK cells (Figure 15). These findings were in line with the reports of other groups who also failed 
to find a linear correlation of MHC class I expression and the NK cell-mediated killing of cancer 
cells, including melanoma (Andalib et al., 2000; Pena et al., 1990). A possible explanation for 
these observations might be a saturation of all KIR receptors, so that increased expression will 
only influence the NK cell-mediated killing of target cells with low or absent MHC class I 
expression. This hypothesis would support the findings that restoration of MHC I expression in 
K562 cells reduced their susceptibility to NK cells (Sarin et al., 1995; Tóth and Kubeš, 1993). 
Moreover, it is necessary to consider that the isolated NK cells were derived from donors with 
unknown HLA status. In this allogeneic setting, a KIR-HLA-class I-mismatch is quite likely and 
would explain the missing correlation of this inhibitory ligand and the susceptibility of melanoma 
cells towards “unlicensed” NK cells. Nevertheless, it has been shown that also autologous NK 
  Discussion 
104 
cells were able to kill melanoma cells expressing matched MHC I molecules (Carrega et al., 2009). 
Therefore, the impact of MHC class I surface expression on the NKiToxMel is still 
controversially discussed. 
The involvement of NKG2D/NKG2DL engagement in the NK cell-mediated killing of 
melanoma and other cancers seems to be more profound (Casado et al., 2009; Frazao et al., 2019; 
Morgado et al., 2011; Raulet, 2003) and was partly validated in the experimental data of this 
thesis. A higher abundance of MICA/MICB and ULBPs was associated with an increased 
NKiToxMel (Figure 16). These NKG2D ligands were commonly but heterogeneously expressed 
on melanoma cells (Casado et al., 2009; Vetter et al., 2002). Moreover, there are multiple 
indications that the expression levels of these ligands inversely correlate with tumour progression 
and patient survival due to an increase of soluble NKG2D ligands in the serum of cancer 
patients, including melanoma patients (Maccalli et al., 2017; Paschen et al., 2009; Shen et al., 2017; 
Vyas et al., 2017). This ‘shedding’ not only reduced density of these ligands on the cell surface but 
also induced the downregulation of surface NKG2D expression diminishing NK cell recognition 
even further (Salih et al., 2002). Experimental data obtained via flow cytometry only detect 
proteins expressed on the cell surface so that the shedding of ligands as well as intracellular 
molecules could not be inspected with this approach. Therefore, the NKG2D ligand expression 
shown in Figure 16 might be underestimated. In addition to the NKG2D receptor, also NCRs 
are important for melanoma detection by NK cells. One of them is Nkp30, whose known ligand 
B7-H6 has been shown to be expressed in about 20 % of cancer cell lines including melanoma 
(Bjornsen et al., 2019; Brandt et al., 2009). The abundance of B7H6 on the investigated 
melanoma cells was only marginal but showed the expected trend of higher B7H6 levels in the 
more susceptible melanoma cell lines (Figure 16). In sum, melanoma susceptibility to NK cells 
was associated with increasing activating ligands. However, the actual impact of individual ligands 
on the NK cell-mediated killing could only partially be resolved with the expression analysis 
obtained by flow cytometry. Additionally, the limited number of surface expressed ligands and 
the investigation of three cell lines, give only a limited view of the ligand profile of melanoma 
cells. 
Despite the distinct NK cell detection, also the mode of melanoma cell death might be different. 
As already discussed, NK cells can kill tumour cells via necrosis and apoptosis (Backes et al., 
2018). Taken that these processes have different kinetics, the observed killing curves could be 
partly a result of a heterogeneous preference to a distinct killing mode dependent on the 
melanoma cell line. Nevertheless, it is very plausible that universal protein expression patterns 
determine the heterogeneous NK cell-mediated killing of melanoma cells.  
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5.4 Reverse phase protein array reveals proteins correlating with susceptibility to 
NK cells 
The flow cytometry-based analysis of a limited number of potential melanoma ligands was not 
sufficient to understand the heterogeneous susceptibility of the melanoma cell lines to NK cells. 
On the other hand, reverse phase protein array (RPPA) allows sensitive and high throughput 
detection of more than 300 cancer-related proteins (MD Anderson, 2019; Tibes et al., 2006). 
RPPA was performed to further characterise the melanoma cell lines used in this study and 
allowed the identification of melanoma proteins that correlate with the determined NK cell-
mediated killing of melanoma cells. Intensive literature research for all proteins (marked in bold) 
of this melanoma killing signature revealed a melanoma phenotype switch determining the 
susceptibility to primary NK cell killing.  
Tumour growth and survival are parameters, which are dependent on environmental signals such 
as growth factors and nutrients. The receptors sensing and transducing these signals are thus 
important regulators of cell survival, proliferation, but also invasion. Multiple surface receptors 
were identified within the melanoma killing signature (Figure 17). One of the receptors that 
positively correlated with the NK cell-mediated killing was the transferrin receptor (TFRC). 
This receptor is involved in iron uptake and therefore plays an essential role in the cellular iron 
metabolism (Shen et al., 2018). High expression of TFRC was associated with enhanced cell 
proliferation (Trowbridge and Omary, 1981) and tumour progression. (Jones et al., 2006; Shen et 
al., 2018). Another identified receptor was the platelet derived growth factor receptor beta 
(PDGFRB). A decreased PDGFRB protein level diminished proliferation rate and invasion 
potential in several cancers (Fujino et al., 2018; Melaiu et al., 2017). PDGFR signalling is 
positively controlled by AKT and mediates tumour glycolysis (Ran et al., 2013). Furthermore, this 
receptor was found to be co-expressed with genes involved in EMT and has shown to be a 
characteristic of a mesenchymal phenotype in colorectal tumour cells (Steller et al., 2013). 
However, in melanoma the expression of PDGFRB has been shown to correlate with lower 
metastatic potential (McGary et al., 2004) and resistance to vemurafenib (Shi et al., 2011). 
Interestingly, PDGF-DD, one of the four polypeptides of the platelet-derived growth factor 
(PDGF) is an identified ligand for NKp44 (Barrow et al., 2018). Therefore, the relation of soluble 
PDGF and receptor bound growth factors might affect NK cell killing. A receptor that correlated 
with higher NK cell resistance was c-MET, that is known to bind hepatocyte growth factor and 
leads to the activation of several pathways e.g. PI3K/AKT and MAPK (Zhang et al., 2018). 
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Accordingly, this transmembrane receptor has shown to have increased activity in several cancer 
types including melanoma (Gherardi et al., 2012; Zhang et al., 2018) and thus promote 
tumourigenesis and cancer progression (Demkova and Kucerova, 2018). Furthermore, c-MET 
signalling was shown to promote EMT by disrupting cadherin-based cell–cell contacts (Zhou et 
al., 2019b). Another receptor found to negatively influence the NK cell-mediated killing was the 
progresterone receptor (PGR). Its general role in cancer progression and prognostic value is 
still controversy discussed. In prostate cancer, PGR was associated with disease progression 
(Grindstad et al., 2018), whereas in breast cancer mainly the opposite was reported (Yeung et al., 
2016). However, breast cancer patients expressing this receptor had better prognosis (Lim et al., 
2016a). In melanoma, progesterone has shown to inhibit cell growth, whereby the progesterone 
receptor itself does not seem to be involved (Ramaraj and Cox, 2014). Nevertheless, in breast 
cancer there is evidence that progesterone receptor suppress tumour growth by reducing 
translation of certain proteins (Finlay-Schultz et al., 2017). Furthermore, it has been reported that 
PGR-positive tumours may escape immune surveillance by downregulation of STAT-1 mediated 
IFN-γ signalling (Goodman et al., 2019). Also in melanoma, tumour immune escape was shown 
to be controlled by STAT-1 (Cerezo et al., 2018; Osborn and Greer, 2015).  
Another cell signal transducer found to be associated with increased NK cell resistance was the 
well-established oncogene NRAS. Although NRAS is highly mutated and constitutively active in 
melanoma (Davies et al., 2002), the investigated melanoma cell lines for establishing the 
melanoma killing signature are known as NRAS WT. However, its proliferative function is not 
only determined by the absolute expression level but also its activation status. The RAS activation 
is regulated by the adapter molecule growth factor receptor-bound protein 2 (GRB2). PDGFRB 
(pY716) mediates direct binding of GRB2 and decreased the RAS activity. (Arvidsson et al., 
1994). As this protein is also inversely correlated to the killing, one could conclude that 
melanoma cells more susceptible to NK cells had also higher NRAS activity independent from its 
expression level and mutational status. In addition, there are several indications that NRAS 
mutated melanoma patients show a better response to immunotherapies (Johnson et al., 2015; 
Kirchberger et al., 2018; Munoz-Couselo et al., 2017). COPS5 can affect several signalling 
pathways that are known to be involved in carcinogenesis. Furthermore, its overexpression was 
observed in many cancers (Liu et al., 2018). 
The identified proteins downstream of this signalling cascade were part of the PI3K-AKT-mTor 
and Hippo pathways. Proline-rich Akt substrate of 40 kDa (PRAS40), also known AKT1 
substrate 1, is part of the mTOR complex 1 and a known target of AKT. The phosphorylation of 
PRAS40 allows dissociation of the complex and hence releases the repression of mTORC1. 
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Based on these observations, it was proposed that elevated phosphorylation of PRAS40 is often 
associated with tumour progression. (Lv et al., 2017; Madhunapantula et al., 2007). However, 
only the total, non-phosphorylated PRAS40 was included in the RPPA-based melanoma killing 
signature. Threonine 246 is the only phosphorylation site of AKT1S1 included in the performed 
RPPA. Taken that PRAS40 has several phosphorylation sites, the RPPA cannot give a complete 
information about the phosphorylation status of this protein in the investigated melanoma cell 
lines. Furthermore, PRAS40 was shown to promote melanoma survival as it protects against 
apoptosis (Madhunapantula et al., 2007). RICTOR is a protein involved in assembly and 
function of mTOR complex 2 that regulates cytoskeleton remodelling and cell survival (Saxton 
and Sabatini, 2017). Although the mTORC1 dependent S6K1 was shown to phosphorylate 
RICTOR at T1135, the effect on the complex activity remains controversial. (Boulbes et al., 
2010; Dibble et al., 2009). Nevertheless, there are indications that phosphorylation at this tyrosine 
residue might inhibit mTORC2 activity (Julien et al., 2010). The mTORC2 was also suggested to 
promote aerobic glycolysis i.e. the ‘Warburg effect’ via upregulation of c-Myc (Masui et al., 2014) 
In addition, RICTOR expression is associated with tumour growth, cell migration and invasion, 
and inversely correlated with patient survival (Liang et al., 2017; Schmidt et al., 2018). WW 
Domain Containing Transcription Regulator 1 (WWTR1) is one of the downstream effectors of 
the Hippo signalling pathway that controls organ size through strict regulation of apoptosis and 
cell proliferation (Zhao et al., 2010a). WWTR1 is upregulated in many solid tumours and is 
associated with elevated invasion, angiogenesis and metastasis, but also stemness maintenance in 
several cancers including melanoma (Boopathy and Hong, 2019; Chen et al., 2019a; Feng et al., 
2018; Wei et al., 2019a). In addition, several proteins of the melanoma killing signature involved 
in metabolism suggested that melanoma cells with increased glycolysis were more susceptible to 
NK cells. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) is a crucial enzyme in 
glycolysis as it catalyses the conversion of glycerinaldehyde 3-phosphate to 1,3-bisphospho-
glycerate (Nicholls et al., 2012). Moreover, GAPDH is involved in the regulation of mTORC1 
activity as it prevents Rheb from binding to mTOR under low-glucose conditions (Lee et al., 
2009). However, its role is not only restricted to its central role in cell metabolism (Nicholls et al., 
2012). Several studies showed its involvement in other processes such as apoptosis through 
mitochondrial membrane permeabilization (Colell et al., 2009; Tarze et al., 2007) and EMT via 
SNAI1 upregulation (Liu et al., 2017a). As posttranslational modifications control the activity and 
function of GAPDH (Colell et al., 2009; Zhang et al., 2015), the RPPA failed to provide further 
information regarding a connection between GAPDH expression and its function in the context 
of NK cell-mediated killing of melanoma cells. Nevertheless, GAPDH was reported to be 
overexpressed in cancer and correlated with tumour progression in several cancers types 
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including melanoma (Hao et al., 2015; Ramos et al., 2015; Tang et al., 2012). Another important 
enzyme in the metabolic context is Hexokinase 2 that catalyses the phosphorylation of glucose 
in the first step of glycolysis. It promotes tumour growth and increases the metastatic potential in 
numerous cancers (Anderson et al., 2017; Lee et al., 2019; Siu et al., 2019). In addition, HK2 
binds voltage-dependent anion channels (VDACs) in the outer mitochondrial membrane. This 
suppresses the release of proteins such as cytochrome c or DIABLO, thereby inhibiting 
apoptosis and promoting cell survival (Pastorino and Hoek, 2003).  
One essential hallmark of cancer is resisting cell death (Weinberg et al., 2019). As discussed 
above, NK cells are able to kill cancer cells in distinct modes. The activation of NK cells 
mediates the release of perforin that can lead to membrane disruption and necrotic cell death. 
Annexin A7 (ANXA7) is part of the plasma membrane repair system (Sonder et al., 2019), so 
that increased level of ANXA7 might protect melanoma cells form NK cell killing. The role of 
ANAX7 in tumour progression seems to be dependent on the cancer type (Guo et al., 2013). 
However, in melanoma its expression was mainly connected to a less invasive phenotype 
(Kataoka et al., 2000). BAD is a pro-apoptotic protein that binds anti-apoptotic proteins such as 
Bcl-2 and allows the initiation of apoptosis (Anvekar et al., 2011). The activity of BAD is 
negatively regulated by phosphorylation at several residues. Several kinases including ribosomal 
protein S6 kinase alpha-1 (RPS6K1) phosphorylate BAD at serine residue 112 and prevent its 
pro-apoptotic activity (Stickles et al., 2015). Therefore, pBAD is associated with cancer 
development (Bui et al., 2018; Stickles et al., 2015) and therapy resistance (Chon et al., 2012; 
Marchion et al., 2011). Besides its role in apoptosis, there is evidence, that it is also involved in 
cell metabolism via the activation of glucokinase (Gimenez-Cassina et al., 2014). CASP3 is a 
known executioner caspase in the apoptosis process. Nevertheless, melanoma cells expressing 
more CASP3 seem to be better protected against the NK cell killing. This might be a contra 
intuitive finding, but the result could be explainable by considering the non-apoptotic protein 
functions of CASP3. CASP3 mediates stem cell differentiation (Abdul-Ghani and Megeney, 
2008), promotes cell migration as well as invasion of melanoma (Liu et al., 2013) and other 
cancers (Zhou et al., 2018b). DIABLO was shown to be the most negative regulator of NK cell-
mediated killing of melanoma. DIABLO is a mitochondrial protein that acts pro-apoptotic by 
blocking the inhibitors of apoptosis (Du et al., 2000). Therefore, its decreased expression will 
inhibit apoptosis and promote cell survival (for more details see chapter 5.6.1). Heat shock 
protein beta 1 is a negative regulator of ferroptosis, an iron dependent programmed cell death 
(Sun et al., 2015). Furthermore, HSPB1 is also involved in regulating tumour invasion, metastasis 
and survival (Arrigo and Gibert, 2014; Gibert et al., 2012; Straume et al., 2012). HSPB1 
transfected melanoma cell showed increased expression of E-cadherin (Aldrian et al., 2002). 
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Taken together, the apoptosis-related proteins indicate that melanoma cells with lower apoptotic 
threshold show a higher susceptibility to NK cell killing. Nevertheless, this observation might 
also be a result of faster detection of necrotic cells than apoptotic cells, hence, negative 
correlation of apoptosis-related proteins with NKiToxMel.  
In this study, melanoma cells susceptible to NK cells were not only characterised by a higher 
proliferation rate (Figure 34) but also by their staging (Figure 35) and invasion potential. 
Epithelial-mesenchymal transition plays a crucial role in cell invasion and tumour progression as 
it allows the generation of mesenchymal cells with motile properties to establish distant 
metastasis (Yeung and Yang, 2017). SNAI1, one of the top hits, is a known mediator of EMT 
(Kaufhold and Bonavida, 2014; Wang et al., 2013). This EMT-like phenotype switching has been 
also reported in melanoma (Li et al., 2015a). In addition to SNAI1, other proteins such as the 
adhesion molecules TWISTs also act as EMT promoters (Kang and Massague, 2004). TWIST2 
that was shown to be associated with NK cell resistance, is often overexpressed in human cancer, 
particularly in melanoma (Ansieau et al., 2008). Furthermore, it contributed to tumour 
progression in breast cancer (Fang et al., 2011) However, in breast cancer the differential cellular 
distribution of this protein determines its function regarding tumour progression. Nuclear 
TWIST2 initiates EMT and tumour invasion, whereas cytoplasmic TWIST2 maintains the 
epithelial-like and non-invasive cancer phenotype (Mao et al., 2012). Although TWIST1 and 
TWIST2 show structural homology and some functional redundancy, TWIST2 cannot be 
associated with cell invasion and patient survival in hepatocellular cancer patients (Sun et al., 
2010). In prostate cancer, there is even evidence that TWIST2 could function as a tumor 
suppressor (Zhao et al., 2019). As the RPPA do not reveal information about the localization and 
function of TWIST2 in the investigated melanoma cells, the negative association to the NK cell-
mediated killing may be a result of cytoplasmic localization and possible tumour suppressor 
function in melanoma. That mesenchymal phenotypes favour NK cell-mediated killing is further 
supported by the identification of L1CAM as a significant hit (Chen et al., 2018; Kiefel et al., 
2012). In melanoma, it is involved in cell motility (Yi et al., 2014) as well as in metastatic spread in 
a xenograft model of human melanoma (Ernst et al., 2018). In addition, the protein tyrosine 
kinase 2, also known as focal adhesion kinase is involved in cellular adhesion and cytoskeleton 
organization (Mitra et al., 2005). It has been frequently overexpressed in cancers (Prickett et al., 
2009; Zhou et al., 2019a) and is constitutively active in malignant melanoma (Kahana et al., 2002). 
Furthermore, it was shown that FAK inhibition reduces melanoma metastasis (Jeong et al., 2019; 
Kircher et al., 2019). This might be a result of a negative modulation of PTK2 in the E-cadherin 
dependent cell-cell-adhesion, leading to EMT (Giehl and Menke, 2008; Kleinschmidt and 
Schlaepfer, 2017). The reversion of EMT was followed by increased Napsin A expression (Zhou 
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et al., 2018a). Napsin A is a functional aspartic proteinase that is a known marker for primary 
lung adenocarcinoma (Ueno et al., 2003) and showed association with differentiation grade of 
adenocarcinoma. It was already shown to act as a suppressor of tumour growth (Ueno et al., 
2008). An unexpected protein found in the melanoma killing signature was LCK. Beyond its 
function as a mediator of the TCR signalling, LCK seems to also play role in other cellular 
processes such as carcinogenesis and cancer cell phenotype switch (Bommhardt et al., 2019). In 
melanoma, it was shown that high LCK protein expression was associated with enhanced patient 
survival (Cancer Genome Atlas, 2015). The underlying molecular reasons are not known yet, but 
it might be connected to its repressing function in oxidative phosphorylation (Vahedi et al., 
2015). One of the causes of melanoma is UV light exposure leading to DNA damage (Gandini et 
al., 2005b; Kulichova et al., 2014). The X-Ray Repair Cross Complementing 1 (XRCC1) is 
involved in DNA damage repair. Therefore, it is hardly surprising that the loss of XRCC1 was 
found to correlate with melanoma progression and poor patient survival (Bhandaru et al., 2014). 
In addition, single nucleotide polymorphisms (SNPs) in XRCC1 was also shown to increase 
cancer risk in some cancer types (Meng et al., 2017; Smolarz et al., 2019; Yin et al., 2007).  
This newly established melanoma protein signature suggested that melanoma cells with a more 
invasive i.e. aggressive (mesenchymal) phenotype that rely more on aerobic glycolysis might pose 
a better target for NK cell killing. This hypothesis is summarised in Figure 43. 
 
Figure 43. Melanoma cell phenotype determines susceptibility to NK cell killing.  
This melanoma cell phenotype is also in line with the gene signature predicting NK cell 
infiltration and melanoma patients’ survival (Cursons et al., 2019). According to this work, less 
mesenchymal melanoma tumours had a lower NK cell infiltration (NK score), whereas highly 
mesenchymal tumours had higher range in their NK cell score. Surprisingly, TGF-β specific 
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metabolic reprogramming of cancer cells during EMT (Kang et al., 2019). Melanoma cells with 
more invasive, mesenchymal properties tend to rely more on glycolysis than oxidative 
phosphorylation (OXPHOS) (Bettum et al., 2015). In addition, tumour progression was also 
associated with the aerobic glycolysis (Warburg effect) (Lee et al., 2018; Lu et al., 2015) 
In sum, the RPPA based melanoma killing signature allowed the further characterisation of 
melanoma cells with higher susceptibility to NK cells. However, this method is limited by the 
restricted number of proteins selected due to their association with cancer. Therefore, RPPA can 
only provide a partial impression regarding the interconnection between melanoma phenotype 
and NK cell-mediated killing. Nevertheless, it allows the development of a limited but robust 
prediction model that can be extended and validated in further experiments.  
5.5 Melanoma protein signature allows the prediction of susceptibility to NK 
cells 
The expression levels of melanoma proteins correlating with the susceptibly to NK cells (protein 
signature) was used to predict the response to NK cell-mediated killing. A weak point of the 
prediction model is that the actual impact of the single proteins to the susceptibility were 
neglected and hence all proteins had an equal weight in the signature. To minimize the overfitting 
of the model, we refrained from weighting the single proteins according to the strength of their 
influence on the killing or their correlation. Trials to include this information to the model led to 
overfitting and impaired the prediction, so that this attempt was abandoned. The chosen 
prediction model is based on the linear correlation of the protein signature of the melanoma cell 
lines to their susceptibility to NK cells. The resulting equation of the linear regression analysis 
allowed prediction of eight additional, previously non-tested melanoma cell lines (Figure 18). 
Although the killing efficiency was not always fully fitting to the prediction, the actual 
susceptibility of the majority of tested melanoma cells corresponded to the predicted values 
(Figure 19) and only one cell line (WM3682) clearly failed the prediction. Notably, this cell line 
bears a NRAS mutation at codon 61 (Q61L), which might increase the susceptibility to NK cells 
as several studies showed that NRAS mutated tumours benefit from immunotherapies (Johnson 
et al., 2015; Kirchberger et al., 2018; Munoz-Couselo et al., 2017). This theory is, however, 
contradicted by the WM3268 cell, which harbors a common mutation at codon 61 (Q16K) 
(Dumaz et al., 2019), but showed low susceptibility to NK cells. The NRAS (Q61) variant 
showed pronounced MAPK signalling in comparison to NRAS (G12) variants (Posch et al., 
2016). If the distinct substitution of glutamine (Q) to leucin (L) or lysine (K) affects this signalling 
behavior is not known. Taken together, NRAS mutation status does not provide a full 
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explanation of the failed prediction of WM3682 and this issue needs further experimental 
analysis. 
The killing information of the additional melanoma cell lines was used to identify crucial proteins 
controlling the susceptibility of melanoma cells to NK cells. Therefore, the RPPA analysis was 
repeated including the additional seven melanoma cell lines. The distinct disease stages and 
genetic backgrounds of these melanoma cell lines may mask the similarities of the molecular 
determinants of the NK cell-mediated killing. Therefore, it was not unexpected that the inclusion 
of all melanoma cell lines reduced the number of identified proteins. Interestingly, SNAI1 and 
DIABLO remained as strongest positive and negative regulators of the NKiToxMel, respectively.  
5.6 Single regulators of the melanoma cell susceptibility to NK cell killing 
DIABLO and SNAI1 were the most promising regulators of the NK cell-mediated killing. 
Therefore, it was assumed that manipulation of these proteins should influence the melanoma 
killing.  
5.6.1 DIABLO is a potential negative regulator of NK cell-mediated killing 
In agreement with the RPPA data, the expression of DIABLO in the melanoma cell lines 
inversely correlated with their susceptibility to NK cells (Figure 20). This seemed contra intuitive 
as DIABLO promotes apoptosis by inhibiting iAPs. The mitochondrial release of DIABLO is 
the major initiator of the extrinsic apoptosis pathway (TRAIL) (Zhang et al., 2003). The 
progression in melanoma is associated with decreased expression of death receptors for tumour 
necrosis factor-related apoptosis-inducing ligands (Zhuang et al., 2006). This also fits to the 
finding that 1205Lu cells are TRAIL resistant. (Phipps et al., 2011). In sum, this knowledge 
suggests that the NKiToxMel is not mediated by the extrinsic pathway. Nevertheless, DIABLO 
was one of the strongest RPPA-identified hits (Figure 17). Depending on the cancer type, 
DIABLO abundance might promote or suppress tumour progression (Martinez-Ruiz et al., 
2008). The decrease of DIABLO after knockdown augments the NKiToxMel (Figure 23). Given 
that in other biological contexts DIABLO is reported to promote apoptosis, which does not 
explain our observations regarding its negative correlation with melanoma susceptibility to NK 
cell killing, it is likely that the actual function of DIABLO in the NK killing context is not 
designated to affect apoptosis. Notably, DIABLO was shown to repress cell differentiation 
(Arbiser, 2018) and has an additional role in tumour formation by affecting phospho lipid 
synthesis (Paul et al., 2018). Indeed, a changed composition of the phospholipid layer might 
favour the NK cell detection or the general susceptibility to the lytic granules.  
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5.6.2 SNAI1- a positive regulator  
SNAI1 is a known regulator of EMT and was shown to correlate with the susceptibility to NK 
cells (Figure 17). The RPPA data were confirmed by mRNA expression levels, which also 
correlate with NK cell killing (Figure 24). The here presented result that SNAI1 expression 
increases NK cell-mediated killing is supported by the findings of (Lopez-Soto et al., 2013). They 
overexpressed SNAI1 in HT29M6 colon cancer cells and could observe an upregulation of 
NKG2D ligands (mainly MICA/MICB and ULBP2/3). This increase in activating ligands also 
resulted in enhanced NK cell-mediated killing of these colon cancer cells. However, the authors 
failed to examine the mechanism by which SNAI1 upregulation alters cancer cell susceptibility 
towards NK cells. Moreover, it was shown that upregulation of SNAI1 represses the E-cadherin 
expression in melanoma (Poser et al., 2001). E-cadherin is mainly expressed in melanocytes and 
primary melanoma cell lines, whereas invasive metastatic melanoma cell lines lack it in vitro 
(Danen et al., 1996). The loss of E-cadherin is often accompanied by the gain of N-cadherin in 
melanoma (Hao et al., 2012; Lade-Keller et al., 2013; Marcelina et al., 2016). This so called 
‘cadherin switch’ was shown to be associated with tumour progression (Yan et al., 2016) and 
enhanced invasion potential (Ciolczyk-Wierzbicka and Laidler, 2018; Li et al., 2001; Molina-Ortiz 
et al., 2009). E-cadherin is a known ligand for the inhibitory killer cell lectin-like receptor 
subfamily G member 1 (KLRG1) (Ito et al., 2006; Li et al., 2009). Therefore, a decreased E-
cadherin expression should increase the NK cell activation threshold and protect melanoma cells 
against NK cells. This is in line with the study of (Shields et al., 2018) showing that exogenously 
expressed E-cadherin in a B16F10 melanoma mouse model enhanced melanoma immune 
surveillance and caused a higher susceptibility to immune checkpoint blockade therapies. In 
addition, the induction of EMT in lung cancer promoted the susceptibility to NK cell-mediated 
cytotoxicity (Chockley et al., 2018). The authors provide evidence that this is mainly caused by 
the downregulation of the KRLG1 ligand E-cadherin, but not by the observed increased 
expression of NKG2D ligands. Although EMT contributes to a metastatic phenotype (Alonso et 
al., 2007; Kudo-Saito et al., 2009) and a poor prognosis (Aruga et al., 2018; Yan et al., 2016), the 
susceptibility of melanoma cells with intrinsically higher mesenchymal properties to NK cells was 
increased (Figure 43). The SNAI1 expression in melanoma was associated with NKiToxMel 
(Figure 24). Only WM3918 showed low SNAI1 levels despite its high susceptibility. This is in line 
with its observed low invasive potential (Ma et al., 2011). As a transcription factor, the function 
of Snail is not restricted to inducing EMT. SNAI1 was shown to play an important role in the 
energy metabolism. Although SNAI1 suppressed aerobic glycolysis in breast cancer cells by 
repression of phosphofructokinase-1 and can act as metabolic switch to pentose phosphate 
pathway (Kim et al., 2017), it enhanced glycolysis during EMT in gastric cancer (Yu et al., 2017). 
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Furthermore, it should be noted that NK cells are able to kill cancer cells with cancer stem cell 
(CSC) characteristics (Ames et al., 2015; Pietra et al., 2009; Sultan et al., 2017) this was often 
associated with EMT (Liu and Fan, 2015; Singh and Settleman, 2010). Hence, NK cell based 
immunotherapy targeting of CSC might prevent tumour relapse and metastasis (Luna et al., 2017; 
Melaiu et al., 2019). 
5.7 Susceptibility of melanoma cells towards NK-92 killing shows heterogeneity 
similar to primary NK cell killing 
The NK cell line NK-92 revealed a lower cytotoxicity against melanoma cells in comparison to 
primary NK cells (Figure 26). Responsible for this difference is most likely the receptor profile of 
the cell line. Although NK-92 cells express several important activating receptors, including 
NKG2D, NKp30 and NKp46, other activating receptors such as NKp44 and CD16 are absent 
(Klingemann et al., 2016). In addition, the cell line NK-92 lacks most KIR receptors (with 
exception of KIR2DL4) (Suck et al., 2016). However, the cytotoxic potential seems to be 
determined by a repertoire of activating receptors. The relative cytotoxicity of primary NK cells 
and NK-92 cells against the cancer cell lines showed similar heterogeneity. These observations 
support the hypothesis that the heterogeneous susceptibility of melanoma to NK cells is not 
determined by the amount of MHC class I molecule on the melanoma cell surface. However, the 
NK-92 cell line shows the expression of the inhibitory receptor CD94/NKG2A (Suck et al., 
2016). This receptor specifically binds to HLA-E, a non-classical MHC class I molecule (Brooks 
et al., 1999; Lee et al., 1998), that is also expressed by melanoma cells (Derre et al., 2006). Despite 
the lower cytotoxicity of NK-92, the susceptibility of melanoma cells to NK-92 strongly 
correlated to the data obtained with primary NK cells (Figure 26). Therefore, additional RPPA 
analysis with nine melanoma cell lines that were killed by NK-92, would support the 
identification of a universal protein signature that determines the melanoma cell phenotype and 
hence susceptibility to NK cells killing.  
Although the melanoma NK-92 killing signature lacks some proteins of the protein signature 
correlating with primary NK cell killing, the top regulators SNAI1 and DIABLO as well as 
several other proteins were present in both signatures. A closer look at the additional identified 
proteins supports the previously described melanoma cell phenotype susceptible to NK cell 
killing. Melanoma cells with mesenchymal properties were more susceptible to NK cell killing. In 
addition to SNAI1, a potent EMT inducer (Kaufhold and Bonavida, 2014), also other proteins 
involved in EMT were identified as positive regulators of the NK 92-induced cytotoxicity against 
melanoma cells. XBP1, a transcription factor that promotes cell proliferation and tumour 
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progression in several cancers including melanoma was identified (Chen and Zhang, 2017; Shi et 
al., 2019). XBP1 is known to induce SNAI1 expression and hence promoting EMT resulting in 
increased cancer invasion and metastasis (Li et al., 2015b; Shi et al., 2019). In addition, XBP1 
expression correlated with an upregulation of PI3K-mTOR signalling (Yang et al., 2015), which is 
also reflected in the protein signature by the activated ribosomal S6 protein kinases (RPS6KB1 
and RPS6K, also known as p70S6 kinase). Furthermore, phosphatidylinositol 3-kinase regulatory 
subunit alpha also referred as p85 alpha (PIK3R1) was identified as a negative regulator of 
NKiToxMel. PIK3R1 is a tumour suppressor gene that binds and stabilizes p110, the catalytic 
subunit of PI3K, hence maintaining PI3K in an inactive conformation (Cheung and Mills, 2016; 
Vallejo-Diaz et al., 2019) until growth factor stimulation activates it. PIK3R1 is frequently 
mutated in cancer and was shown to promote cell survival and proliferation (Jaiswal et al., 2009; 
Urick et al., 2011). This would explain why PIK3R1 was found to be upregulated in melanoma 
(Aziz et al., 2009) Another EMT inducer that is activated by MAPK and PI3K-AKT signalling, is 
the Y-box-binding protein 1 (YBX1) (Kosnopfel et al., 2018). The expression of YBXI is 
increased during melanoma progression and its nuclear localisation is associated with invasive and 
metastatic potential in melanoma (Schittek et al., 2007; Sinnberg et al., 2012). Transglutaminase 
(TGM2) is a transpeptidase that functions as a signal transducer and regulates extracellular matrix 
stability and cell adhesion (Akimov et al., 2000; Menter et al., 1991). In melanoma, higher levels 
of TGM2 were positively linked to tumour growth (Kozlowska et al., 1991) and metastasis (Fok 
et al., 2006; van Groningen et al., 1995; Xu et al., 2006). TGM2 was shown to activate PI3K-
AKT signalling that leads to a SNAI1 induced EMT (Lin et al., 2011). Furthermore, TGM2 is 
involved in self-renewal (Eckert et al., 2015; Kang et al., 2018), chemoresistance (Verma and 
Mehta, 2007) and induces the activation of epidermal growth factor receptor (EGFR) (Eom et 
al., 2014) that was also identified as a positive regulator of NKiToxMel. EGFR transcription is 
additionally induced by YBX1(Stratford et al., 2007). EGFR is a growth-factor-receptor tyrosine 
kinase that positively regulates cell proliferation and survival after binding of EGFR (Herbst, 
2004). In cancer, it is often associated with poor patient’s survival (Nicholson et al., 2001), so that 
EGFR signalling was targeted in cancer therapy by specific monoclonal antibodies such as 
cetuximab or tyrosine inhibitors such as gefitinib (Seshacharyulu et al., 2012). Although EGFR is 
also involved in melanoma progression and metastasis, its prognostic significance in melanoma 
could not be validated (Boone et al., 2011). Its activation was shown to be associated with 
increased activation of AKT-PI3K-mTOR signalling and other pro-oncogenic signalling 
pathways (Wee and Wang, 2017). Moreover, it was shown to promote aerobic glycolysis (Lim et 
al., 2016b; Makinoshima et al., 2014) and initiate G1/S cell cycle progression (Baker and Yu, 
2001; Lo and Hung, 2006). Cyclin-dependent kinase inhibitor 1B (CDKN1B) is another cell 
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cycle-related protein that is part of the melanoma NK-92 killing signature as well. CDKN1B is a 
tumour suppressor that arrest G1 cell cycle progression by binding to cyclin E-CDK2 or cyclin 
D-CDK4 complexes (Besson et al., 2008). However, elevated CDKN1B levels correlated with 
tumour progression in melanoma (Sanki et al., 2007). This can be explained by its dominant 
cytoplasmic localisation in melanoma (Chen et al., 2011; Denicourt et al., 2007) that increases 
migration potential and hence promotes metastasis (Wu et al., 2006). The cytoplasmic localisation 
seems to be determined by protein phosphorylation of CDKN1B tyrosine residues T157 and 
T198 (Larrea et al., 2009; Wander et al., 2011) and was regulated and stabilised by kinases such as 
RAS (Liu et al., 2000), AKT (Viglietto et al., 2002) and MEK1 (Cheng et al., 1998). The dual 
specificity mitogen-activated protein kinase kinase 1 (MEK1) is not only associated with 
tumourigenesis (Govindarajan et al., 2003) but also part of the RAS-RAF pathway that was 
shown to be highly activated in melanoma (Davies et al., 2002).  
Phosphorylated PEA15 (S116) showed the highest positive correlation to the NK-92-mediated 
killing. In contrast to its known tumour suppressor functions, the phosphorylation of PEA-15 
has shown to increase MAPK signalling by allowing nuclear translocation of ERK (Mace et al., 
2013). This tumour promoting function is further supported by its binding to FADD and by 
preventing the DISC assembly, thereby inhibiting apoptotic signalling (Sulzmaier et al., 2012). 
Furthermore, it was shown that PEA-15 and hexokinase 2, which is also highly correlated to the 
killing, act together as sensors of metabolic state determining cell fate (Mergenthaler et al., 2012).  
The NK-92 derived killing signature also contains proteins involved in regulation of apoptosis. In 
addition to DIABLO, BCL-2, member of the anti-apoptotic Bcl-2 subfamily, is highly expressed 
in melanoma and shows the highest average expression for any cancer type other than leukemia 
(Placzek et al., 2010). How BCL-2 levels correlate with melanoma progression and metastasis is 
controversially discussed (Anvekar et al., 2011). Nevertheless, many studies are in line with our 
findings that BCL-2 expression decreases during melanoma progression (Divito et al., 2004; 
Saenz-Santamaria et al., 1994; van den Oord et al., 1994; Vlaykova et al., 2002). Although BCL-2 
inhibits apoptosis initiation, the expression of BCL-2 alone does not determine the apoptotic 
threshold of the target cells. In addition, other pro-apoptotic as well as anti-apoptotic Bcl-2 
family members regulate this process. In this regard, it was shown that BAX/BCL-2 ratio 
determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis 
(Raisova et al., 2001). Besides its role in apoptosis, BCL-2 was also shown to be involved in 
calcium homeostasis regulation (Bonneau et al., 2013). Another player in the NK-92 cell-
mediated killing was the major stress-induced chaperone HSP70. It has been shown to be 
overexpressed in many cancers, including melanoma (Farkas et al., 2003; Sherman and Gabai, 
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2015). Its role in cancer progression seems to be dependent on the cancer type. In melanoma, the 
expression of HSP70 was associated with improved survival (Ricaniadis et al., 2001). This can be 
explained by an increased NK cell activity against HSP70 expressing and releasing tumours 
(Botzler et al., 1998; Elsner et al., 2007). However, the immune supporting effect was limited to 
tumour cells expressing NKG2D ligands (Elsner et al., 2007). These results seem to contradict 
our findings were melanoma cells with lower HSP70 were better NK cell targets. However, this 
expression pattern might be the result of the immunoediting process in the melanoma patients. 
The melanoma cell lines that were used in this study were established from patients at distinct 
melanoma stages. Melanoma cells that form distant metastasis have already evaded immune 
response and may express lower HSP70 level than the primary tumour. Besides its direct role in 
immune surveillance, HSP70 is involved in controlling the energy metabolism. To this end, 
overexpression of HSP70 in HeLa cells shifted the energy metabolism from (OXPHOS) to 
glycolysis (Wang et al., 2012). However, the results of (Leu et al., 2017) in melanoma cells draw 
the opposite picture. The treatment of melanoma cells with HSP70 inhibitors impaired 
OXPHOS accompanied by lowered oxygen consumption rate as well as adenosine triphosphate 
(ATP) production and reduced mitochondrial membrane potential (Leu et al., 2017). 
Furthermore, there is evidence that HSP70 silencing enhances metastatic potential by 
deregulation of E-cadherin expression and acquired a mesenchymal-like-phenotype (Kasioumi et 
al., 2019). However, it was also shown that HSP70 is overexpressed in metastatic melanoma and 
supports tumour progression by promoting FAK dependent invasion (Budina-Kolomets et al., 
2016). Beside DIABLO, the most important negative regulator of the NK-92-mediated killing is 
DVL3. The dishevelled proteins are involved in the Wnt signalling pathway by preventing beta-
catenin degradation in the cytoplasma (Kafka et al., 2014). This allows accumulation of beta-
catenin and induction of EMT by upregulation of SNAI1 and SLUG (Gasior et al., 2017). Thus, 
the decreased expression of DVL3 would counteract the other EMT inducer. However, Dvl 
proteins, in particular DVL3, are also part of the non- canonical Wnt signalling and were shown 
to activate JNK (Li et al., 1999; Zhao et al., 2010b) that was shown to support cell survival and 
proliferation in melanoma (Alexaki et al., 2008; Jorgensen et al., 2006).  
Although the identified proteins of the RPPA analysis of NK-92 cells were not completely 
identical to melanoma killing signature (primary NK cells), both analysis revealed a similar 
melanoma phenotype that determine susceptibility to these effector cells. 
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5.8 Inhibition of the PI3K-AKT-mTOR signalling pathway decreases melanoma 
susceptibility to NK cells 
The melanoma killing signature only considers the relative protein abundance and its influence on 
the NK cell-mediated killing of melanoma cells. Furthermore, focusing on individual proteins 
neglect the synergistic effects of several proteins involved in pathways resulting in the same 
melanoma phenotype.  
The PI3K-AKT-mTOR pathway is a highly regulated intracellular signalling pathway controlling 
cell cycle, cell survival/apoptosis as well as protein biosynthesis (Fingar and Blenis, 2004; Saxton 
and Sabatini, 2017). The RPPA analysis revealed that the PI3K-AKT-mTOR pathway might play 
an important role in the susceptibility of melanoma cells towards NK cell killing. Its central role 
in cell survival, proliferation and cell metabolism makes it an attractive target for cancer therapy 
(Porta et al., 2014). Therefore, many drugs were developed to target this pathway in cancer cells. 
In this study, several of these drug inhibitors were used to test the role of PI3K-AKT-mTOR 
signalling in the NKiToxMel.  
Rapamycin is one of the first inhibitors known to inhibit mTORC1specifically (Benjamin et al., 
2011). Rapamycin treatment of melanoma was shown to decrease melanoma cell proliferation 
(Bundscherer et al., 2008; Ciolczyk-Wierzbicka and Laidler, 2018) as well as invasive potential 
(Ciolczyk-Wierzbicka et al., 2020; Yang et al., 2010). However, the melanoma proliferation even 
at concentrations higher than 5 nM was only reduced by about 20 % (Lasithiotakis et al., 2008). 
This is in line with the observed reduction in WM3734 cell viability of maximum 23 % after 
treatment with 2.5-20 nM rapamycin (Figure 29). Nevertheless, rapamycin in the used 
concentrations were shown to diminish melanoma cell proliferation and metastatic potential 
(Molhoek et al., 2005; Rosenberg et al., 2015). 
The treatment with rapamycin decreased susceptibility of WM3734 cells and 1205Lu cells to NK 
cells significantly after 24 h. That this effect was even more pronounced after a longer treatment 
period, might be caused by an additional inhibition of mTORC2 assembly, which was observed 
in other cancer cell lines (Sarbassov et al., 2006). According to the RPPA data, 1205Lu cells 
should have a higher PI3K-AKT-mTOR pathway activity than WM3734 cells. Therefore, it is 
reasonable that the effect of rapamycin treatment in 1205Lu is more dominant.  
MK2206 is a known allosteric pan AKT inhibitor that inhibits AKT phosphorylation in a non-
ATP competitive manner (Nitulescu et al., 2016). The usage of MK2206 showed promising 
clinical effects in combination with other cytotoxic and targeted therapies in advanced solid 
tumours, whereas monotherapy mainly failed (Molife et al., 2014; Xing et al., 2019). MK2206 
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inhibits AKT activity in multiple cancer cell lines, but the downstream effects differed a lot 
depending on the concentration and the targeted cell line. Effective inhibition of invasion and 
migration of glioblastoma cells was only observed at MK2206 concentrations higher than 5 µM, 
whereby 1 µM already reduced AKT activity (Narayan et al., 2017). In endometrial cancer cells, 
already 1 µM significantly decreased invasion (Winder et al., 2017). Also glycolytic metabolic 
effects by the decrease in glutamate and increase in glucose were more pronounced after 
MK2206 treatment with higher concentrations (3-5 µM) in human colorectal and prostate 
carcinoma (Al-Saffar et al., 2018). The reduced expression levels of glycolytic enzymes including 
hexokinase II (HK2) and lactate dehydrogenase alpha (LDHA) after MK2206 treatment 
explained the metabolic changes in these experimental settings. In addition, 5 µM MK2206 
represses colorectal cancer-initiating stem cells (Malkomes et al., 2016). In melanoma, different 
cell lines were susceptible to concentrations above 300 nM after 24 h treatment (Rebecca et al., 
2014). Nevertheless, cell growth and survival were rather not affected at concentrations lower 
than 1 µM. These findings are in line with the low toxicity in the investigated melanoma cell line 
(Figure 29). However, MK2206 significantly reduced the susceptibility of 1205Lu cells to NK 
cells (Figure 31G-L), which might be caused by the mutational status of this cell line. 1205Lu cell 
line has a deletion of PTEN. Given that PTEN is inhibiting the PI3K-AKT-mTOR pathway, 
PTEN loss would lead to the hyperactivation of this pathway (Carracedo and Pandolfi, 2008). 
Since other additional pathways feeding PI3K-AKT-mTOR signalling are less active, MK2206 
and other drug inhibitors may have a stronger effect on 1205Lu cells. Interestingly, the 
susceptibility of WM3734 cells was not altered following MK2206 treatment. The PTEN status 
of WM3734 cell line is not known. Nevertheless, an active PTEN as well as other redundant 
signalling ways can lead to mTOR activation. WM3734 cells might rely less on AKT activity and 
can compensate the inhibition by MK2206 better. Accordingly, longer incubation of WM3734 
cells with MK2206 even increased their susceptibility to NK cells after 2 h. AKT is a kinase with 
many substrates, thereby influencing distinct cellular mechanisms such as apoptosis. Activated 
AKT phosphorylates and inhibits the pro-apoptotic proteins such as BAD, thereby preventing 
the initiation of apoptosis (del Peso et al., 1997). MK2206 inhibits this anti-apoptotic function 
and can lower the apoptosis threshold of the melanoma cells. Since the two cell lines 1205Lu and 
WM3734 have distinct expression levels of proteins involved in apoptosis, this pro-apoptotic 
effect of the drug inhibitor influences the melanoma cell lines to a different extent.  
PI3K inhibitors can be used for inhibiting the pathway upstream of AKT and mTOR. The pan 
PI3K inhibitor BKM120 exhibited strong cytotoxic effects on different tumour cell lines, 
including melanoma cells (Aasen et al., 2019; Hu et al., 2015; Koul et al., 2012; Niessner et al., 
2016). Already 1 µM decreased cell viability of WM3734 cells after 48 h (Figure 31). Similar to 
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MK2206, also BKM120 decreased the susceptibility of melanoma cell lines to NK cells. 
However, the effects were stronger after 72 h of treatment, which might be caused by the high 
redundancy of neighboring pathways feeding the PI3K-AKT-mTOR signalling even after 
blocking of PI3K. Similar to MK2206 also BKM120 (1-2 µM) decreased the cell migration and 
invasion potential in glioblastoma cells and melanoma (Aasen et al., 2019; Speranza et al., 2016). 
Moreover, this drug also eliminated the stem cell subpopulation of breast cancer cells (Hu et al., 
2015) and modulated the metabolic phenotype of AML cells to reduced basal glycolysis and 
glycolytic capacity (Allegretti et al., 2015).  
The used inhibitors affect not only cancer cells but could also diminish NK cell cytotoxicity. 
Although residual drug concentration during the cytotoxicity experiments is negligibly low, 
possible negative side-effects on NK cells were experimentally excluded. The acute addition of 
2.5 nM rapamycin in the assay did not decrease the susceptibility of the non-pretreated melanoma 
cell lines WM3734 and 1205Lu to NK cells (Figure 33 A+B). In addition, the killing of rapamycin 
pre-treated K562 was even slightly accelerated, which would contradict the assumption of an 
effective inhibition of NK cells by remaining or released drug inhibitor (Figure 32). These results 
are in agreement with the observations of Yang and colleagues showing that 4 h treatment with a 
relatively high concentration of 100 nM rapamycin did not impair NK cell cytotoxicity to 
sensitive target cells (Yang et al., 2018). On the contrary, rapamycin has shown to restore NK cell 
cytotoxicity in patients suffering from primary immunodeficiencies caused by PI3K110 delta 
mutations (Ruiz-Garcia et al., 2018). Since MK2206 pre-treatment enhanced NK cell cytotoxicity 
against WM3734 (Figure 31 D-F), inhibitory effects of MK2206 on NK cells during the killing 
can be excluded. This conclusion is further supported by the observation that only the NK cell-
mediated killing of non-treated WM3734 was affected in the presence of 1 µM MK2206 (Figure 
33 C+D). Nevertheless, MK2206 in concentrations of 1 µM and higher can affect cell 
proliferation of distinct immune cell populations (Abu-Eid et al., 2014; Ding et al., 2014). Further 
information about the effect of MK2206 on NK cell functionality are not available. BKM120 
during the assay lowered the NK cell-mediated killing of non-treated and drug pre-treated 
WM3734 (Figure 33 E+F). Therefore, it seems to be likely that 1 µM BKM120 also inhibits NK 
cell function. It was shown that other PI3K inhibitors suppressed the movement of lytic granules 
to the immunological synapse and hence tumour lysis mediated by NK-92 (Jiang et al., 2000; Yea 
et al., 2014). However, the expected concentration during the killing assay should be dramatically 
lower. Furthermore, an impaired NK cell cytotoxicity alone would not explain the considerably 
reduced NK cell-mediated killing BKM120 pre-treated WM3734 cells in comparison to non-
treated melanoma cells Figure 33 E+F).  
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In sum, targeting the PI3K-AKT-mTOR pathway with drug inhibitors reduced the susceptibility 
of melanoma cells towards NK cell killing. The usage of drugs inhibiting PI3K or mTOR was 
shown to alter the ligand expression profile on cancer cells. Rapamycin treatment decreased the 
surface expression of MICA in K562 (Boissel et al., 2006) and MICA/B  as well as ULBPs in 
acute myeloid leukemia (Zhu et al., 2019). In addition, LY294002, another PI3K inhibitor, 
inhibited the expression of MICA/B in several breast cancer cell lines (Okita et al., 2012) as well 
as the expression of PD-L1 in prostate cancer cells (Xu et al., 2018a). Furthermore, the inhibition 
of mTOR also induced alterations in the MHC I immunopeptidome as 13 % of the MHC I-
associated peptides were significantly overexpressed after rapamycin treatment (Fortier et al., 
2007). Besides these direct effects on the ligand profile, the used drug inhibitors were shown to 
induce a cancer phenotype that was characterised by decreased migratory and invasive potential 
as well as lower glycolytic capacity. This is in line with the RPPA analysis, which revealed 
melanoma cells with more epithelial properties and lower glycolytic activity to be less susceptible 
to NK cells.  
5.9 Melanoma-NK cell-co-cultures 
Although natural killer cells have shown often promising success in many in-vitro studies, NK cell 
based immunotherapies are still not extensively used in clinical practice. One of the difficulties is 
the underestimation of reciprocal cell interactions and the development of therapy resistance. 
The establishment and further characterisation of melanoma co-cultures with primary NK cells 
and NK-92 allowed the investigation of NK cell -immune evasion of melanoma.  
5.9.1 NK cell susceptibility of melanoma cells after co-culturing with NK cells 
Melanoma cells co-cultured with primary NK cells or NK-92 cells were less susceptible to NK 
cells. This adaption correlated with increasing E:T ratio and the duration of the melanoma-NK 
cells-co-culture (Figure 36 and Figure 38). Similar results have been reported by (Balsamo et al., 
2012), where the magnitude of NK cell resistance in melanoma increased with higher E:T ratio. 
Moreover, the authors observed an increase of classical (HLA A,B,C) and non-classical (HLA 
E,G) MHC class I molecules as well as the downregulation of MICA on melanoma cells co-
cultured with NK cells for 2 days. These adaptions lowered the activation threshold of the NK 
cells as the effector cells receive enhanced inhibitory signals and decreased activating stimuli at 
the same time. The lower expression of MICA could be caused either by a complete 
downregulation or by shedding of these ligands. Notably, the authors showed that the ligand 
shedding promotes downregulation of the NKG2D receptor (Casado et al., 2009) and provided 
  Discussion 
122 
an explanation why soluble MICA and ULBP2 are associated with poor prognosis and tumour 
progression (Paschen et al., 2014). The observed alterations in the ligand profile together with 
associated NK cell susceptibility of melanoma were completely reversible in absence of NK cells 
(Balsamo et al., 2012). Therefore, it can be assumed, that the acquired resistance during co-
culture is most likely not caused by a selection process, but rather through an adaption of 
melanoma cells against NK cell cytotoxicity. However, longer co-culture periods reduced the 
susceptibility of the untreated WM3734 control as well. A high grade of genetic instability of 
cancer cells (Hanahan and Weinberg, 2011) could lead to mutation enrichment and hence an 
altered ligand profile of melanoma cells.  
NK-92 cells, similarly as the primary NK cells, induced NK cell resistance in melanoma cells in a 
dose-dependent manner (Figure 38). In the absence of NK-92, the melanoma cell susceptibility 
recovered almost completely after 3 days. The reduced susceptibility was already detectable 24 h 
after co-culturing with NK-92 cells (Figure 39). Interestingly, melanoma co-cultured with NK-92 
also induced a partial cross-resistance to primary NK cells (Figure 40). This finding indicated that 
co-culturing induces general molecular changes in melanoma cells that will affect the 
susceptibility to NK-92 as well as primary NK cells. In comparison to primary NK cells, NK-92 
have a different receptor profile (less KIR receptors) as well as a lower cytotoxicity against 
melanoma. Therefore, the adaption to NK-92 might differ and hence may affect the melanoma 
killing mediated by primary NK cells to a lower level. 
During the co-culture process, melanoma cells experienced an EMT-induced phenotype switch 
that mediates resistance to NK cells (Huergo-Zapico et al., 2018; Terry et al., 2017). This process 
was dependent on cell-to-cell interactions, receptor-ligand engagement as well as cytokine release. 
Key cytokine in this process is melanoma cell secreted cytokine TGF-β a known potent inducer 
of EMT (Xu et al., 2009). Although TGF-β induced EMT resulted in melanoma cells with 
mesenchymal properties (Huergo-Zapico et al., 2018), this TGF-β mediated melanoma 
phenotype did not correlate with a higher NK cell score. This can be explained by the inhibitory 
effect of TGF-β on NK cells. Melanoma secreted TGF-β caused a downregulation of NKG2D 
(Morgado et al., 2011) and inhibited the IL-2 induced upregulation of NKp30 and NKp44 (Pietra 
et al., 2012a) on NK cells. These phenotype changes have also been observed in melanoma 
progression in patients (da Silva et al., 2014). These exhausted NK cells were characterised by 
higher levels of inhibitory receptors (KIR3DL1 and KIR2DL3) and lower levels of activating 
receptors (NKG2D, NKp46, and DNAM-1) (da Silva et al., 2014). Without the inhibitory effects 
of TGF-β on NK cells, EMT-induced mesenchymal cells might enhance NK cell killing 
(Chockley and Keshamouni, 2016; Okita et al., 2018) and support the previous hypothesis that 
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melanoma cells with more mesenchymal properties (Figure 43) are more susceptible to NK cell 
killing.  
Although the mode of killing is not further analysed in this thesis, several studies reported that 
melanoma cells, which failed to undergo complete apoptosis have a distinct phenotype. They 
gained invasiveness and migratory potential in vitro and in vivo (Berthenet et al., 2019). However, 
in the cited study apoptosis was induced by doxycycline and can probably not be comparable 
with cell-mediated apoptosis. Furthermore, it was shown that apoptosis reversal promoted cancer 
stem cell formation (Xu et al., 2018b).  
Furthermore, it should be noted that soluble factors released by NK cells additionally affect the 
melanoma cell secretome and NK cell ligand profile. During the co-culture process, activated NK 
cells release IFN-γ that induces the secretion of IDO and PEG2 by melanoma cells and enhance 
the downregulation of activating receptors (Pietra et al., 2012a). In addition, IFN-γ showed a pro-
tumour effect by increasing the expression of HLA-E in melanoma (Derre et al., 2006) and MHC 
class I and II molecules as well as PD-L1 in other cancers (Castro et al., 2018). These effects 
might contribute to the observed reduced melanoma susceptibility to NK cells after melanoma-
NK cell co-culture.  
5.9.2 RNA sequencing  
RNA sequencing of melanoma cells co-cultured with primary NK cells or NK-92 cells revealed 
around 100 genes that were differentially expressed in both co-cultures compared to the control. 
However, only a small number of genes showed significantly different expression in both data 
sets. Interestingly, WM3734 cells co-cultured with NK-92 cells showed higher (~4 times) fold 
changes than WM3734 cells co-cultured with primary NK cells. The invariable cytotoxicity of the 
NK cell line in contrast to changing primary NK cell donors allows a more specific adaption to 
this cell line and might cause the higher fold-changes.  
Most of the hits presented in Table 23 (marked in bold) are associated to the antigen-presenting 
machinery. After co-culturing, melanoma cells expressed more beta-2-microglobulin, which is a 
component of the MHC class I molecules (Wieczorek et al., 2017) and was shown to be 
associated with poor prognosis(Cursons et al., 2019). Moreover, HLA-B as a MHC class I 
molecule showed an increased gene expression, although the NK cell receptor KIR3DL1 
responsible for HLA-B detection is only poorly expressed on NK-92 (Tao et al., 2014). The 
majority of melanoma cell lines (67 %) have alterations in the surface expression of HLA class I 
molecules. In particular HLA B is most frequently downregulated (35 %) in melanoma (Mendez 
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et al., 2009). These adaptions allow the evasion of T-cell recognition and hence ensure melanoma 
persistence. However, during the performed melanoma NK cell co-cultures, additional MHC 
class I molecules protect the melanoma cells against NK cell recognition, so that their 
upregulation increases the NK cell resistance. In addition to HLA-B, HCP5, a long non-coding 
RNA with retroviral origin and located centromeric of the HLA-B gene, was increased after co-
culturing. Although HCP5 is not coding for a protein, it was shown to have regulatory functions 
that might render tumour malignancy (Kulski, 2019; Wei et al., 2019b). The upregulation of these 
three MHC class I related proteins might be a result of continuous IFN-γ exposure mediated by 
activated and killing NK cells (Castro et al., 2018; Mendez et al., 2009). In addition, genes 
involved in IFN-γ signalling and the antigen presentation machinery showed strongest 
suppression of NK cell killing (Freeman et al., 2019).  
Even more dominant was the upregulation of MHC class II molecules in both co-cultures 
(Table 23). Less than 20 % of melanoma cells have constitutive expression of MHC class II 
molecules, which more than doubled (48.5 %) after IFN-γ treatment (Mendez et al., 2009). 
Although MHC class II molecules are shown to induce immune suppressive cytokines such as 
IL-10, the presence of MHC class II molecules in melanoma was associated with increased 
patient survival (Chen et al., 2019b; Johnson et al., 2016; Mendez et al., 2009). This is in line with 
the finding that some HLA-DP molecules are ligands for NKp44 and can activate NK cells 
(Niehrs and Altfeld, 2020). In contrast, HLA-DR-mediated signalling increased the migration 
and invasion of melanoma cells (Costantini and Barbieri, 2017). This is in agreement with the 
upregulation of the complement component C1S after co-culture (Table 23), which was also 
shown to be associated with the increased cell density and status of the mesenchymal marker 
ALCAM (activated leukocyte cell adhesion molecule) (van Kilsdonk et al., 2012). Also 
TMEM158, a transmembrane protein, was posivtively correlated to cell adhesion molecules and 
hence involved in invasivness of ovarian cancer cells (Cheng et al., 2015). Moreover, TMEM158 
was found to be overexpressed in metastatic melanoma (Eriksson et al., 2016). In contrast, 
absent in melanoma 2 (AIM2) is found predominatly in primary melanoma, whereas metastases 
often lack this protein (de Koning et al., 2014). Restoration of AIM2 was shown to promote an 
invasive phenotype of colorectal cancer (Patsos et al., 2010). In addition, AIM2-mediated IFN-γ 
dependent and independent MHC class II expression in this cancer type (Lee et al., 2012). The 
upregulation of AIM2 during the co-culture process might mediate the increase of MHC II 
molecules on the melanoma cell surface. This can be detected by NK cells and might raise their 
activation treshold. This assumption is in line with the observed lower susceptibility of HLA-
DR1 transfected K562 to PBMCs and to a NK cell line (Jiang et al., 1996).  
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Together with the results from this study, the upregulation of MHC class II molecules seem to be 
involved in the immune escape process of melanoma and could be not only favourable for 
patient’s survival.  
5.10 Concluding remarks 
Despite the recent advances in treating malignant melanoma, new and improved therapeutic 
approaches are needed in order to curb the disease. Natural killer cells are a promising tool for 
melanoma immunotherapy since melanoma cells with mesenchymal phenotype show high 
immunogenicity. This study not only provides a tool to predict the efficiency of NK cell-induced 
cytotoxicity of melanoma cells; it also reveals EMT and PI3K-AKT-mTOR signalling as 
important pathways involved in this immunogenic phenotype. Future therapeutic approaches 
with NK cells should not only target the maintenance of this phenotype by pharmacological 
manipulation but also the tumour microenvironment to prevent NK cell resistance and impaired 
NK cell cytotoxicity. Leading strategies might be the ACT of allogeneic or autologous pre-
activated primary NK cells as well as NK cell lines or pluripotent stem cell-derived NK cells. 
Furthermore, combination therapy with CTLs and NK cells could mimic a functional 
immunosurveillance and lead to tumour clearance.  
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Supplemental table 1. DGE analysis of WM3734 after co-culturing with primary NK cells. LogFC 
is the log fold-change that describes how strong a gene is over- (positive values) or under- (negative 
values) expressed after co-culturing with primary NK cells. The LogCPM are the log counts per million 
and is a measure for the gene expression level. Statistical significance is indicated by p-value and FDR 
(false discovery rate). 
Gene logFC logCPM p-value FDR 
POC1B-GALNT4 9.39 0.32 2.06E-18 2.85E-14 
TBC1D3F 7.05 -1.30 8.67E-09 1.37E-05 
DAPL1 7.02 -1.42 1.82E-05 9.37E-03 
AC005280.1 6.15 2.36 9.54E-06 5.46E-03 
AIM2 4.45 3.22 1.31E-52 7.27E-48 
FAT3 3.53 1.23 4.49E-12 1.78E-08 
TDRD6 3.25 -1.29 1.77E-05 9.19E-03 
RP11-574K11.31 3.14 -0.32 5.94E-06 3.67E-03 
PSKH1 3.00 -0.49 3.64E-10 9.47E-07 
HLA-DQA1 2.98 4.76 1.36E-24 2.69E-20 
ST8SIA5 2.57 2.96 2.14E-08 2.89E-05 
HCP5 2.42 -0.47 9.75E-06 5.52E-03 
PNLIPRP3 2.29 1.48 5.81E-09 1.04E-05 
TMEM158 2.02 4.12 1.45E-24 2.69E-20 
LPHN3 1.94 0.94 2.18E-06 1.51E-03 
SEMA3A 1.71 3.29 2.17E-09 4.45E-06 
LPAR3 1.70 2.15 9.15E-06 5.29E-03 
ADAM19 1.64 3.04 3.76E-10 9.47E-07 
MGLL 1.62 4.69 8.31E-07 6.88E-04 
AIM1 1.59 2.94 2.46E-08 3.25E-05 
SLC16A6 1.57 2.12 6.45E-08 7.61E-05 
COL12A1 1.57 3.17 2.43E-12 1.04E-08 
GLIPR1 1.56 1.66 1.27E-06 9.80E-04 
TXNIP 1.55 1.41 6.15E-06 3.71E-03 
KCNMA1 1.55 1.57 4.46E-07 4.19E-04 
RP11-221J22.2 1.55 2.72 2.75E-09 5.26E-06 
FLT1 1.52 2.55 2.11E-09 4.45E-06 
FAM19A3 1.47 1.30 6.04E-06 3.68E-03 
C1S 1.42 2.81 2.02E-06 1.42E-03 
SPOCD1 1.33 2.77 1.43E-06 1.05E-03 
CIITA 1.30 4.06 1.64E-09 3.65E-06 
ITIH5 1.29 7.74 5.87E-07 5.17E-04 
SPRR2D 1.24 3.82 1.29E-06 9.82E-04 
AHNAK2 1.23 2.82 1.30E-05 7.08E-03 
NR4A1 1.21 2.53 1.52E-06 1.11E-03 
IGFBP5 1.12 6.41 4.19E-07 4.02E-04 
MYOZ2 1.12 5.47 1.72E-10 5.60E-07 
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Gene logFC logCPM p-value FDR 
HLA-DMB 1.11 5.41 7.15E-17 7.92E-13 
COL8A1 1.09 3.65 1.18E-06 9.25E-04 
HLA-DQB1 1.09 7.04 1.44E-15 1.14E-11 
CXCL1 1.01 4.10 8.07E-09 1.32E-05 
NRP1 1.01 6.21 1.15E-07 1.30E-04 
KYNU 0.99 3.70 3.39E-07 3.42E-04 
NLRP1 0.97 3.00 5.95E-06 3.67E-03 
SCARA5 0.92 5.05 1.35E-11 4.68E-08 
NOV 0.92 5.34 8.50E-06 4.96E-03 
HLA-DPA1 0.91 9.32 9.13E-15 6.21E-11 
HLA-DRA 0.90 10.37 1.01E-14 6.21E-11 
PTN 0.90 6.03 8.46E-06 4.96E-03 
HLA-DPB1 0.88 7.30 1.86E-13 1.03E-09 
NRCAM 0.83 4.99 5.02E-08 6.07E-05 
NPPC 0.82 3.45 6.61E-06 3.94E-03 
HLA-DMA 0.80 7.43 6.44E-12 2.38E-08 
ZNF689 0.78 5.08 5.05E-06 3.18E-03 
HLA-B 0.77 8.47 9.69E-09 1.49E-05 
LOXL2 0.77 6.07 1.75E-08 2.43E-05 
SLC20A1 0.76 8.10 1.17E-05 6.47E-03 
RP11-390P2.4 0.76 5.16 8.07E-09 1.32E-05 
CD109 0.75 7.98 2.36E-09 4.68E-06 
RNF128 0.75 5.56 1.47E-05 7.94E-03 
HLA-DRB1 0.74 8.58 1.20E-08 1.74E-05 
FAM133A 0.72 5.67 1.31E-06 9.82E-04 
IVNS1ABP 0.72 6.31 6.55E-07 5.68E-04 
PITPNC1 0.71 4.89 4.63E-06 2.99E-03 
TNC 0.71 8.50 5.04E-08 6.07E-05 
MTPN 0.70 8.25 7.82E-07 6.57E-04 
ITGA1 0.68 5.27 3.96E-06 2.68E-03 
LOXL3 0.66 6.55 4.97E-07 4.52E-04 
B2M 0.65 10.71 4.61E-06 2.99E-03 
ITGB8 0.65 7.24 7.21E-08 8.33E-05 
CD74 0.62 10.74 2.72E-07 2.84E-04 
FRMD4A 0.62 7.89 1.22E-05 6.71E-03 
FAM216A 0.61 4.53 1.51E-05 8.04E-03 
CTSA -0.52 7.78 1.76E-05 9.19E-03 
MGAT1 -0.69 6.13 2.96E-07 3.04E-04 
OR2A9P -0.69 5.18 7.02E-07 5.99E-04 
DGCR6 -0.72 4.05 4.63E-06 2.99E-03 
KRT18 -0.77 5.47 4.41E-06 2.95E-03 
GYPC -0.89 6.58 5.32E-07 4.75E-04 
CERS4 -0.96 2.84 1.89E-05 9.63E-03 
BMP7 -0.96 4.83 1.75E-07 1.90E-04 
MGAT4A -1.00 2.67 4.20E-07 4.02E-04 
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Gene logFC logCPM p-value FDR 
RP11-14N7.2 -1.04 3.90 1.03E-08 1.54E-05 
ATOH8 -1.10 3.84 2.28E-07 2.43E-04 
CRTAC1 -1.10 3.54 1.56E-05 8.25E-03 
PSCA -1.12 6.72 1.03E-09 2.49E-06 
PMEL -1.16 8.48 3.97E-07 3.93E-04 
PRSS33 -1.18 3.97 3.61E-10 9.47E-07 
PIK3R2 -1.37 2.34 1.31E-09 3.03E-06 
RAPGEF3 -1.39 1.86 4.79E-08 6.04E-05 
SPP1 -1.40 6.58 1.01E-06 8.01E-04 
EPHX2 -1.44 2.39 3.02E-10 9.31E-07 
MAFB -1.44 2.32 3.67E-10 9.47E-07 
EPB41L4B -1.47 1.44 4.68E-06 2.99E-03 
MAGI1 -1.52 3.87 9.44E-07 7.64E-04 
BCAN -1.57 2.45 1.57E-07 1.74E-04 
TESC -1.96 1.64 8.21E-13 3.79E-09 
EEF1A2 -2.22 2.72 1.40E-08 1.99E-05 
CKMT1B -2.37 0.93 1.15E-05 6.44E-03 
NUP210 -2.42 1.83 3.86E-06 2.64E-03 
CLU -2.47 0.83 6.40E-09 1.11E-05 
KCNG4 -2.69 -0.07 1.79E-06 1.27E-03 
ZNF382 -2.69 -0.75 4.87E-07 4.50E-04 
ILDR2 -3.39 -0.47 1.75E-06 1.26E-03 
TMEM132D -3.39 0.54 4.06E-08 5.23E-05 
MYADM -4.09 4.10 2.98E-09 5.52E-06 
ADAMTS12 -4.65 -1.97 9.50E-07 7.64E-04 
CTB-43P18.1 -8.12 -1.28 3.57E-13 1.80E-09 
AC008964.1 -8.39 -0.99 3.68E-16 3.40E-12 
 
Supplemental table 2. DGE analysis of WM3734 after co-culturing with NK-92 cells. LogFC is the 
log fold-change that describes how strong a gene is over- (positive values) or under- (negative values) 
expressed after co-culturing with NK-92 cells. The LogCPM are the log counts per million and is a 
measure for the gene expression level. Statistical significance is indicated by p-value and FDR (false 
discovery rate). 
Gene logFC logCPM PValue FDR 
TGIF2-C20orf24 12.58 3.24 1.47E-05 0.009114 
AC000120.7 10.42 1.09 3.83E-07 0.000354 
LGALS17A 9.94 -1.00 4.99E-08 6.24E-05 
IER3IP1 9.71 0.64 6.43E-09 1.07E-05 
AC004889.1 9.08 0.52 1.50E-09 2.91E-06 
IDO1 9.07 3.82 1.96E-09 3.56E-06 
CHRNE 9.04 -0.11 1.94E-07 0.000203 
HCP5 8.19 1.76 9.79E-12 2.63E-08 
HLA-DQA1 7.42 6.86 2.72E-19 1.39E-15 
XAF1 7.29 3.39 4.68E-13 1.39E-09 
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Gene logFC logCPM PValue FDR 
AIM2 6.88 5.02 4.65E-10 1.01E-06 
APOL3 6.44 2.22 6.89E-10 1.38E-06 
DPH1 6.38 3.60 8.93E-09 1.36E-05 
SERPING1 6.00 0.70 9.01E-07 0.000769 
GBP1P1 5.84 0.09 2.25E-06 0.001734 
SLC15A3 5.57 -0.26 1.16E-06 0.000977 
BST2 5.39 3.02 1.54E-06 0.001235 
HLA-DOA 5.37 4.15 6.46E-09 1.07E-05 
SPATA21 5.36 1.31 5.28E-06 0.003716 
APOL1 5.34 5.64 2.03E-17 8.16E-14 
IL15RA 4.89 0.63 5.14E-06 0.003662 
IFI27 4.82 2.11 1.24E-05 0.007789 
C1S 4.79 6.25 6.99E-09 1.12E-05 
OAS2 4.73 3.31 1.03E-08 1.53E-05 
A2M 4.51 7.20 1.76E-14 5.82E-11 
HLA-B 3.97 10.19 4.71E-12 1.33E-08 
BATF2 3.85 1.85 2.70E-08 3.53E-05 
WARS 3.68 9.47 4.19E-15 1.48E-11 
SNRPN 3.47 5.11 2.03E-09 3.58E-06 
IRF1 3.46 4.58 7.36E-07 0.000638 
ITIH6 3.39 3.00 4.07E-08 5.21E-05 
HLA-DQB1 3.27 8.11 2.29E-10 5.15E-07 
BOLA2 3.11 4.47 2.40E-07 0.000233 
APOL6 3.11 6.52 9.03E-06 0.005917 
HLA-F 3.06 4.96 1.85E-08 2.61E-05 
RARRES3 3.05 2.47 3.17E-06 0.002351 
KIAA1644 3.04 1.52 7.65E-06 0.005188 
TAP1 2.94 6.68 7.84E-08 9.48E-05 
STAT1 2.78 7.95 1.43E-06 0.001166 
TMEM158 2.74 7.23 4.21E-07 0.000377 
B2M 2.74 11.77 1.01E-05 0.006459 
HLA-DPA1 2.63 9.93 1.35E-06 0.001118 
PLA1A 2.62 7.18 7.92E-08 9.48E-05 
HLA-DRA 2.49 10.89 2.07E-06 0.001618 
HLA-DPB1 2.48 8.23 1.51E-07 0.000165 
HLA-DMB 2.47 6.75 4.62E-06 0.003378 
CD74 2.42 11.60 1.53E-07 0.000165 
HLA-C 2.40 9.49 9.17E-08 0.000105 
UBE2L6 2.08 7.40 6.13E-06 0.004258 
SNURF -2.07 6.52 2.91E-07 0.000278 
ITFG2 -2.10 5.91 2.23E-07 0.00022 
NOMO2 -2.13 3.52 2.62E-06 0.001966 
RPLP0P6 -2.22 3.10 8.24E-06 0.005526 
RP5-940J5.9 -2.31 8.83 2.12E-07 0.000213 
RPS2P46 -2.42 4.01 8.88E-08 0.000104 
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Gene logFC logCPM PValue FDR 
RPS2P5 -2.48 6.17 1.09E-08 1.57E-05 
ACOT1 -2.52 2.87 2.02E-07 0.000206 
CEMP1 -2.93 0.92 1.51E-05 0.009212 
ABCB5 -3.11 2.77 3.56E-07 0.000334 
ST8SIA2 -4.10 -0.70 6.68E-06 0.004589 
SLAMF7 -4.20 3.08 3.78E-11 8.87E-08 
AP000347.4 -4.26 0.57 2.09E-08 2.87E-05 
PMFBP1 -4.94 0.79 2.97E-11 7.28E-08 
CTD-2008A1.2 -6.01 2.33 3.05E-19 1.43E-15 
WNK2 -6.61 -2.48 9.04E-06 0.005917 
CT45A3 -6.99 -1.20 9.83E-06 0.006364 
AP003419.16 -7.13 -1.00 4.96E-06 0.00358 
RP11-211N8.3 -7.15 -2.43 1.05E-05 0.006618 
AL358113.1 -7.33 -1.04 1.73E-06 0.001373 
MRAP -7.55 -1.63 1.55E-07 0.000165 
RP11-264B17.5 -8.09 -0.83 9.37E-08 0.000105 
AC092299.8 -8.14 -0.81 2.56E-06 0.001949 
RP11-504P24.6 -8.23 -1.63 6.79E-07 0.000597 
RP1-63M2.6 -8.27 -1.60 4.07E-07 0.00037 
CYP4F59P -8.33 -0.61 2.15E-08 2.88E-05 
RP11-62J1.3 -8.61 0.07 4.84E-10 1.01E-06 
PCDHGA8 -8.70 -0.19 7.65E-09 1.20E-05 
COMMD3-BMI1 -8.88 0.57 1.09E-11 2.79E-08 
RP11-498C9.3 -8.92 3.81 3.01E-29 2.83E-25 
IDI2 -9.16 0.16 1.72E-09 3.22E-06 
RP1-56K13.3 -9.24 0.68 2.25E-13 7.05E-10 
RP11-589M4.1 -10.28 1.45 6.87E-16 2.58E-12 
RP11-500M8.7 -10.40 1.59 5.55E-18 2.40E-14 
RP11-2C24.6 -10.46 1.19 1.62E-19 9.12E-16 
NICN1-AS1 -10.68 1.66 1.37E-21 8.58E-18 
ATP6V1G2-DDX39B -11.15 2.23 2.32E-26 1.63E-22 
RP11-1100L3.8 -11.23 2.70 6.31E-28 5.08E-24 
AC114546.1 -11.45 3.85 4.70E-32 6.62E-28 
RP11-624G17.3 -11.85 2.92 1.98E-31 2.23E-27 
RP11-1100L3.7 -12.44 3.37 6.05E-35 1.14E-30 
AC005786.7 -14.39 5.21 5.27E-60 1.48E-55 
RP11-161H23.5 -16.05 7.11 3.14E-79 1.77E-74 
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Supplemental table 3. DGE analysis of WM3734 after recovering of NK-92-co-culturing . LogFC is 
the log fold-change that describes how strong a gene is over- (positive values) or under- (negative values) 
expressed after recovering of co-culturing with NK-92 cells. The LogCPM are the log counts per million 
and is a measure for the gene expression level. Statistical significance is indicated by p-value and FDR 
(false discovery rate). 
Gene logFC logCPM p-value FDR 
RP11-161H23.5 15.93 7.11 1.08E-81 6.07E-77 
AC005786.7 13.88 5.21 9.31E-59 2.62E-54 
AC114546.1 13.06 3.85 1.26E-47 2.36E-43 
RP11-1100L3.7 12.08 3.37 5.26E-35 7.40E-31 
RP11-1100L3.8 11.65 2.70 3.44E-33 3.88E-29 
RP11-624G17.3 11.71 2.92 7.25E-33 6.81E-29 
RP11-498C9.3 8.29 3.81 7.12E-28 5.73E-24 
ATP6V1G2-DDX39B 10.99 2.23 1.46E-27 1.03E-23 
CTD-2008A1.2 6.23 2.33 9.44E-23 5.91E-19 
NICN1-AS1 10.36 1.66 9.73E-22 5.48E-18 
WARS -3.23 9.47 2.79E-21 1.43E-17 
PMFBP1 6.47 0.79 7.74E-20 3.63E-16 
RP11-500M8.7 10.40 1.59 1.72E-19 7.43E-16 
RP11-2C24.6 9.63 1.19 3.21E-17 1.29E-13 
DPH1 -6.87 3.60 2.35E-16 8.82E-13 
RP11-589M4.1 10.03 1.45 3.01E-16 1.06E-12 
RP1-56K13.3 9.61 0.68 3.96E-16 1.31E-12 
COMMD3-BMI1 9.63 0.57 1.34E-15 4.20E-12 
APOL1 -3.28 5.64 3.06E-15 9.06E-12 
RP4-545K15.3 -5.56 2.21 3.62E-14 1.02E-10 
IDO1 -7.41 3.82 5.12E-13 1.37E-09 
LGALS17A -9.94 -1.00 2.17E-12 5.56E-09 
RP11-62J1.3 8.90 0.07 6.33E-12 1.55E-08 
SNRPN -2.86 5.11 1.08E-11 2.52E-08 
IRF1 -3.50 4.58 2.27E-11 5.11E-08 
SPATA21 -7.21 1.31 5.53E-11 1.20E-07 
IER3IP1 -9.71 0.64 6.81E-11 1.42E-07 
RP11-651P23.4 5.52 0.96 1.41E-10 2.73E-07 
NLRC5 -2.61 3.54 1.42E-10 2.73E-07 
TAP1 -2.60 6.68 1.46E-10 2.73E-07 
A2M -2.44 7.20 6.25E-10 1.14E-06 
BATF2 -3.09 1.85 7.87E-10 1.38E-06 
RP11-862L9.3 2.74 3.48 1.92E-09 3.28E-06 
IDI2 8.73 0.16 2.67E-09 4.43E-06 
RP11-294J22.6 8.48 -0.85 4.30E-09 6.91E-06 
RPS2P5 2.25 6.17 5.28E-09 8.26E-06 
PCDHGA8 8.39 -0.19 6.93E-09 1.06E-05 
CHRNE -4.78 -0.11 1.34E-08 1.99E-05 
AP003419.16 7.90 -1.00 2.13E-08 3.07E-05 
AL358113.1 7.78 -1.04 3.63E-08 5.11E-05 
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CYP4F59P 7.89 -0.61 4.66E-08 6.40E-05 
SLC15A3 -4.56 -0.26 4.94E-08 6.62E-05 
APOL4 -4.65 0.45 5.81E-08 7.60E-05 
CT45A3 7.76 -1.20 6.38E-08 8.16E-05 
RPL3P4 -2.49 6.77 7.12E-08 8.91E-05 
UBA7 -2.31 2.53 7.76E-08 9.49E-05 
MRAP 7.37 -1.63 8.61E-08 0.000103 
RPS2P46 2.13 4.01 1.03E-07 0.000121 
RARRES3 -2.58 2.47 1.06E-07 0.000122 
RTN4RL2 -2.85 2.53 1.30E-07 0.000147 
STAT1 -2.22 7.95 1.72E-07 0.00019 
PSMB10 -2.00 5.05 1.78E-07 0.000192 
RP11-264B17.5 7.66 -0.83 1.81E-07 0.000192 
YBX1P10 7.95 -1.09 1.89E-07 0.000193 
UBE2L6 -1.81 7.40 1.89E-07 0.000193 
RP11-201K10.3 -8.86 0.14 2.59E-07 0.000261 
RP11-538I12.2 8.05 -1.27 3.06E-07 0.000302 
PSMB8 -1.72 6.51 3.98E-07 0.000387 
AK4P1 7.56 -1.63 4.56E-07 0.000435 
AP000347.4 3.56 0.57 4.72E-07 0.000443 
HLA-B -1.95 10.19 6.12E-07 0.000561 
BGLAP -4.00 -0.20 6.18E-07 0.000561 
SNURF 1.76 6.52 6.34E-07 0.000567 
APOL6 -2.51 6.52 9.65E-07 0.000849 
APOL3 -3.12 2.22 1.09E-06 0.000946 
IFITM1 -3.22 5.23 1.32E-06 0.001127 
AC015987.2 14.69 5.25 1.54E-06 0.001293 
NUDT4P1 7.26 -1.63 1.69E-06 0.001402 
RAD51L3-RFFL -7.60 -1.24 1.85E-06 0.001514 
RP5-940J5.9 1.81 8.83 3.42E-06 0.002752 
PIGY 7.25 -2.00 3.47E-06 0.002752 
RAC2 5.13 -0.18 3.58E-06 0.002796 
NOMO2 1.85 3.52 3.73E-06 0.00288 
ACOT1 1.98 2.87 3.79E-06 0.002888 
RP11-175K6.1 7.05 -2.06 4.03E-06 0.003022 
PTGES3P3 7.16 -1.84 4.18E-06 0.003096 
UBD -7.46 1.46 4.25E-06 0.003109 
GBP2 -1.85 4.95 4.56E-06 0.003294 
TRIM64EP -7.26 -1.64 4.85E-06 0.003458 
AC000120.7 -4.58 1.09 5.43E-06 0.003819 
C1S -2.48 6.25 5.50E-06 0.003826 
RP11-680F20.12 7.37 -1.80 6.11E-06 0.004194 
TAPSAR1 -2.20 3.69 7.93E-06 0.005381 
MT-ATP8 1.68 6.94 8.84E-06 0.005924 
PCDHGB3 6.96 -1.69 9.23E-06 0.006114 
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TYRP1 -1.62 5.79 9.66E-06 0.006327 
MTND2P28 1.67 6.22 1.03E-05 0.006693 
PSME2 -1.42 8.29 1.08E-05 0.006875 
CTB-63M22.1 -1.96 3.08 1.09E-05 0.006875 
HLA-E -1.46 8.28 1.11E-05 0.006957 
PIK3R2 8.50 -0.78 1.16E-05 0.007204 
AC083899.3 2.31 1.27 1.21E-05 0.007435 
ABCB5 2.38 2.77 1.25E-05 0.007572 
IRF9 -1.63 4.65 1.31E-05 0.007755 
SRP9P1 2.93 0.15 1.31E-05 0.007755 
IL15RA -3.15 0.63 1.32E-05 0.007764 
ZNF770 -1.75 4.27 1.39E-05 0.008078 
C1R -1.65 5.26 1.44E-05 0.008291 
AC092299.8 7.38 -0.81 1.46E-05 0.008313 
HLA-C -1.43 9.49 1.54E-05 0.008649 
HLA-DQB1 -1.56 8.11 1.60E-05 0.008899 
RP11-299G20.2 4.07 0.44 1.63E-05 0.009022 
 
Supplemental table 4. DGE analysis of co-culture-recovered WM3734 compared to CTRL. LogFC 
is the log fold-change that describes how strong a gene is over- (positive values) or under- (negative 
values) expressed after recovering of co-culturing with NK-92 cells. The LogCPM are the log counts per 
million and is a measure for the gene expression level. Statistical significance is indicated by p-value and 
FDR (false discovery rate). 
ID logFC logCPM p-value FDR 
HLA-DQA1 6.56 6.86 1.39E-16 7.81E-12 
NAA60 -4.86 0.87 2.34E-10 6.58E-06 
AC004889.1 8.72 0.52 8.28E-09 0.000155 
ITIH6 3.28 3.00 8.87E-08 0.001047 
XAF1 4.91 3.39 9.30E-08 0.001047 
HCP5 6.04 1.76 2.68E-07 0.002513 
RP11-667K14.4 -8.46 -1.37 3.74E-07 0.003007 
RP11-504P24.6 -8.23 -1.63 5.10E-07 0.003072 
RP11-286N22.8 8.03 -1.13 5.27E-07 0.003072 
RP1-63M2.6 -8.27 -1.60 5.46E-07 0.003072 
RP11-201K10.3 -8.88 0.14 7.29E-07 0.00373 
RP11-294J22.6 8.48 -0.85 1.81E-06 0.008473 
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